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ABSTRACT 
Excess food consumption and/or lack of exercise have dramatically contributed to 
the prevalence of overweight (BMI≥25) and obesity (BMI≥30) in modern society. The 
obesity epidemic has been linked to the rise in type 2 diabetes. In recent years, evidence 
has pointed to a close association between mitochondrial dysfunction in white adipose 
tissue (WAT) and insulin resistance, a key feature of type 2 diabetes. In order to dissect 
the cause and effect relationship between WAT mitochondrial dysfunction and insulin 
resistance, we established an in vitro cell line system to investigate this issue. We 
artificially introduced mitochondrial dysfunction in 3T3-L1 adipocytes by depleting the 
mitochondrial transcription factor A (Tfam) during adipogenesis, without changing the 
overall adipocyte differentiation program. We found that these Tfam-depleted 3T3-L1 
adipocytes showed symptoms of insulin resistance, evidenced by impaired insulin-
stimulated GLUT4 translocation and glucose uptake. This result suggested that 
mitochondrial dysfunction could be a primary contributor to insulin resistance in fat 
tissue.  However, the exact mechanism underlying this finding remains unclear. 
As part of a comprehensive understanding of insulin signaling in fat cells, we also 
investigated the involvement of the endosomal protein WDFY2 in the regulation of Akt 
isoform-specific effect on glucose uptake. In 3T3-L1 adipocytes, both Akt1 and Akt2 
isoforms are expressed, but only Akt2 plays an indispensible role in insulin-stimulated 
GLUT4 translocation and glucose uptake. Previous studies implied that endosomal 
proteins may take a part in determining Akt substrate specificity. Here we found that 
WDFY2 preferentially co-localized with Akt2 and that knockdown of WDFY2 inhibited 
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insulin-stimulated glucose uptake in 3T3-L1 adipocytes, suggesting that endosomes are 
involved in this regulation. The effect of WDFY2 knockdown on insulin-stimulated 
glucose uptake worked through the down-regulation of Akt2, but not Akt1, protein level. 
We concluded that, endosomal protein WDFY2, by preferentially interacting with Akt2, 
regulates insulin signaling in glucose uptake in 3T3-L1 adipocytes. Our findings may 
help to develop specific therapeutic interventions for treatment of insulin resistance and 
type 2 diabetes. 
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CHAPTER I 
INTRODUCTION 
With the plentiful food supply of modern society, over eating and/or lack of 
exercise have emerged as major causes for developing metabolic diseases including 
obesity and type 2 diabetes. In 2007-2008, a study conducted by the Centers for Disease 
Control and Prevention (CDC) estimated that 68% of the adults in the US are overweight 
based on the criterion of body mass index (BMI) ≥25, and 33.8% are obese with the BMI 
≥ 30 [BMI, the value of one’s body weight (kg) divided by the square of  his/her height 
(m)] (1). Nearly 24 million Americans or 8% of the US population are diabetic, among 
which 90%-95% have type 2 diabetes, often associated with obesity. The cost of 
diagnosed diabetes in the United States reached approximately $174 billion in 2007  as 
estimated by the CDC (2).  
The occurrence of obesity is largely attributed to the imbalance of high energy 
intake (food consumption) and low energy expenditure (energy required for life 
functions). As a response to this imbalance, fat tissue expands in cell size and number to 
store excessive energy as triglycerides, resulting in adiposity. There is a high correlation 
between excessive adiposity and insulin resistance, type 2 diabetes, and cardiovascular 
disease (3). To better understand the pathology of obesity and its associated diseases, 
more research is being conducted on the biology of adipose tissue. 
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Mitochondrial Dysfunction: Thinking inside the WAT 
Adipose Tissue  
Adipose tissue, consisting of white adipose tissue (WAT) and brown adipose 
tissue (BAT) in mammals, has been recognized as not only an energy-storage and 
expenditure buffer system but also an endocrine organ that secretes adipokines that 
regulate whole body energy homeostasis (4). WAT stores excess energy in the form of 
triglycerides during a fed state and serves as a source of energy in the form of fatty acids 
during starvation. BAT is highly packed with mitochondria and is specialized to produce 
heat by burning fat without creating ATP, thereby dissipating energy through a process 
known as non-shivering thermogenesis (5).  Until recently, it was believed that BAT was 
nonexistent in  adult humans (6). However, new technology using fluorodeoxyglucose 
positron-emission tomography (FDG-PET) revealed that BAT actually exists in several 
different areas in the human body such as the supraclavicular and the neck regions (7-8). 
As a result of these studies, the biology of BAT is now being more interested. 
On the other hand, considerable effort has been put into the study of adipogenesis 
and the endocrine function of WAT in the past two decades. The transcriptional 
components of adipogenesis have been intensely investigated, with the peroxisome 
proliferator-activated receptor γ (PPARγ) and CCAAT enhancer binding proteins (C/EBP) 
in the center of its regulatory circuit (9). More recently, the discovery of the zinc finger 
protein 423 (Zfp423) (10) and PRD1-BF1-RIZ1 homologous domain containing 16 
(PRDM16) (11) has revealed even more details of the shared and divergent aspects of the 
transcriptional control of BAT and WAT. The discovery of the BAT in human adults also 
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raises the interests in the origins of BAT and WAT in vivo, as well as the potential 
conversion of WAT into BAT. Morphologically, WAT has unilocular fat droplets and 
white-like color while BAT has multilocular fat droplets and a more brown-like color, a 
result of numerous densely-packed mitochondria. BAT is also characterized by the 
expression of uncoupling protein-1 (UCP-1), which is not found in WAT. Studies showed 
that it is possible to confer a BAT-like phenotype to WAT by increasing the expression 
of UCP-1 or by stimulating mitochondrial biogenesis through PPARγ co-activator 1α 
(PGC-1α) (12-13). Additionally, it was reported that the BAT can arise from WAT by 
cold exposure (14). Some have proposed the concept that these two tissues are 
intermingled together and can convert to each other (15). If the transdifferentiation from 
white to brown adipocytes naturally occurs in vivo under certain conditions such as cold 
exposure, warm exposure and dietary change, the manipulation of the conversion of 
WAT to BAT would be applicably feasible and therapeutically beneficial. However, the 
mechanism of transdifferentiation between WAT and BAT needs to be carefully 
determined. 
Mitochondria 
Mitochondria are intracellular membrane-enclosed organelles found in most 
eukaryotic cells. They are considered the “powerhouse” of a cell, providing fuel in the 
form of ATP through oxidative phosphorylation (OXPHOS). The number of 
mitochondria in a cell varies by tissue and organism, as well as by different physiological 
conditions, including obesity, weight loss, aging, treatment with anti-diabetic agents, and 
in response to genetic alterations in insulin receptor number (16-27). In general, 
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mitochondria are usually concentrated in energy demanding tissues like heart and muscle. 
Classic mitochondrial biology describes the mitochondria as dispersed, rod-shape 
organelles; however, mitochondria are highly dynamic and form an interconnected 
reticulum-like network in live cells. They undergo fission and fusion to allow 
communication and exchange of the internal contents, including mitochondrial DNA 
(mtDNA) and proteins (28). The proper dynamics of mitochondria are physiologically 
important for cell function; abnormal mitochondrial dynamics are associated with a wide 
range of diseases such as type 2 diabetes, vascular proliferative disorder and 
neurodegenerative diseases (29). 
Mitochondria maintain their own genome, a 16.5 Kb circular mitochondrial DNA 
molecule which encodes only thirteen proteins.  More than a thousand proteins needed 
for mitochondrial functions in energy metabolism and other pathways are encoded by the 
nucleus. The thirteen mtDNA-encoded proteins are subunits for the electron transport 
chain (ETC) complex I, III, VI and ATP synthase embedded in the mitochondrial inner 
membrane, highlighting the importance of mtDNA in OXPHOS function. The 
transcription of mtDNA and the nuclear genome is highly regulated to support normal 
mitochondrial functions (30). While the transcription of mtDNA occurs in the 
mitochondrial reticulum, all the proteins needed for the transcription machinery are 
encoded by the nucleus. These proteins are translated in the cytoplasm and are 
transported to the mitochondria to fulfill their function. The most characterized 
transcription factor involved in mtDNA transcription is transcription factor A, 
mitochondrial (Tfam). This nuclear encoded, mitochondrial specific factor is not only 
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crucial for the transcription of mtDNA, but also necessary for the maintenance of mtDNA 
integrity (31). Other components like transcription factor B1, mitochondrial (TFB1M) 
and transcription factor B2, mitochondrial (TFB2M) work together with Tfam and 
mitochondrial RNA polymerase to transcribe mtDNA.  Perturbation of Tfam causes both 
impaired mtDNA replication and transcription, resulting in a net decrease in mtDNA-
encoded transcripts for respiratory complexes (32). The abnormality of Tfam has been 
reported to be associated with some diseases such as infantile mitochondrial myopathy 
(33), age-related type 2 diabetes (34), Down’s syndrome (35), Alzheimer’s  disease and 
Parkinson’s disease (36). 
Besides generating ATP, mitochondria are involved in other cellular functions 
including the generation of reactive oxygen species (ROS), calcium signaling, and 
apoptosis. Mitochondrial dysfunction has been linked to a spectrum of human diseases in 
multiple tissues like heart, brain, muscle and pancreas (37). In fat tissue, it is a well 
established notion that the high density of mitochondria in BAT supports its energy 
expenditure function. However the importance of mitochondrial function in WAT 
remains largely undetermined, partly due to the historic neglect of their abundance in this 
seemingly inactive tissue. With the recent discoveries that mitochondrial biogenesis is 
inherent during in vitro 3T3-L1 adipogenesis and in WAT from ob/ob mice or diabetic 
patients treated with insulin sensitizer (22, 25-26), the pathological relevance of 
mitochondria dysfunction in WAT has become more interesting.  
The following section of the introduction focuses on two aspects of white adipose 
tissue activity: 1) fat as an energy buffering system; and 2) fat as an endocrine organ. I 
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will discuss the role of mitochondrial function in these two adipose tissue functionalities 
and try to establish the hypothesis that mitochondria in white adipose tissue play a central 
role in regulating WAT function. 
Mitochondria in WAT Function 
WAT as an Energy Buffering System 
Depending on whole body energy balance, WAT can either store fatty acids as 
triglycerides or release them from triglycerides to supply energy for other tissues as 
needed. Specifically, under fed conditions, fatty acids are esterified to form triglycerides 
by a process known as lipogenesis while under starved conditions, fatty acids are released 
from triglycerides during a process known as lipolysis. These two opposite processes 
constitute an important role of WAT as an energy buffering system. Obesity is the 
consequence of an imbalance of energy homeostasis, with triglycerides storage in WAT 
exceeding their dissipation.  
It is now known that white adipocytes are enriched with mitochondria, as 
observed during in vitro adipogenesis and in animals treated with Rosiglitazone (25-26), 
a PPARγ agonist, which is a master regulator of adipogenesis. Although the 
mitochondrial density in WAT is still relatively low compared to BAT, it is much higher 
than in preadipocytes. We found that differentiated 3T3-L1 adipocytes and WAT have 2-
5-fold more mtDNA compared to preadipocytes (Figure 2-1, B and data not shown). 
Since WAT is not an energetically demanding tissue compared to muscle and brain, the 
high density of mitochondria might function in the regulation of whole body lipid 
metabolism rather than in the generation of ATP. In comparison, mitochondria in BAT 
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are more specialized for energy dissipation in the form of heat from the futile electron 
transport chain in the presence of uncoupling protein UCP-1. The idea that mitochondria 
in WAT have a function distinct from the mitochondria in BAT is supported by the 
discovery that the proteomic compositions of the mitochondria from these two tissues are 
substantially different (38). Specifically, WAT mitochondria preferentially express 
proteins supporting anabolic functions such as glycerolipid and fatty acid biosynthesis, 
while BAT mitochondria are characterized by proteins involved in oxidative 
phosphorylation, fatty acid metabolism and citrate cycle, which is more similar to muscle 
(38).  
Although lipogenesis is traditionally thought to occur exclusively in the 
cytoplasm, there is a definite requirement for mitochondria during lipogenesis (39). In 
fact, a strong association between mitochondrial DNA copy number and lipogenesis in 
human white adipocytes exists (17). One of the mitochondrial functions in lipogenesis is 
to provide the triglyceride building block glycerol 3-phosphate through a pathway 
defined as glyceroneogenesis (40). In rat adipose tissue glyceroneogenesis accounts for 
approximately 90% of the total triglyceride backbone. This holds true even when the rats 
are starved for 48 hours (41). The tricarboxylic acid cycle (TCA cycle) occurs in the 
mitochondrial intermembrane space, where the metabolic intermediate oxaloacetate is 
produced. In the process of glyceroneogenesis, the cytosolic phosphoenolpyruvate 
carboxykinase (PEPCK-C) catalyzes the conversion of oxaloacetate to 
phosphoenolpyruvate (PEP), which is a critical step for both gluconeogenesis and 
glyceroneogenesis. PEP is then converted to glycerol 3-phosphate through several 
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reversible reactions in the glycolysis pathway. Mitochondria contain a different version 
of PEPCK, PEPCK-M. Although the function of PEPCK-M is less defined, it is 
reasonable to speculate that it may have a similar metabolic role as PEPCK-C does in 
gluconeogenesis and glyceroneogenesis.  
Supporting the idea that mitochondria are involved in lipogenesis, the enzymes 
that directly catalyze the formation of triglycerides were found to be localized or 
associated with the mitochondrial outer membrane. These include glycerol-3-phosphate 
acyltransferase 1 and 2 (GPAT1, GPAT2) and diacylglycerol O-acyltransferase 2 
(DGAT2) (42-43).  Interestingly, GPAT1, 1-acylglycerol-3-phosphate O-acyltransferase 
2 and 3 (AGPAT2 and AGPAT3), diacylglycerol O-acyltransferase 1 (DGAT1), 
acylglycerol kinase (Agk), and acid phosphatase 6 (Acp6) are specifically enriched in the 
mitochondria from WAT but not BAT (38). This underscores the importance of 
mitochondrial function in WAT lipogenesis. On the other hand, mitochondria may 
participate in the process of de novo synthesis of fatty acids, the other building block of 
triglycerides. It has been reported that the impaired mitochondrial function due to 
oxidative phosphorylation uncoupling decreases the de novo fatty acid synthesis (44). 
Taken together, these studies suggest a strong relationship between mitochondria 
function and lipogenesis in WAT. 
The reverse process of lipogenesis is lipolysis, which breaks down the 
triglycerides into fatty acids and glycerol. The mitochondrial role in WAT lipolysis 
remains largely unknown, but released free fatty acids from lipolysis are known to be 
oxidized in mitochondria through the β-oxidation pathway. This could be an important 
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source of ATP when the energy demand increases and glucose is scarce, for instance, 
under the conditions of fasting or extended exercise. Maintaining a stable ATP supply in 
WAT may be critical for adipocytes to undergo active lipolysis and provide fatty acids 
for other tissues.  A drop in intracellular ATP levels by mitochondrial ETC uncouplers or 
inhibitors can decrease lipolysis induced by the adrenal hormone catecholamines (45).  
When activated, the AMP-activated protein kinase (AMPK) that senses the energy state 
determined by mitochondrial ATP production can decrease lipolysis (46). Taken together, 
these data support a mitochondrial function in WAT lipolysis. 
WAT as an Endocrine Organ 
Aside from its ability to store and mobilize energy, WAT has been recognized as 
an important endocrine organ in recent years. It has been found to secrete an array of 
hormones and cytokines called adipokines, which participate in a variety of signaling 
pathways regulating whole body energy homeostasis (4, 47). The list of adipokines has 
grown rapidly and includes leptin, adiponectin, resistin, serpin, lipocalin-2, PAI-1, RBP4, 
Zn α-2 glycoprotein, vaspin, visfatin, omentin, apelin, chemerin, TNFα, IL-6 and MCP-1 
(48).  Mitochondrial function may play a role in at least three aspects of the regulation of 
adipokine production in WAT: 1) the expression level; 2) the post-translational 
modification and folding; and 3) secretion. For example, it has been reported that 
adiponectin synthesis is induced by rosiglitazone treatment through mitochondrial 
biogenesis (49). Adiponectin exists in plasma as a multimer and requires extensive 
folding using ATP supplied by the mitochondria (50). High glucose increases adiponectin 
production and secretion in 3T3-L1 adipocytes while it decreases resistin production and 
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secretion through the overproduction of reactive oxygen species in mitochondria (51).  
Interestingly, adipokines have also been shown to target mitochondria in skeletal muscle. 
For example, apelin can induce skeletal muscle mitochondrial content (52) and 
adiponectin regulates mitochondrial bioenergetics (53). 
Mitochondrial Dysfunction in WAT and Diseases 
Defects in mitochondrial oxidative phosphorylation have been studied in many 
animal models. These include defects of nuclear-encoded components of the OXPHOS 
complexes, and factors involved in mtDNA integrity and transcription (54-55). Due to the 
embryonic lethality of such defects, most mitochondrial dysfunction transgenic models 
are tissue-specific; and the heart and skeletal muscle are the most targeted and studied 
tissues because of their high demand for energy from oxidative phosphorylation (54-55). 
However, due to the lack of WAT-specific knockout models, it is difficult to assess the 
pathological contribution of WAT mitochondrial dysfunction in diseases. Meanwhile, 
evidence shows that the adipose mitochondrial dysfunction is associated with obesity and 
diabetes (19-20, 25), but the underlying mechanisms are not yet understood. To directly 
test the cause and effect relationship between adipose mitochondrial dysfunction and 
diseases, perturbation of mitochondrial function in WAT needs to be established.   
At the in vitro level, mitochondrial dysfunction has been studied in 3T3-L1 white 
adipocytes by depleting Tfam, a crucial factor for mtDNA integrity and transcription 
(Chapter II). The depletion of Tfam causes decreased mtDNA copy number as well as 
decreased mtDNA-encoded transcripts, resulting in blunted OXPHOS function in 
adipocytes. The consequence of this manipulation is decreased insulin-stimulated glucose 
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uptake, a hallmark of insulin resistance in adipose tissue (56).  The mechanism of Tfam-
depletion induced glucose uptake impairment is not fully understood; and it appears that 
insulin activation of the Akt pathway is not inhibited by Tfam-depletion (56). It should be 
noted that the Tfam knockdown is performed during adipogenesis; therefore it might 
cause a general phenotypic change in those 3T3-L1 adipocytes. However, several 
functional assays and whole genome expression profile analysis do not support such a 
hypothesis.  For example, fat accumulation and adiponectin secretion are not affected in 
Tfam-depleted adipocytes (Figure 2-7). Less than 0.2% of total gene expression is up or 
down-regulated more than 50% and almost all the genes involved in mitochondrial 
OXPHOS and TCA cycle are not affected by Tfam-depletion (Table 4-1). Taken together, 
mitochondrial dysfunction induced by Tfam-depletion has a causative effect on insulin 
resistance in 3T3-L1 adipocytes without changing general adipogenesis. 
Although a direct WAT-specific in vivo mitochondrial dysfunction model is not 
available, many studies have shown a clear correlation between WAT mitochondrial 
dysfunction and obesity or type 2 diabetes (19-20, 25). In fact, the mitochondrial 
abundance from epididymal fat of ob/ob mice, which are genetically predisposed for 
obesity and insulin resistance, is only half of that from control mice; and rosiglitazone 
treatment, which improves the insulin sensitivity in these ob/ob mice, also triggers 
mitochondrial biogenesis in white adipocytes (25), suggesting a positive mitochondrial 
role in insulin sensitivity. A systematic gene expression comparison between control and 
two mouse models of obesity and type 2 diabetes: db/db mice and high-fat diet (HFD) fed 
mice, shows that mitochondrial biogenesis from these mice is compromised, as revealed 
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by the down-regulation of genes encoding for mitochondrial ATP production, ETC 
uncoupling, as well as those for mitochondrial ribosome proteins, membrane translocases 
and heat-shock proteins (57). Pioglitazone, another insulin sensitizer, induces 
mitochondrial biogenesis through the activation of PGC-1α and β-oxidation in 
subcutaneous fat from diabetic individuals (22). The expression of PGC-1α, a master 
inducer of mitochondrial biogenesis, is down-regulated in adipose tissue from morbidly 
obese patients (58). Taken together, the abnormal mitochondrial function in WAT is 
highly associated with the pathophysiology of obesity and type 2 diabetes. Studies with 
WAT-specific mitochondrial dysfunction model will help to clarify the in vivo cause and 
effect relationship. 
Insulin Signaling and Akt Regulation in Glucose Uptake 
Insulin Signaling Overview 
Insulin plays a central role in energy homeostasis and glucose metabolism. The 
general effect of insulin is to control blood glucose homeostasis. Specifically, insulin 
stimulates glucose uptake in muscle and adipose tissue, and stimulates anabolic processes 
to store glucose as glycogen in liver and muscle, and as triglycerides in adipose tissue. In 
addition, insulin prevents the utilization of fatty acids, inhibits lipolysis in adipose tissue 
and liver gluconeogenesis, a process that maintains blood glucose supply during fasting. 
The effects of insulin are regulated at multiple levels, from its biosynthesis, secretion 
from the pancreas, stimulation of target cells, to as well as downstream intracellular 
signal cascades. Insufficient insulin production or activity results in diabetes mellitus: 
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type 1 diabetes results from the failure of the pancreatic insulin production; and type 2 
diabetes is characterized by the inability of normal or even higher level of insulin to 
stimulate target cells. 
Intracellular insulin signaling is mediated by the insulin receptor (IR) located on 
the cell surface. The insulin receptor is a transmembrane tyrosine kinase that undergoes 
autophosphorylation/activation upon insulin binding. The secondary messengers, insulin 
receptor substrates (IRS), are then phosphorylated at specific tyrosine residues, providing 
docking sites for further downstream Src Homology 2 (SH2)-domain containing proteins. 
One such SH2-domain containing protein is phosphatidylinositol 3-kinase (PI-3K), which 
binds to the phosphorylated tyrosine residues of IRS and is activated near the cell surface. 
PI-3K catalyses the formation of phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3 
or PIP3) and the later activates 3-phosphoinositide-dependent protein kinase 1(PDK1) and 
PDK2 (also known as mammalian target of rapamycin complex 2, mTORC2), which 
phosphorylate protein kinase B (or Akt) on residue Thr308 and Ser473, respectively. In 
muscle and adipocytes, phosphorylated Akt facilitates glucose uptake by mobilizing 
glucose transporter 4 (GLUT4)-containing vesicles towards the cell membrane. The 
mechanism of PI-3K dependent GLUT4 translocation in adipocytes is believed to involve 
the activation of Akt. The establishment of a direct link between Akt kinases and GLUT4 
vesicle trafficking is largely attributed to the identification of Akt substrates AS160 and 
TBC1D1(59).  
The signaling transduction from the insulin receptor to downstream effectors is a 
complex network. Many intermediates lead to branched or parallel pathways, giving the 
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entire network more flexibility and greater complexity. For example, there are four 
closely related insulin receptor substrates (IRS-1, 2, 3, 4) in mice; each variant has a 
distinct spatial expression and substrate specificity (60). Akt not only regulates glucose 
uptake, but also participates in other cellular functions such as cell survival, glycogen 
synthesis and apoptosis (61). In addition, Akt also has multiple isoforms Akt1, Akt2 and 
Akt3, which have different physiological roles in development and disease (62). 
Insulin Signaling in Adipocyte Glucose Uptake 
In adipocytes, the most studied metabolic regulatory function of insulin is its 
potent stimulation of glucose uptake.  Glucose uptake is mediated through a solute carrier 
family of proteins, the facilitated glucose transporters (GLUT). There are currently more 
than a dozen GLUTs identified, among which GLUT1-GLUT4 are the most characterized. 
GLUT1 is expressed widely in fetal tissues and enriched in adult erythrocytes and 
endothelial cells of the blood-brain barrier. GLUT2 is expressed in renal tubular cells and 
small intestinal epithelial cells, as well as in liver and pancreatic β cells. GLUT3 is 
mostly expressed in neurons and placenta. GLUT4 is expressed in adipose tissue and 
muscle, and is the transporter that is responsive to insulin stimulation (63).  
The study of the mechanism of insulin-stimulated glucose uptake has mainly 
focused on the activation of insulin signaling transduction and the trafficking of GLUT4-
containing vesicles. The PI-3K pathway plays an important role in insulin signaling and 
glucose uptake. The activation of PI-3K results in the accumulation of PIP3, which 
recruits pleckstrin homology (PH)-domain containing proteins to the plasma membrane 
including the serine/threonine protein kinase Akt. Akt is activated through 
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phosphorylation by PDK1 and PDK2 (mTORC2) on Thr308 and Ser473 respectively and is 
proposed to play a vital role in insulin-stimulated glucose uptake. A variety of studies 
support the Akt role in glucose uptake. The dominant negative form of Akt and siRNA-
directed knockdown of Akt both inhibit insulin-stimulated glucose uptake and GLUT4 
translocation (64-66). Conversely, expression of a constitutively active form of Akt can 
mimic the insulin effect on GLUT4 translocation and glucose uptake (67-72). Finally, 
Akt2 knockout mice demonstrate traits of insulin resistance and type 2 diabetes (73-74).  
Some studies suggest that the FYVE finger containing phosphatidylinositol 3P-5 
kinase (PIKfyve) may be involved in insulin-stimulated GLUT4 translocation.  PIKfyve 
binds to phosphatidylinositol (3)-phosphate (PI3P) and catalyses the conversion of PI3P 
to PI (3, 5) P2. However the function of PIKfyve in insulin-stimulated glucose uptake is 
controversial. Over-expression of inactive PIKfyve or RNAi depletion of PIKfyve 
reduces insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes (75); but PIKfyve 
has also been shown to have a negative effect on GLUT4 translocation, as over-
expression of a PIKfyveS318A mutant in 3T3-L1 adipocytes enhances insulin-stimulated 
GLUT4 vesicle translocation to the plasma membrane (76). It is possible that PIKfyve 
changes the equilibrium of phospholipids PIP2 and PIP3, thus influencing insulin 
signaling and GLUT4 translocation, but further studies are needed. 
Another pathway may participate in insulin-stimulated glucose uptake is PI-3K 
independent, and involves the adaptor protein containing a pleckstrin homology and SH2 
domain (APS), the oncoprotein c-Cbl and CAP (c-Cbl associating protein). APS 
facilitates the tyrosine phosphorylation of c-Cbl by the insulin receptor, and GLUT4 
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translocation in 3T3-L1 adipocytes (77). However, this CAP/APS/c-Cb1 pathway in 
insulin-stimulated glucose uptake is elusive. In 3T3-L1 adipocytes, siRNA knockdown of 
TC10α, a GTPase thought to mediate CAP/APS/c-Cbl pathway, causes partial inhibition 
of insulin-stimulated glucose uptake and GLUT4 translocation (78); however knockdown 
of CAP, c-Cbl, have no effect on insulin-stimulated glucose uptake (79). APS knockout 
mice exhibit increased insulin sensitivity and hypoinsulinaemia (80); while knockout of 
c-Cbl has no effect on insulin sensitivity (81). 
The Role of Akt Substrates in Glucose Uptake 
Akt constitutes a node downstream of PI-3K for many signaling cascades, 
regulating metabolism, protein synthesis, cell growth and survival, and plays an 
important role in insulin-stimulated glucose uptake in muscle and adipose tissue. The 
missing gap between insulin stimulation of Akt and GLUT4 translocation is partially 
filled by the identification of the Akt substrates, AS160 and TBC1D1. Kane et al. 
discovered AS160 in an effort to screen insulin-stimulated phospho-proteins using an 
antibody that recognizes phosphorylated Akt substrates in 3T3-L1 adipocytes (82). 
AS160, also known as TBC1D4, contains two phosphotyrosine binding domains (PTB) 
and a Rab GTPase-activating protein (GAP) domain. Akt phosphorylates AS160 at six of 
its seven potential phosphorylation sites in vivo (82-83), suggesting a phosphorylation 
regulatory mechanism.  The phosphorylation defective mutant AS1604P, when over-
expressed in 3T3-L1 adipocytes, inhibits the insulin-stimulated membrane translocation 
of a tagged GLUT4 transporter (83).  AS160 is believed to regulate GLUT4 translocation 
through its GAP activity on related Rab proteins, a class of small GTPases. One model 
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suggests that the GAP domain of AS160 facilitates the GTP hydrolysis of active GTP-
bound Rabs and thereby inhibits their function in vesicle trafficking, thus retains GLUT4 
in the intracellular compartment, while AS160 phosphorylation by Akt serves as a 
suppressor of its GAP activity. This model is supported by the various Rab components 
of GLUT4-containing vesicles which are critical for GLUT4 translocation. Rabs are a 
large family of evolutionarily conserved small GTPases that coordinate vesicle 
trafficking (84). In humans, more than 60 Rab members have been identified (84). Rab10 
is found to be in GLUT4-containing vesicles and is a target of AS160 GAP activity; and 
the knockdown of Rab10 in adipocytes results in decreased GLUT4 translocation (85-86). 
Rab8A and Rab14 (in vitro targets of AS160) are found to be able to rescue the inhibition 
of GLUT4 translocation caused by AS1604P in L6 muscle cells (87). A systematic RNAi 
screening of the Rab family proteins in 3T3-L1 adipocytes shows that many are involved 
in insulin-stimulated glucose uptake, and have either a positive or negative effect. 
Interestingly, RNAi knockdown of many 3T3-L1 Rabs alters Akt phosphorylation by 
insulin stimulation (data not shown and Figure 4-1, A), further complicating this pathway. 
It is therefore important to distinguish both the direct and indirect involvement of Rabs in 
GLUT4 translocation.   
TBC1 domain family member 1 (TBC1D1), a GAP-containing protein related to 
AS160, is also found to be involved in insulin-stimulated GLUT4 translocation in 
adipocytes (88), but its exact role is unknown. Although TBC1D1 over-expression 
inhibits GLUT4 translocation in adipocytes (88), the knockdown of TBC1D1 has no 
effect (89), suggesting that the endogenous TBC1D1 in adipocytes has no function in 
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insulin-stimulated GLUT4 translocation. This could result from the very low expression 
levels of TBC1D1 in adipocytes. A coding variant R125W in TBC1D1 is associated with 
the predisposition of severe obesity (90-91), suggesting a role of TBC1D1 in energy 
metabolism. Subsequent work showed that TBC1D1 is a substrate that can be 
phosphorylated by AMP-activated protein kinase (AMPK) on Ser237 (89, 92).This finding 
together with the fact that TBC1D1 is expressed highly in muscle (89, 93) underscores a 
pathway through which contraction-activated AMPK signaling stimulates glucose uptake 
in skeletal muscle (94). More recently, the different mechanism of TBC1D1 in insulin-
stimulated and contraction-induced GLUT4 translocation is being revealed in more 
details (95-98). Studies suggest that insulin-stimulated phosphorylation of TBC1D1 is PI-
3K/Akt dependent; while the contraction-induced phosphorylation of TBC1D1 is AMPK 
dependent (98). Insulin regulation of TBC1D1 is similar to that of AS160, where 
TBC1D1 phosphorylation by Akt increases GLUT4 translocation (97). While insulin 
only stimulates the phosphorylation of Thr596 on TBC1D1, contraction induces the 
phosphorylation of both Ser237 and Thr596 (96).  Disruption of AMPK signaling abolishes 
both insulin and contraction-induced TBC1D1 phosphorylation (96). 
Akt Isoform Specificity  
By interacting with an array of different substrates, Akt fulfills various distinct 
functions in cells. Adding to its already versatile signaling pathways, Akt has three 
isoforms Akt1, Akt2 and Akt3. They all contain an N-terminal PH-domain that binds to 
phospholipids PIP3 or PIP2 and a C-terminal serine/threonine kinase domain. From Akt 
isoform-specific knockout mouse models, it has become clear that Akt isoforms exhibit 
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distinct but overlapping functions.  Akt1-/- mice are smaller, indicating a critical role for 
Akt1 in cell growth (99-100); Akt2-/- mice exhibit a type 2 diabetes phenotype, with 
decreased insulin sensitivity, suggesting a role for Akt2 in the glucose homeostasis (73); 
and Akt3-/- mice have impaired brain development, suggesting a major defect in neurons 
(101). Interestingly, Akt1-/-Akt3-/- or Akt1-/-Akt2-/- double knockout mice are embryonic 
lethal or die after birth (102) (103), while Akt2-/- Akt3-/- double knockout mice are viable 
(104). This shows that despite the distinct function of the three isoforms, there is 
overlapping function.  
Isoform-specific studies have provided more information about the diversity of 
Akt signaling pathways, but the mechanism of isoform specificity remains poorly 
understood.  There could be several different models to explain or contribute to the 
isoform specificity.  First, each isoform may have distinct intrinsic kinase activity on 
specific substrates; second, each isoform may have differential temporal and spatial 
distribution, such as tissue specific expression and intracellular compartmentalization; 
and third, each isoform may respond to different stimuli such as different extracellular 
environmental conditions, different ligands, or different membrane receptors. 
One prominent example of Akt isoform specificity is Akt2 in insulin-stimulated 
GLUT4 translocation and glucose uptake in adipose and muscle. In these tissues, both 
Akt1 and Akt2 are expressed, but only Akt2 appears to be crucial for insulin-stimulated 
glucose uptake. The over-expression of Akt1 fails to rescue the impaired insulin-
stimulated glucose uptake in Akt2-deficient adipocytes (105-106), arguing against Akt1 
and Akt2 having the identical function in the same tissue. This failure of rescue could 
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result from Akt1 not being properly activated. However, the extent to which the Akt 
isoforms are activated depends on what readout is used. For example, the 
phosphorylation of Thr308 and Ser473 on Akt is usually considered a prerequisite for Akt 
activation. Based on this criterion, both Akt1 and Akt2 are activated by insulin in 3T3-L1 
or primary adipocytes (106-107).  
Insulin activation of Akt is facilitated by Akt translocation to the cell membrane. 
Preferential translocation to the cell membrane may contribute to isoform specificity in 
Akt function.  In adipocytes, it has been observed that Akt2 is recruited to the cell 
membrane to a greater extent than Akt1; and the decrease in Akt2 membrane 
accumulation, but not activation, causes impaired GLUT4 translocation (106). Increasing 
the Akt1 membrane accumulation by expressing a mutant version of Akt1, Akt1E17K
 
(106), 
or a myristoylated Akt1 (67) can confer Akt2-like signaling to Akt1, resulting in GLUT4 
translocation and glucose uptake. These data suggest that the subcellular distribution, 
rather than the kinase activation, is important for isoform specificity in insulin-stimulated 
glucose uptake. Akt kinase binds to phospholipids PIP3 or PIP2, generated by PI-3K on 
the cell membrane, through its PH-domain. In fact, the PH-domain only protein PHLDA3 
can compete with Akt for PIP3 binding, therefore suppressing Akt activation and activity 
(108). The differences in membrane accumulation of Akt1 and Akt2 could be due to 
different affinities for PIP3 or PIP2 by their PH-domains. However, replacing the PH-
domain of Akt1 with that of Akt2 failed to mimic the Akt2-like insulin-stimulated 
membrane accumulation (106), suggesting that the PH-domain is not the sole determinant 
that confers isoform specificity to Akt1 and Akt2.  
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In the case of GLUT4 translocation, Akt isoform specificity might also rely on 
preferential association with its intracellular target.  Biochemical separation of cellular 
fractionation in adipocytes shows that Akt2, but not Akt1, is associated with GLUT4-
containing vesicles after insulin stimulation (109-110). The preferential association could 
also occur between Akt kinase and its substrates. The most characterized Akt substrate 
mediating insulin signaling and GLUT4 translocation is AS160. RNAi depletion of Akt2 
but not Akt1, has a strong effect on insulin-stimulated AS160 phosphorylation in 
adipocytes (106) and muscle (111). It appears that only Akt2 co-localizes with AS160 at 
the cell membrane with insulin stimulation (106).  Two other proteins Myosin 5a and 
syntaxin interacting protein (Synip) were also reported to be important for insulin-
stimulated glucose uptake, modulating GLUT4 vesicle translocation, and membrane 
docking and fusion, respectively. Both Myosin 5a and Synip appear to be Akt2-specific 
substrates (112-113). The mechanism of Akt specificity on substrate is poorly understood. 
One possibility is that Akt isoforms have distinct intrinsic kinase activity on specific 
substrates. This is supported by our own observation that HA-Akt1 has a stronger 
phosphorylation activity than HA-Akt2 on a GSK-3α/β peptide in an in vitro kinase assay 
(Figure A-2, B). However, the kinase and substrate interaction in vivo is subjected to 
additional spatial and accessibility limitation, therefore may exhibit extra levels of 
regulation. 
Several studies provide evidence showing that the endosomes are involved in the 
Akt isoform and substrate specificity. Adaptor protein containing PH-domain, PTB 
domain, and leucine zipper motif 1 (APPL1), an endosomal protein, was reported to 
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physically associate with Akt2 in a complex and can be reciprocally co-
immunoprecipitated (114-115). In zebrafish, Akt was found to specifically co-localize 
with its substrate GSK-3β but not TSC2 in APPL1-containing endosomes (116). We 
recently showed that Akt2, but not Akt1, co-localizes with WDFY2 (WD40 and FYVE 
domain containing protein 2)-containing endosomes and that RNAi depletion of WDFY2 
decreases the protein level of Akt2 but not Akt1 (Chapter III). Since endosomes are 
highly dynamic organelles, the involvement of endosomes in the regulation of Akt 
isoforms brings about a new level of flexibility and complexity. 
Recent studies imply that the two phosphorylation sites of Akt, Thr308 and Ser473 
(numbered as for Akt1), may actually determine substrate specificity. mTORC2 was 
identified as the kinase that phosphorylates Akt at Ser473 (117). Disruption of mTORC2 
ablates the phosphorylation of Ser473 but not Thr308, and Akt phosphorylation of 
FOXO1/3α, but not GSK-3 or TSC2 (118-119).  These data suggest that phosphorylation 
of Akt Ser473 is only required for Akt to phosphorylate certain substrates. Additionally, 
the levels of PTEN (phosphatase and tensin homolog) protein modulate Akt 
phosphorylation on Ser473, but not on Thr308 (120). Functionally, the level of AKT 
phosphorylation on Thr308, but not on Ser473 is associated with high-risk cytogenetics and 
predicts poor overall survival in acute myeloid leukaemia (121). Although it is not fully 
understood when or how Akt1 and Akt2 are differentially phosphorylated at Thr308 and/or 
Ser473, the hypothesis that Akt1 and Akt2 acquire substrate and functional specificity 
through their own differential phosphorylation status of Thr308 and/or Ser473 is tempting. 
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AktT308A and AktS473A phospho-defective transgenic animal models will help to elucidate 
the distinct Akt functions determined by site-specific phosphorylation.  
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Protein Synthesis Regulation by Insulin 
This section of introduction is to provide some background related to protein 
synthesis and its regulation by insulin. It helps to understand the work described in the 
Appendix, which does not constitute a complete result chapter. 
Protein Synthesis 
Protein biosynthesis begins with the transcription of DNA into an mRNA 
template, followed by translation of the mRNA into a protein, which can then be post-
translationally modified and delivered to its appropriate intracellular locations. 
Translation of mRNA into protein consists of three steps: initiation, elongation and 
termination, all of which are subjected to regulation.  In the initiation stage, the 40S small 
subunit of the ribosome binds to the 5’ end of the mRNA with the help of other protein 
factors called initiation factors (IFs). The 60S large subunit of the ribosome then binds to 
the initiation complex. Once translation is initiated, the transfer RNA (tRNA) carries the 
appropriate amino acid to the site of polypeptide elongation. Another set of proteins 
called elongation factors (EFs) participate in this process to ensure the continuation of the 
amino acid addition to the nascent polypeptide chain. Once the translational machinery 
reaches the stop codon, the translation is stopped through a termination process, during 
which release factors (RFs) recognize the stop codon and facilitate the termination of 
translation and release of the protein from the last tRNA. 
Insulin Regulation of Protein Synthesis 
Insulin stimulates protein translation in cells and tissues with either a rapid or 
long-term effect. The rapid effect involves fast activation of existing translational 
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machinery while the long-term effect functions through increased protein synthesis 
capacity, including an increase in the number of ribosome. This insulin regulation of 
protein synthesis is mediated through a series of phosphorylation events downstream of 
PI-3K/Akt.  
mTOR and Its Regulation in Protein Synthesis by Insulin 
The kinase mammalian target of rapamycin (mTOR) plays an important role in 
insulin-stimulated protein synthesis. mTOR forms two functionally distinct complexes, 
mTORC1 and mTORC2, with distinct partners. mTORC1, containing Raptor, is the 
major complex involved in insulin-stimulated protein synthesis. mTORC2, containing 
Rictor, is rapamycin-insensitive and is the kinase that phosphorylates Akt on Ser473.  
mTORC1 regulates insulin-stimulated protein synthesis through two parallel pathways. 
One pathway is through p70 S6K and the other is through eIF4E binding protein 1 (4E-
BP1); both S6K and 4E-BP1 are direct targets of mTORC1. Phosphorylation of S6K by 
mTORC1 activates S6K kinase activity. The first S6K substrate to be discovered is the 
ribosomal protein S6 (rpS6). However the effect of rpS6 phosphorylation on protein 
synthesis and cell size control seems elusive (122). Mice with a phospho-defective 
version of rpS6 show increased protein synthesis in mouse embryonic fibroblasts (MEF) 
despite the fact that those MEFs are smaller (122). Since rpS6 is not the only S6K 
substrate involved in protein synthesis, the net effect of S6K activation by mTORC1 is 
not solely determined by rpS6. Among the nine known S6K substrates (123), eIF4B and 
eEF2K play a positive role in protein synthesis when phosphorylated by S6K. 4E-BP1 
interacts with and blocks eukaryotic initiation factor 4E (eIF4E) association with eIF4G 
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to form initiation complexes. mTORC1, upon activation by insulin, phosphorylates 4E-
BP1 and leads to its release from eIF4E, thus enhancing the formation of initiation 
complex and protein synthesis. It is worth noting that mTOR signaling is also activated 
by amino acids largely independent of PI-3K (124). Thus mTOR integrates different 
stimuli including growth factors, such as insulin and IGF-1, and nutrients, such as amino 
acids and energy to regulate protein synthesis.  
 The mechanism of insulin activation of mTORC1 signaling is believed to be 
mediated by Akt phosphorylation of the tuberous sclerosis complex (TSC) (125). The 
TSC is a tumor suppressor and consists of TSC1 and TSC2, which work together as a 
functional complex. TSC2 contains a GAP domain that acts on the small GTPase, Rheb 
(126). The activation of mTORC1 activity by Rheb is GTP-dependent; and the TSC2 
GAP activity promotes the hydrolysis of Rheb-GTP, thus inhibiting Rheb activation of 
mTORC1 (127). TSC2 is a direct Akt substrate and its phosphorylation by Akt disrupts 
the functional TSC2/TSC1 complex, leading to the de-repression of Rheb and mTORC1 
signaling (128). Thus, insulin regulates protein synthesis through modulating mTORC1 
activity, linked by Akt, TSC2/TSC1 and Rheb.  
Eukaryotic Initiation Factor Regulation by Insulin 
Protein synthesis initiation starts with the tRNAmet joining the ribosome at the 
start codon facilitated by eukaryotic initiation factor 2 (eIF2). eIF2 forms a ternary 
complex with GTP and tRNAmet  before joining the 40S ribosome to form a 43S 
preinitiation  complex. During initiation, the eIF2 GTP is hydrolyzed and the GDP-bound 
eIF2 is then release and renewed by a GDP/GTP exchange factor, eIF2B, which is 
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suppressed by GSK-3 kinase (129). Insulin activates translational initiation by inhibiting 
GSK-3 kinase activity, which in turn dephosphorylates and activates eIF2B (129-130).  
GSK-3 kinase inactivation is mediated by Akt phosphorylation, elicited by insulin/PI-3K 
signaling activation. eIF2 is also regulated by phosphorylation. The phosphorylation of 
eIF2 by any one of the four mammalian eIF2 kinases impairs the GTP-eIF2 recycling and 
translational initiation (131). 
Eukaryotic initiation factor 4B (eIF4B) lacks catalytic activity and acts as a 
cofactor of eukaryotic initiation factor 4A (eIF4A), which is an RNA helicase that 
unwinds mRNA secondary structure (132). It has been shown that S6K kinases 
phosphorylate eIF4B on Ser422 and that an alanine substitution for Ser422 decreases 
translation activity in vivo (133). The phosphorylation of eIF4B Ser422 by S6K can be 
induced by insulin or mitogen in a rapamycin sensitive manner (134); and this 
phosphorylation is required for the assembly of the translation preinitiation complex 
(135).  
Eukaryotic Elongation Factor Regulation by Insulin 
The eukaryotic protein translation elongation requires two eukaryotic elongation 
factors (eEF), eEF1 and eEF2. eEF1 is a macromolecule composed of two components: 
eEF1A and eEF1B. eEF1A, a GTPase, carries the aminoacyl-tRNA to the A site of the 
ribosome when in the active GTP-bound state. Upon anti-codon recognition and GTP 
hydrolysis, GDP-bound eEF1A is released and regenerated to the GTP-bound active form 
by the guanine nucleotide exchange factor (GEF), eEF1B. There are three subunits in 
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eEF1B, namely eEF1Bα, eEF1Bδ and eEF1Bγ.  While eEF1Bα and eEF1Bδ have GEF 
activity, eEF1Bγ seems to only have a structural role.  
eEF1 was first reported to be phosphorylated in response to phorbol ester PMA 
(136), a protein kinase C (PKC) activator, or directly by PKC (137); and the 
phosphorylation enhances the eEF1 GDP/GTP exchange activity (138). Later, it was 
found that insulin-stimulated phosphorylation of eEF1 enhanced its elongation activity in 
3T3-L1 adipocytes, and this stimulation appeared to be mediated primarily by the 
multipotential S6 kinase (139). We recently found that Akt phosphorylates eEF1A on 
Thr269 and Thr432 in vitro; and these two phosphorylation sites seem to affect the stability 
of eEF1A (Appendix). In all cases, insulin acts as an upstream stimulus of eEF1 
phosphorylation, based on its capability to activate PKC, S6K and Akt.  However, 
regulation of protein synthesis through insulin-stimulated eEF1 phosphorylation has not 
been clearly established. 
eEF2 is a translocase that moves the ribosome along the mRNA by three 
nucleotides during each protein synthesis elongation cycle. The continuation of peptide 
elongation is coordinated by the alternate binding of eEF1 and eEF2 to the ribosome, 
with eEF1 recruiting one aminoacyl-tRNA to the ribosome to form a new peptide bond, 
and eEF2 moving the ribosome to the next codon.  Phosphorylation of eEF2 impairs its 
ability to bind to the ribosome and thus decreases its elongation activity (140).  eEF2 is 
phosphorylated by the Ca2+/CaM-dependent kinase eEF2K, which itself can be inhibited 
by phosphorylation. Insulin causes a decrease in eEF2K activity, resulting in 
dephosphorylation of eEF2, and an increased eEF2 activity and accelerated elongation 
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(141).   mTOR signaling is involved in insulin-stimulated inactivation of eEF2K. This 
mTOR-dependent signaling phosphorylates eEF2K on at least three sites, Ser366, Ser359 
and Ser78 (142-144). S6K1, a direct target of mTORC1, phosphorylates eEF2K 
Ser366(142), but the kinase(s) responsible for phosphorylation of Ser359 and Ser78 is not yet 
known. It is possible that insulin-activated kinases phosphorylate eEF2K on the other 
sites and therefore regulate eEF2 activity and translation elongation.  
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Rationales and Study Aims 
1. WAT Mitochondrial Dysfunction and Insulin Resistance 
The strong association between impaired mitochondrial function in white adipose 
tissue and insulin resistance in diabetes (20, 57) raises the question of whether the WAT 
mitochondrial dysfunction is a contributor to or just a secondary effect of insulin 
resistance. To answer this cause and effect question, we decided to directly introduce 
mitochondrial dysfunction into white adipocytes and to investigate its effect on insulin 
sensitivity. The mitochondrial DNA transcription factor Tfam is critical for mtDNA 
transcription and replication. We hypothesized that the depletion of Tfam would 
specifically interfere with mtDNA and its encoded gene expressions, which are key 
components of the electron transport chain complexes; and this manipulation would 
enable us to directly investigate the effect of mitochondrial dysfunction on insulin 
sensitivity in adipocytes. 
2. Isoform-specific Regulation of Akt Signaling  
The existence of three Akt isoforms and their overlapping but distinct functions in 
cells raises an important question of how Akt isoform specificity is achieved. In 3T3-L1 
adipocytes, two isoforms of Akt, Akt1 and Akt2 are expressed, but only Akt2 plays a 
central role in insulin regulated glucose metabolism. Endocytic pathways are involved in 
modulating signal transduction (145); and endosomal protein may regulate Akt substrate 
specificity (116). Previously our lab has identified an endosomal protein WDFY2 in a 
distinct set of endosomes (146). We investigated whether WDFY2 plays a role in 
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determining Akt1 and Akt2 isoform specificity in glucose uptake and the insulin 
signaling pathway. 
3. Identification of a Akt substrate and Its Implication in Protein Synthesis and 
Cell Growth (Appendix) 
Akt plays such a pluripotent role in signal transduction that the identification of 
its many substrates will help to elucidate its signaling pathways controlling certain 
physiological functions. The availability of PAS antibody, which recognizes a 
phosphorylated serine or threonine in an optimal motif RXRXXp(S/T), where R 
represents arginine and X any amino acid, enables us to identify potential Akt substrates. 
We identified the eukaryotic elongation factor 1a (eEF1A) as a PAS recognizable 
phospho-protein elicited by insulin treatment in 3T3-L1 adipocytes. Akt phosphorylation 
of eEF1A was confirmed in vitro and two phosphorylation sites were determined. The 
exact role of the eEF1A phosphorylation in protein synthesis and cell growth needs to be 
determined. 
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CHAPTER II 
PARADOXICAL EFFECT OF MITOCHONDRIAL 
RESPIRATORY CHAIN IMPAIRMENT ON INSULIN SIGNALING 
AND GLUCOSE TRANSPORT IN ADIPOSE CELLS 
This chapter is in the format that it was published in the J Biol Chem. 
2008;283(45):30658-67, as written by the authors, Shi X, Burkart A, Nicoloro SM, 
Czech MP, Straubhaar J and Corvera S. 
 
Sarah Nicoloro processed the samples for Affymetrix GeneChip analysis 
described in this chapter. Juerg Straubhaar analyzed the GeneChip data and generated a 
searchable database. Alison Burkart provided 3T3-L1 preadipocytes. The fluorescence 
activated cell sorting (FACS) experiments were performed with assistance from the flow 
cytometry core facility at University of Massachusetts Medical School. Silvia Corvera 
and I were responsible for designing and performing all the other experiments described 
in this chapter. 
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Abstract 
Adipocyte function is crucial for the control of whole body energy homeostasis. 
Pathway analysis of differentiating 3T3-L1 adipocytes reveals that major metabolic 
pathways induced during differentiation involve mitochondrial function. However, it is 
not clear why differentiated white adipocytes require enhanced respiratory chain activity 
relative to preadipocytes. To address this question, we used small interference RNA to 
interfere with the induction of the transcription factor Tfam, which is highly induced 
between days 2 and 4 of differentiation and is crucial for replication of mitochondrial 
DNA. Interference with Tfam resulted in cells with decreased respiratory chain capacity, 
reflected by decreased basal oxygen consumption, and decreased mitochondrial ATP 
synthesis, but no difference in many other adipocyte functions or expression levels of 
adipose-specific genes. However, insulin-stimulated GLUT4 translocation to the cell 
surface and subsequent glucose transport are impaired in Tfam knockdown cells. 
Paradoxically, insulin-stimulated Akt phosphorylation is significantly enhanced in these 
cells. These studies reveal independent links between mitochondrial function, insulin 
signaling, and glucose transport, in which impaired respiratory chain activity enhances 
insulin signaling to Akt phosphorylation, but impairs GLUT4 translocation. These results 
indicate that mitochondrial respiratory chain dysfunction in adipocytes can cause 
impaired insulin responsiveness of GLUT4 translocation by a mechanism downstream of 
the Akt protein kinase.  
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Introduction 
A large body of evidence has pointed to a close relationship between ectopic fat 
accumulation in tissues such as muscle and liver and the development of insulin 
resistance (147-149). The primary defense against such ectopic lipid accumulation is a 
well functioning adipose tissue, capable of sequestering excess calories in the form of 
stored triglycerides (150). In addition to this crucial role, adipose tissue is an endocrine 
organ that controls whole body energy homeostasis by secreting multiple cytokines that 
signal to other tissues (151-152). The central role of adipose tissue in energy homeostasis 
is underscored by recent findings indicating that adipose tissue is a primary locus for the 
alterations induced by caloric restriction that accompany longevity (153-154). Thus, the 
cell biological mechanism involved in optimal adipose tissue development and function 
are crucial for the control of whole organism energy homeostasis and the determination 
of life span.  
Adipocyte differentiation is accompanied by an expansion of mitochondrial mass 
(17, 26),but the functional role of the relatively high levels of mitochondria in white 
adipocytes compared with those in adipose stroma and other tissues is not clear. High 
mitochondria levels may be required for the support of adipocyte-specific ATP-requiring 
processes (155), or to support metabolic functions such as glyceroneogenesis, which is 
required for triglyceride deposition (40, 156). White adipocyte mitochondria levels in 
rodents and humans change markedly under different physiological conditions, including 
obesity, weight loss, aging, treatment with anti-diabetic agents, and in response to genetic 
alterations in insulin receptor number (16-27). Mitochondrial levels correlate with insulin 
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sensitivity, where decreased mitochondrial content correlates with diminished insulin 
responsiveness, and enhanced mitochondrial mass associates with increased insulin 
sensitivity. However, given the complexity of whole animal models, a cause-effect 
relationship between mitochondrial mass and insulin sensitivity in adipocytes has not 
been established.  
Mitochondrial biogenesis depends on a coordinated interaction between nuclear 
and mitochondrial genomes (157-159). The vast majority of mitochondrial proteins are 
produced from ∼1500 different nuclear localized genes. In contrast, the mitochondrial 
genome produces only 13 proteins, but among these are key components of the 
respiratory chain. The replication and transcription of the mitochondrial genome is 
absolutely dependent on Tfam, a transcription factor encoded in nuclear DNA (31, 160). 
Tfam is critical for mitochondrial biogenesis during development and for the 
maintenance of mitochondrial DNA copy number in mature tissues.  
To directly determine the functional role of mitochondrial biogenesis in 
differentiated adipocytes, we have used siRNA to silence Tfam during the differentiation 
process. This manipulation results in the generation of adipocytes that contain only 
double the mitochondrial levels of preadipocytes. Analysis of these cells reveals a 
specific impairment in insulin-stimulated glucose transport, which occurs distal to early 
insulin signal transduction events. These results point to a previously unknown 
interaction between the mitochondrial respiratory chain and insulin sensitivity of the 
glucose transport pathway and provides evidence that mitochondrial dysfunction could be 
a primary cause of insulin resistance in adipose cells.  
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Experimental Procedures 
Materials 
Real-time PCR primers were designed using the Primer Bank 
(pga.mgh.harvard.edu/primerbank/index.html). All the PCR primers were synthesized by 
Operon. Primer sequences are available upon request. Rabbit anti-Tfam antibody was 
purchased from Aviva Systems Biology; goat anti-Glut4 antibody was from Santa Cruz 
Biotechnology (Santa Cruz, CA); rabbit anti-Acrp30/adiponectin antibody was from 
Affinity Bioreagents, Inc.; mouse anti-phospho-Akt and anti-Akt antibodies, and rabbit 
PAS antibodies (cat # 9611 and #9614, mixed 1:1 and used with a 1:1000 dilution) were 
from Cell Signaling; mouse anti-phosphotyrosine antibody was from Upstate; and mouse 
anti-β-Actin antibody was from Sigma.  
Cells Culture and Differentiation 
3T3-L1 preadipocytes were maintained in Dulbecco's modified Eagle's medium 
supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml 
streptomycin in an atmosphere of 10% CO2 at 37 °C (complete medium). Three days 
post-confluence (day 0), cells were induced to differentiate by adding a hormone mixture 
(0.5 mM 3-isobutyl-1-methylxanthine, 1 µm dexamethasone, and 5 µg/ml insulin). 72 
hours later, the differentiation medium was replaced by complete medium, which was 
replaced every 48 hours until analysis.  
Transfection of siRNA 
siRNA against mouse Tfam mRNA was purchased from Dharmacon in a duplex 
form with 3′-dTdT protective overhangs (sense sequence is 5′-GAAUGUGGAUCGUG-
CUAAAdTdT-3′). At day 2 of differentiation, medium was collected and cells were 
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trypsinized and transfected with Tfam or scrambled siRNA by electroporation. Briefly, 5 
nmol of siRNA was used for each 150-mm plate of cells in a 0.4-cm GenePulser® 
cuvette. After electroporation (180 V, 950 microfarads), cells were resuspended in the 
collected day 2 medium and re-plated to 6-, 12-, or 24-well plates according to the 
experiment. 24 hours later, the differentiation medium was replaced by complete medium 
and the medium was refreshed every 2 days afterward.  
Quantitative RT-PCR 
Total RNA were extracted with TRIzol® Reagent. After RNase-free DNase I 
digestion, RNA was purified with a Qiagen RNeasy® MinElute™ cleanup kit. The 
purified RNA was then used to synthesize cDNA (iScript™ cDNA Synthesis Kit). Real-
time PCR was performed with iQ™ SYBR® Green Supermix on MyiQ single-color real-
time PCR detection system from Bio-Rad. The 2-∆∆CT method was used to analyze the 
relative mRNA level. Ferritin heavy chain mRNA was used as the internal control.  
Cell Lysate Preparation and Western blot 
Cells were lysed in a buffer composed of 300 mM NaCl, 20 mM NaF, 1 mM 
NaPPi, 10 mM HEPES, pH 7.4, 1% SDS, and protease inhibitors. 20 µg of cell lysate was 
resolved on 10% or 15% SDS-PAGE and transferred to nitrocellulose membrane. The 
blots were blocked with 5% fat-free milk in TBST and incubated with primary antibodies 
at 4 °C over night. After three washes with TBST and incubation with secondary 
antibody, the blot was detected by enhanced chemiluminescence (PerkinElmer Life 
Sciences) and exposure to film.  
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2-Deoxyglucose Uptake and 3-O-Methylglucose Uptake 
 Glucose transport was determined by measuring 2-deoxyglucose uptake in a 24-
well plate. After 2-hours serum starvation in Krebs-Ringer HEPES (KRH) buffer (130 
mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.3 mM MgSO4, and 25 mM HEPES, pH 7.4, 
supplemented with 0.5% BSA, and 2 mM sodium pyruvate), the adipocytes were 
stimulated by insulin for 30 minutes. Glucose uptake was initiated by addition of [1,2-
3H]2-Deoxy-D-glucose to a final assay concentration of 100 µm for 5 minutes at 37 °C. 
After three washes with ice-cold phosphate-buffered saline (PBS), the cells were lysed 
with 0.4 ml of 1% Triton X-100. The 3H was then determined by scintillation counting. 
Nonspecific 2-deoxyglucose uptake was measured in the presence of 20 µm cytochalasin 
B and subtracted from each determination. 3-O-Methylglucose uptake was carried out in 
a similar way with the following differences: instead of 2-deoxyglucose, the 3-O-[methyl-
14C]-D-glucose was added to the cells to 35.4 µm and allowed to be incubated for 60 s. 
Cells were then washed three times with cold PBS plus 1 mM HgCl2.  
Mitochondrial Staining and Flow Cytometry 
Cells were trypsinized and incubated in KRH buffer without or with 100 nM 
MitoTracker® GreenFM for 30 minutes at 37 °C. 1 × 106 cells were then resuspended in 1 
ml of ice-cold phosphate-buffered saline with 0.5% BSA and analyzed on an LSR II 
cytometer analyzer (BD Biosciences). Data were gated using non-stained cells to 
represent MitoTracker® GreenFM staining.  
Mitochondrial DNA Measurement 
Total DNA was extracted by DNeasy® tissue kit. Primer pairs corresponding to 
Nd1 (mitochondrial) and Actb (nuclear) were used to amplify a mitochondrial and 
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nuclear DNA fragment, respectively. The 2-∆∆CT method was used to analyze the relative 
mtDNA level.  
Oxygen Consumption Assay 
The oxygen consumption was measured using live intact cells with BD™ Oxygen 
Biosensor System. Cells (500,000 cells/ml) were suspended in KRH buffer supplemented 
with 0.5% BSA and 2 mM pyruvate. 150 µl of cell suspension was added to triplicate 
wells in an Oxygen Biosensor System 96-well plate. Fluorescence signal was read using a 
TECAN Safire2 microplate reader continuously every 2 minutes at 37 °C. Oxygen 
concentration was calculated from the fluorescence intensity according to the 
manufacturer's instructions.  
Intracellular and Dynamic ATP Measurement 
ATP level was measured using a CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega, Madison, WI). Equal numbers of control or knockdown cells were 
trypsinized and incubated in an opaque 96-well plate in six replicates for 1 hour. 100 µl 
of the reaction reagent was directly added to each well, and after 10 minutes the 
luminescence signal was detected using a microplate reader. To measure ATP synthesis 
dynamically, cells were first suspended in respiration buffer (0.1% BSA, 75 mM 
mannitol, 25 mM sucrose 100 mM KCl, 10 mM KH2PO4, 5 mM MgCl2, 20 mM, Tris, pH 
7.5, 106 cells/ml), and 10 µg/ml digitonin was added for 5 minutes. Digitonin was 
removed by resuspending the permeabilized cell in the same volume of respiration buffer. 
Vehicle or 10 µg/ml oligomycin was added and mixed well by gentle inverting. 100 µl of 
cell suspension were then transferred to wells of a 96-well plate, which contained 
substrates (1 mM ADP and 10 mM succinate final concentration) for different time 
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periods. ATP synthesis was stopped by adding 100 µl of CellTiter-Glo® reagent and 
luminescence was read using a Safire2 microplate reader. ATP synthesized from 
mitochondria was derived by subtracting the oligomycin-treated reading from those 
untreated.  
Reactive Oxygen Species Measurement 
Cells were seeded to a 24-well plate in medium without phenol red, and incubated 
without or with 50 ng/ml TNFα for 3 hours. Following two washes with PBS, cells were 
incubated with 10 µm 5-(and 6-)chloromethyl-2′,7′-dichlorodihydroflioresceindiacetate, 
acetyl ester (CM-H2DCFDA) (Invitrogen) in Krebs-Ringer bicarbonate buffer for 15 
minutes at 37 °C. The fluorescent signal was read at excitation of 485 nm and emission of 
530 nm in a microplate reader.  
Triglyceride Content Measurement 
Cells in 6-well multiwell dishes were scrapped into 200 µl of PBS and sonicated 
for 20 s on ice. The lysate was subject to total glycerol determination using a Serum 
Triglyceride Determination Kit (Sigma, TR0100). Briefly, 10 µl of lysate or standard was 
mixed with 1 ml of Triglyceride Working Reagent and incubated for 30 minutes at 37 °C. 
The absorbance was read at 540 nm, and glycerol concentration was then calculated from 
the standard curve.  
Oil Red O Staining for Lipids 
Cells were washed with PBS twice and fixed in 4% formaldehyde for 1 hour at 
room temperature. After three washes with water, the cells were incubated with 5 mg/ml 
Oil Red O in 60% triethyl phosphate for 30 minutes. Cells were then washed with water 
at least six times before imaging.  
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Total Internal Reflection Fluorescence Microscopy 
Cells seeded on coverslips were serum-starved for 2 hours in KRH buffer 
supplemented with 0.5% BSA and 2 mM pyruvate and were then stimulated by 0, 0.1, or 
1 µm insulin for 30 minutes. Cells were fixed in 4% paraformaldehyde for 15 minutes at 
room temperature, permeabilized with 0.5% Triton X-100 plus 1% fetal bovine serum in 
PBS, and stained with goat anti-GLUT4 (1:200) antibodies overnight at 4 °C. Alexa 
Fluor® 488 donkey anti-goat secondary antibodies were used to detect bound primary 
antibody. TIRF images were taken for 10 random fields from each coverslip. Background 
areas containing no cells were used to threshold the images, and the total fluorescence 
intensity of the whole area was then obtained.  
Affymetrix GeneChip Expression Analysis 
Total RNA was prepared from three 150-mm dishes of 3T3-L1 cells at each day 
of differentiation. Affymetrix protocols were followed for the preparation of cRNA from 
total RNA, which was hybridized according to Affymetrix instructions to a MOE430-2 
Chips. The GeneChips were washed with a GeneChip Fluidics Station 400 and were 
scanned with an HP GeneArrayScanner (Affymetrix). Raw expression data were 
analyzed with the Bioconductor statistical environment using RMA and MAS5, a 
Bioconductor implementation of the MAS 5.0 algorithm (Affymetrix). The “-fold change” 
for each gene was determined by dividing the mean of the average difference from three 
independent experiments.  
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Results 
Mitochondrial Gene Expression and Insulin Responsiveness 
Previously we have found that differentiation of 3T3-L1 adipocytes is 
accompanied by increased mitochondrial biogenesis, assessed primarily by mass 
spectrometry of peptides increased during adipogenesis (26). A more in-depth analysis of 
Affymetrix databases obtained from 3T3-L1 cells at different days during differentiation 
reveals that a marked increase in expression of mitochondrial genes occurs between days 
2 and 4 of differentiation. This is the period at which the most pronounced changes in 
gene expression occur, evidenced by the many changes in both non-mitochondrial and 
mitochondrial transcripts (Table 2-1). Of all transcripts changed between days 2 and 4 of 
differentiation, approximately half were increased and half decreased (2229 increased, 
1888 decreased by >1.25-fold between days 0 and 6 of differentiation). In contrast, of the 
transcripts identified by the gene ontology term “mitochondrion,” many more were 
increased than decreased in the same interval (435 increased, 37 decreased by >1.25-fold). 
The overrepresentation of mitochondrial genes in the pool of genes that increased during 
differentiation was also seen when only high abundance (i.e. signals > 1500) genes 
undergoing changes of >1.5-fold were counted (Table 2-1, lower half). Their high 
representation is also reflected when the numerical averages of all observed changes are 
plotted (Figure 2-1, A). The predominant increase in mitochondrial gene expression 
occurs between days 2 and 4 of differentiation and is stable thereafter (Figure 2-1, A). 
The relevance of mitochondrial gene expression during adipocyte differentiation is 
underscored by pathway analysis using the Kyoto Encyclopedia of Genes and Genomes 
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(161). The top 20 pathways that are highly enriched in genes that increase during 
adipocyte differentiation are shown in Table 2-2; 14 of these pathways, including the top 
5, are mitochondrial metabolic pathways.  
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Table 2-1 Number of probes displaying changes at specific interval during 
differentiation 
 
 
  
Table 2-2 Top 20 Kyoto Encyclopedia of Gene and Genome (KEGG) pathways 
enriched for genes that increase between days 0 and 6 of differentiation 
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The pronounced changes in expression of mitochondrial proteins could produce 
mitochondrial remodeling, without necessarily requiring mitochondrial biogenesis, 
understood here as a process of expansion of mitochondrial mass and mitochondrial DNA 
copy number. Nevertheless, a significant increase in mitochondrial DNA did occur 
between days 2 and 4 of differentiation (Figure 2-1, B). Importantly, this increase 
coincided with the differentiation-dependent induction of insulin responsiveness, as seen 
by the magnitude of the effect of insulin on the stimulation of glucose transport at 
different days of differentiation (Figure 2-1, C). Mitochondrial DNA replication requires 
the transcription factor Tfam, and indeed Tfam mRNA increased significantly between 
days 2 and 4 of differentiation (Figure 2-1, D). Interestingly, although the levels of 
mitochondrial DNA remained high after day 4 of differentiation, Tfam levels decreased, 
suggesting that the maintenance of mitochondrial DNA in these cells is not sensitive to 
Tfam levels over this short time period. These results also suggest that interference with 
Tfam induction prior to day 4 of differentiation could produce cells harboring a selective 
impairment in those mitochondrial functions dependent on mitochondrial DNA-encoded 
transcripts.  
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Figure 2-1  Changes in mitochondrial gene expression during 3T3-L1 adipogenesis 
(A), “All probes” refers to those detected with the MOE430-2 Affymetrix GeneChip, with 
a signal > 50. “Mito Probes” refers to probes annotated with gene ontology cellular 
component term “mitochondrion” retrieved directly from the Affymetrix website. Plotted 
are the average of all -fold increases and decreases in probe signal between the days of 
differentiation indicated on the abscissa. (B), total DNA was extracted at the days 
indicated on the abscissa. Mitochondrial DNA (mtDNA) copy number was determined by 
qRT-PCR taking nuclear DNA as internal control and expressed as -fold change over day 
0 of differentiation. (C), the uptake of 2-deoxyglucose was measured after 30 minutes of 
incubation with the indicated concentrations of insulin at the times of differentiation 
indicated. Points represent means, and lines ±S.E. of two independent experiments 
performed in triplicate. (D), Tfam mRNA expression determined by qRT-PCR, using 
ferritin mRNA as internal control and expressed as -fold change over day 0 of 
differentiation.  
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Tfam-depletion and Impaired Respiratory Chain Function 
The effectiveness of Tfam knockdown by siRNA oligonucleotides, introduced on 
day 2 of differentiation, was evaluated by measuring both mRNA and protein levels at 
day 5 of differentiation. Compared with cells electroporated with scrambled control 
oligonucleotides, Tfam knockdown cells displayed an 80% reduction in Tfam mRNA 
(Figure 2-2, A). Tfam protein levels, evaluated by western blot, were concomitantly 
reduced by ∼70% (Figure 2-2, B). Tfam knockdown led to a 30% decrease in mtDNA 
copy number compared with cells electroporated with scrambled control oligonucleotides 
(Figure 2-2, C). Thus, whereas in control cells mtDNA increased by ∼2-fold from days 2 
to 5, in the Tfam knockdown cell mtDNA increased by only ∼33% (Figure 2-2, D). 
Consistent with our observation that Tfam does not appear to be absolutely required for 
maintenance of mtDNA in these cells over the period of time studied, mtDNA was not 
reduced when Tfam siRNA was introduced at day 6 of differentiation and mtDNA copy 
number measured at day 9 (data not shown) 
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Figure 2-2  Inhibition of Tfam induction and mtDNA amplification 
Cells were transfected with scrambled (Scr) or Tfam-directed (siTfam) siRNA 
oligonucleotides at day 2 of differentiation. 72 hours later: (A), Tfam mRNA levels were 
determined by qRT-PCR. (B), Tfam protein levels were analyzed by western blot and 
densitometry. Actin levels are included as a loading control. (C), mtDNA copy number 
was assessed relative to nuclear DNA. (D), comparison of mtDNA increase from the time 
of transfection (day 2) to day 5, in cells transfected with scrambled or Tfam-directed 
siRNA oligonucleotides. *, p < 0.05 relative to Scr, using two-tailed paired Student t tests 
with a minimum of three independent experiments. 
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Because transcripts from mtDNA might be expected to have different lifetimes 
than mtDNA itself, we tested the effect of siRNA against Tfam on genes encoded by 
mtDNA. Nd1, Cytb, Cox1, and Atp6 encode for polypeptides that form part of 
respiratory chain complexes I, III, IV, and V, respectively. The levels of all four of these 
transcripts were reduced by ∼30% in cells transfected with siRNA against Tfam 
compared with scrambled control (Figure 2-3, A). We then investigated if the reduced 
mtDNA expression of these subunits had a functional effect on electron transport. 
Oxygen is consumed in the end step of the respiratory chain. Thus, the rate of oxygen 
consumption provides a global estimate of the functionality of the entire respiratory chain. 
Oxygen consumption can be measured in 96-well multiwell plates using the BD™ 
Oxygen Biosensor System, in which the quenching by ambient oxygen of a fluorophore 
embedded on the bottom of the well is measured continuously in a fluorescence 
microplate reader. Figure 2-3, B illustrates the typical readout from this assay, where 
quenching occurs in a non-linear fashion, which depends on the number of cells plated, 
and is responsive to changes in respiratory rate, as seen in the accelerated response in 
cells pre-treated with carbonyl cyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP), 
and the impaired response in cells pretreated with rotenone, an inhibitor of complex I. 
The activity of the electron transport chain was significantly impaired as estimated by the 
decrease in oxygen consumption seen in Tfam knockdown cells compared with controls 
(Figure 2-3, C). This impairment persisted in the presence of FCCP, which by uncoupling 
the proton gradient maximizes electron transport and thereby oxygen consumption. Thus, 
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the maximal capacity of the electron transport chain was diminished in adipocytes in 
which Tfam induction was impaired during differentiation.  
As an alternative way to monitor the activity of the electron transport chain, the 
capacity of mitochondria to synthesize ATP was measured. Digitonin-permeabilized 
adipocytes were incubated in the presence or absence of oligomycin A, to inhibit the 
activity of the mitochondrial ATPase. ATP synthesis driven by ADP and succinate was 
then measured dynamically using a luciferase-based ATP assay. Mitochondrial ATP 
synthesis was obtained by subtracting the values obtained in the presence from those in 
the absence of oligomycin A. A significant impairment in mitochondrial ATP production 
was seen in Tfam knockdown cells compared with controls (Figure 2-3, E), whereas no 
difference was seen in non-mitochondrial ATP levels, which remained unchanged during 
the incubation (not illustrated).  
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Figure 2-3  Decreased levels of mitochondrial DNA-encoded genes and respiratory 
chain function in Tfam knockdown cells  
(A), mRNA levels of four mtDNA encoded genes determined at day 5 in cells transfected 
at day 2 with scrambled (Scr) or Tfam-directed (siTfam) siRNA oligonucleotides. Bars 
represent values in siTfam cells relative to Scr. Statistical significance was calculated 
using two-tailed paired Student t tests; *, p < 0.05. (B), adipocytes at day 6 were aliquoted 
into a BD Oxygen Biosensor System 96-well plate. FCCP or rotenone was added, and 
recording of fluorescence was immediately initiated. (C) and (D), control and Tfam 
knockdown cells at day 5 were aliquoted into a BD Oxygen Biosensor System 96-well 
plate and fluorescence was recorded in the absence (C) or presence (D) of FCCP. 
Fluorescence was monitored every 2 minutes at 37 °C and is expressed as fluorescence 
units relative to time 0 values. Plotted are the means, and vertical lines represent ±S.E. of 
three independent experiments preformed in triplicate. p values obtained from paired 
two-tailed Student t tests of the means were: 3.1E-17 for Scr versus siTfam; 5.2E-32 for 
Scr versus Scr+FCCP; 9.9E-34 for Scr+FCCP versus siTfam+FCCP; and 1.7E-35 for 
siTfam versus siTfam+FCCP. (E), mitochondrial ATP production in digitonin-
permeabilized cells. Shown is a representative example of three independent experiments 
performed in triplicate. p value obtained from paired two-tailed Student t tests from the 
means of three experiments was 0.0025 for Scr versus siTfam.  
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Unchanged Nuclear Gene Expression and Mitochondrial Mass 
The vast majority of mitochondrial proteins are encoded by nuclear DNA. To 
determine whether siRNA to Tfam might indirectly affect the expression of nuclear-
encoded mitochondrial genes, we examined the levels of mRNA for enzymes involved in 
the tricarboxylic acid cycle, fatty acid oxidation, and oxidative phosphorylation. No 
significant changes in these mRNAs were seen in response to Tfam knockdown (Figure 
2-4, A). Moreover, functional assessment of fatty acid oxidation using exogenous 
palmitate revealed no significant changes in response to Tfam knockdown (not 
illustrated). We also determined the expression of a group of nuclear encoded regulators 
of mitochondrial biogenesis, which were also unchanged in Tfam knockdown cells 
(Figure 2-4, B). Consistent with a lack of effect of Tfam-depletion on non-mtDNA 
encoded mitochondrial genes, the overall cellular abundance of mitochondria assessed by 
staining with specific fluorescence marker MitoTracker® GreenFM was found to be 
unchanged in Tfam knockdown cells; neither fluorescence-activated cell sorting analysis 
of live cells stained with MitoTracker® GreenFM (Figure 2-4, C) nor visual inspection of 
individual cells (Figure 2-4, D) revealed any detectable difference in density or 
mitochondrial morphology.  
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Figure 2-4  Nuclear encoded mitochondrial gene expression and mitochondrial mass 
in Tfam knockdown cells 
The relative mRNA level of various nuclear-encoded mitochondrial genes (A) and 
nuclear encoded mitochondrial related regulators (B) was determined by qRT-PCR at day 
5 in cells transfected at day 2 with scrambled or Tfam-directed siRNA oligonucleotides. 
Results are expressed relative to scrambled control values. Cells were stained with 
MitoTracker Green and subjected to fluorescence-activated cell sorting analysis (C) or 
visualized by fluorescence microscopy (D).  
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Insulin-stimulated Glucose Uptake is Impaired 
Alterations in adipose tissue mitochondrial gene expression correlated with 
insulin sensitivity in animal models, but this correlation may be spurious, or perhaps even 
secondary to altered insulin sensitivity. 3T3-L1 adipocytes depleted of Tfam provide a 
straightforward model system to determine whether impairment of adipose respiratory 
chain function can affect insulin sensitivity. To this end, we examined the effects of 
insulin on glucose uptake in Tfam-depleted cells. Preadipocytes were transfected with Scr 
or Tfam-directed siRNA oligonucleotides at day 2 of differentiation, and glucose 
transport was measured at day 6. A clear response to insulin to stimulate 2-deoxyglucose 
uptake could be observed at day 6 (Figure 2-5, A). Although Tfam-depletion did not 
significantly affect basal 2-deoxyglucose uptake, the stimulatory effect of insulin was 
significantly impaired in Tfam knockdown cells (Figure 2-5, A). To rule out the 
possibility that impaired insulin responsiveness could be due to off-target effects of the 
silencing oligonucleotides, cells were electroporated on day 6 of differentiation, and 
glucose uptake was measured on day 8, a period during which Tfam-directed siRNA has 
no effect on mtDNA levels, as described above. No differences in basal or insulin-
stimulated glucose uptake were seen between cells transfected with Scr or Tfam-directed 
siRNA at day 6 (4508 ± 212 versus 4433 ± 298 cpm Scr or Tfam-directed siRNA in 
response to 0.1 µM insulin). Thus, impairment of insulin-stimulated glucose uptake 
correlates specifically with suppression of Tfam induction.  
Impaired 2-deoxyglucose uptake can result from a decreased rate of glucose 
transport across the plasma membrane, or from a decreased rate of phosphorylation of 2-
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deoxyglucose by hexokinase. To distinguish between these possibilities, we measured the 
uptake of 3-O-methylglucose in response to insulin, which specifically reflects transport, 
and found that it was also impaired by Tfam-depletion (Figure 2-5, B). Thus impairment 
in respiratory chain function results in impaired insulin action to stimulate glucose 
transport, independently of glucose metabolism.  
To determine whether decreased insulin-stimulated glucose transport was due to 
alterations in GLUT4 translocation to the cell surface, we analyzed GLUT4 trafficking 
using total internal reflection fluorescence (TIRF). This imaging technique allows the 
specific visualization of fluorophores residing ∼100 nm from the plasma membrane 
(162). Because insulin stimulates translocation of GLUT4 to the TIRF zone as well as 
fusion with the plasma membrane (85), TIRF imaging of endogenous GLUT4 provides a 
direct estimation of insulin action on GLUT4 trafficking. Insulin-stimulated recruitment 
of endogenous GLUT4 to the TIRF zone was significantly impaired in Tfam knockdown 
cells (Figure 2-5, C and D). This decrease did not result from decreased protein levels of 
GLUT4, assessed by western blot analysis of total cell extracts (Figure 2-5, E). Thus, 
insulin stimulation of GLUT4 translocation and subsequent glucose transport are 
impaired in adipocytes with decreased respiratory chain function.  
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Figure 2-5  Glucose transport and GLUT4 trafficking in Tfam knockdown cells  
Cells were transfected with scrambled (Scr) or Tfam-directed (siTfam) siRNA 
oligonucleotides at day 2 of differentiation. At day 6, cells were serum-starved for 2 
hours; (A), the uptake of 2-deoxyglucose was measured after 30 minutes of incubation 
with the indicated concentrations of insulin. Points represent means, and lines are ±S.E. 
of three independent experiments performed in triplicate. p values obtained by two-tailed 
paired Student t tests were 0.0039 and 0.0057 for Scr versus siTfam at 0.1 and 1 µm 
insulin, respectively. (B), measurement of 3-O-methylglucose under the same conditions 
as in A. p values obtained by two-tailed paired Student t tests were 0.07 and 0.0025 for 
Scr versus siTfam at 0.1 and 1 µm insulin, respectively. Cells treated with the indicated 
concentrations of insulin were fixed and stained with antibodies to endogenous GLUT4 
and imaged by TIRF. (C), representative images of random fields; (D), quantification of 
average intensity of random fields. Points represent means of four independent 
experiments from which 10 random fields from each coverslip were averaged. Lines 
represent ± S.E. p values obtained by two-tailed paired Student t tests were 0.008 and 
0.006 for Scr versus siTfam at 0.1 and 1 µm insulin, respectively. (E), representative 
western blot of GLUT4 in cells transfected with scrambled (Scr) or Tfam-directed 
(siTfam) siRNA oligonucleotides at day 2 of differentiation and lysed at day 6. Similar 
results were obtained in three independent experiments.   
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ATP Level and Phosphorylation of Akt 
One possible mechanism by which insulin-simulated glucose uptake might be 
impaired in Tfam knockdown cells would be through decreased ATP levels, which would 
in these cells lead to impairment in insulin signal transduction (155). Steady-state ATP 
levels in Tfam knockdown cells were indeed decreased, albeit only by a small (∼10%) 
amount (Figure 2-6, A). This decrease did not result in impaired insulin signaling, as 
assessed by the levels of tyrosine phosphorylation and Akt phosphorylation in response to 
insulin (Figure 2-6, B). Indeed, a highly reproducible increase in Akt phosphorylation 
was consistently observed in Tfam knockdown cells (Figure 2-6, C). This effect 
contrasted markedly with that seen in response to rotenone, an acute inhibitor of Complex 
I. After 60 minutes, rotenone decreased ATP levels by an amount only slightly greater 
than that produced by Tfam knockdown (Figure 2-6, A). However, rotenone treatment 
markedly impaired insulin-stimulated Akt phosphorylation (Figure 2-6, D) and 
adiponectin secretion (data not shown). These results point to important differences in 
cellular response to acute versus progressive impairment of electron transport. A large, 
transient decrease in ATP levels and stimulation of glucose uptake are known to occur 
within minutes after rotenone exposure (163). These changes are not observed in Tfam 
knockdown cells, where Complex I dysfunction is probably less severe than that elicited 
by direct chemical inhibition, and in which compensatory changes can occur during 
several days of differentiation.  
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Figure 2-6  ATP levels and insulin signaling in Tfam knockdown cells 
(A), cells were transfected with scrambled (Scr) or Tfam-directed (siTfam) siRNA 
oligonucleotides at day 2 of differentiation, and at day 6 ATP levels were determined by 
luminescence. Where indicated, rotenone (5 µm) was added to control cells for 60 
minutes prior to measurement. Bars are means, and lines are ±S.E. of three experiments 
performed in triplicate. p values obtained by one-tailed paired Student t tests were 0.048 
and 0.00018 Scr versus siTfam and control versus rotenone, respectively. (B), cells 
prepared as above were stimulated with 10 nM insulin for 15 minutes and then harvested 
in lysis buffer with phosphatase and protease inhibitors. Western blots were performed 
using antibodies to phospho-Akt (serine 473) and phosphotyrosine antibody (4G10), 
respectively. Shown is the area of the gel (∼180 molecular weight) showing maximal 
stimulation in phosphotyrosine signal. Antibodies to total Akt and actin were used to 
control for loading. (C), quantification of Akt phosphorylation from four independent 
experiments. *, p value obtained by one-tailed Student t tests was 0.031 for Scr versus 
siTfam in the presence of insulin. (D), adipocytes at day 6 of differentiation were treated 
without (Control) or with 500 nM rotenone for 60 minutes, and then with the indicated 
concentrations of insulin for 15 minutes prior to lysis and western blot with anti-phospho 
Akt antibody. The values from the densitometry scan of this representative experiment 
are shown below each band.  
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Unaffected Adipocyte Functions in Tfam Knockdown Cells 
The observed small decrease in ATP levels and impaired respiratory chain 
function in Tfam knockdown cells was also without a detectable effect on numerous 
parameters that reflect basic functional characteristics of differentiated adipocytes, 
including mRNA levels of adipogenic genes (Figure 2-7, A), triglyceride accumulation 
(Figure 2-7, B and C), and basal adiponectin secretion (Figure 2-7, D). This later lack of 
effect is also indicative of the differences between acute versus chronic impairment in 
respiratory chain function, as adiponectin secretion has been shown to decrease in 
response to acute inhibition of mitochondrial ATP synthesis, and is not inconsistent with 
prior studies where Tfam-depletion mitigates the enhancement of adiponectin secretion 
seen in response to enhanced mitochondrial biogenesis (49). Thus, the results shown here 
indicate that progressive impairment of respiratory chain function through Tfam 
knockdown in adipocytes leads to impaired insulin-stimulated glucose uptake, by a 
mechanism probably unrelated to changes in ATP levels. Moreover, insulin signaling to 
Akt is in fact significantly increased in cells with impaired respiratory chain function.  
Other signaling pathways in adipocytes that involve mitochondrial function 
include those elicited by inflammatory cytokines. The effects of TNFα, for example, 
involve changes in mitochondrial reactive oxygen species (ROS) production (164-165). 
To explore whether this pathway would be affected in cells depleted of mtDNA, control 
and Tfam knockdown adipocytes were treated with 50 ng/ml TNFα, and ROS was then 
measured in live cells. Basal ROS production was indistinguishable between control and 
Tfam knockdown cells, as was the 40% increase in ROS production elicited by TNFα 
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(Figure 2-7, E). Thus, chronic impairment in respiratory chain function results in a 
specific impairment of glucose transport stimulation by insulin, without detectable effects 
on multiple other adipocyte-specific functions or signal transduction events.  
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Figure 2-7  Adipocyte functions in Tfam knockdown cells 
(A), the relative mRNA level of various transcription factors and adipocyte-specific 
proteins was determined by qRT-PCR at day 5 in cells transfected at day 2 with 
scrambled or Tfam-directed siRNA oligonucleotides. Results are expressed relative to 
scrambled values. (B) and (C), Oil red O staining and triglyceride content of cells at day 5. 
(D), cells were washed in PBS and placed in fresh medium. An aliquot of the medium 
was collected at the time points indicated and analyzed by western blot with an antibody 
to adiponectin (Acrp30). (E), cells were incubated without or with 50 ng/ml TNFα for 3 
hours, and reactive oxygen species were measured by 5-(and 6-)chloromethyl-2',7'-
dichlorodihydroflioresceindiacetate, acetyl ester fluorescence, detected directly in cells 
grown on 24-well multiwell plates using a TECAN Safire2 microplate reader.  
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Tfam Knockdown Effect on Insulin Signaling Pathway  
To better understand the mechanism by which insulin signaling to glucose 
transport might be affected by Tfam knockdown, additional pathways downstream of 
insulin receptor activation were analyzed. Neither the stimulation of ERK1 and -2 
phosphorylation (Figure 2-8, A), nor the phosphorylation of the S6 protein (Figure 2-8, B) 
by insulin were significantly affected by Tfam knockdown. To analyze whether the 
observed enhancement of Akt phosphorylation seen in Tfam knockdown cells was 
accompanied by changes in the phosphorylation of Akt substrates, we utilized phospho-
specific antibodies directed to Akt substrates (PAS, Figure 2-8, , C and D) (82, 166). 
Several insulin-stimulated phosphoproteins could be observed, including bands at ∼75, 
105, 160, and 250 kDa that have been previously reported in 3T3-L1 adipocytes (166). 
Several of these were increased in intensity in Tfam knockdown cells in response to 
insulin (Figure 2-8, C, arrowheads), consistent with the increased phosphorylation of Akt 
(Figure 2-6, ). However, one phosphoprotein, at ∼49 kDa, seen at higher exposures, was 
significantly decreased in response to Tfam knockdown (Figure 2-8, D, arrow). 
Preliminary experiments using antibodies and siRNA to a previously identified 47-kDa 
Akt substrate (167) suggest that the Tfam-sensitive phosphoprotein is different and has 
not been previously identified. These results indicate that, whereas most signal 
transduction events downstream of insulin receptor activation and Akt phosphorylation 
are not impaired by Tfam knockdown, at least one specific protein is impaired under 
these conditions. This impairment correlates with the observed inhibition of insulin-
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stimulated glucose uptake, but more experiments, including the positive identification of 
this protein, will be required to establish a causal correlation between these two events.  
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Figure 2-8  Effect of Tfam knockdown on insulin signaling pathways 
Cells were transfected with scrambled (Scr) or Tfam-directed (siTfam) siRNA 
oligonucleotides at day 2 of differentiation, and at day 6 were stimulated with the 
indicated concentrations of insulin for 15 minutes prior to harvest in lysis buffer with 
phosphatase and protease inhibitors. Western blots were performed using antibodies to 
ERK1 and -2 (A), Phospho S6 protein (B), and PAS antibodies (C and D). Shown are 
representative blots at lower (C) or higher (D) exposures. Arrowheads point to substrates 
that were increased, and the arrow points to one substrate detected that was decreased by 
Tfam knockdown. Similar results were obtained in three independent experiments.  
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Discussion 
A possible relationship between mitochondrial levels and adipose tissue function 
has been inferred from results in animals and humans indicating that alterations in 
mitochondrial levels correlate with changes in insulin sensitivity (16-19, 21-27). In this 
report we have turned to a simple model, 3T3-L1 adipocytes, to determine whether a 
direct relationship between mitochondrial function and insulin sensitivity might indeed 
exist. Our results indicate that impaired induction of Tfam during differentiation results 
in cells with a relative deficiency in respiratory chain function but that still display many 
of the phenotypic characteristics of normal adipocytes. However, these cells have a 
reduced responsiveness to the stimulatory action of insulin on glucose transport. These 
results strongly suggest a specific link between respiratory chain function and glucose 
transport in adipose cells.  
An unexpected finding in this study is that insulin stimulation of Akt 
phosphorylation is significantly increased in the Tfam-depleted cells. Thus, impairment 
of insulin action on glucose transport in cells depleted of Tfam is not due to defects in the 
early steps of the insulin-signaling pathway. This finding reveals a direct link between 
mitochondrial function and insulin action, where the activity of the respiratory chain 
impacts negatively upon insulin signaling to Akt. Importantly, these results are consistent 
with those seen in mice lacking apoptosis-inducing factor in muscle and liver, which 
display a progressive decrease in mitochondrial respiratory chain function (168), but have 
increased insulin sensitivity assessed by Akt phosphorylation and insulin tolerance. These 
findings as well as ours are also consistent with the finding that muscle-specific Tfam 
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knockout mice have enhanced glucose tolerance (169) , possibly resulting from improved 
insulin signaling. Thus, in muscle, liver, and 3T3-L1 adipocytes, a progressive defect in 
respiratory chain function results in enhanced insulin stimulation of Akt phosphorylation.  
However, in contrast to that observed in vivo in muscle or liver of mice, glucose 
transport is clearly impaired in 3T3-L1 cells with respiratory chain deficiency. One 
potential cause for this difference is that the levels of GLUT4 and GLUT1 transporters 
are increased in muscle and liver of respiratory chain-deficient mice (168), yet no 
increase in expression of these transporters is seen in Tfam-depleted 3T3-L1 adipocytes. 
Moreover, compensatory mechanisms involving other tissues and longer adaptation times 
may resolve an initial impairment in insulin-stimulated glucose transport in muscle of 
respiratory chain-deficient mice. It also remains possible that the response of muscle and 
adipose tissue to respiratory chain dysfunction may differ in vivo. Further work to 
determine the effect of adipose-tissue-specific impairment of mitochondrial function on 
glucose homeostasis in whole animals will be required to answer these questions. 
Nevertheless, the results presented here provide evidence that, in adipose cells, impaired 
respiratory chain function results in impaired insulin-stimulated glucose transport under 
conditions where compensatory adaptative mechanisms are minimized.  
The results shown here point to independent links between mitochondrial function, 
insulin signaling, and glucose transporter trafficking. The mechanisms by which a 
relative deficiency in respiratory chain activity could lead to enhanced insulin signaling 
to Akt are not known but are areas of great interest. Mitochondrial products that are 
known to enhance Akt phosphorylation include H2O2 and perhaps other ROS (170-171). 
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However, we do not see any increase in ROS in Tfam KO cells (Figure 2-7, ), and 
elevated ROS was not seen in tissues from apoptosis-inducing factor knockout mice 
(168), perhaps reflecting the requirement for integrity of the electron transport chain for 
ROS production (172-174). Elucidating the mechanisms that link mitochondrial 
respiratory chain deficiency to enhanced insulin signaling will require identification of 
the potential compensatory pathways elicited by Tfam-depletion in adipose cells.  
With respect to the mechanisms by which Tfam knockdown might lead to 
impaired glucose transport despite enhanced insulin signaling to Akt, the results shown 
here using antibodies directed to phospho-Akt substrates suggest the possibility that 
mitochondrial dysfunction might affect specific substrates potentially involved in GLUT4 
translocation. A clear defect in the insulin-stimulated phosphorylation of a substrate of 
∼49 kDa is seen in Tfam knockdown cells, which correlates with the impairment in 
insulin-stimulated glucose transport. Although Akt substrates such as AS160 have been 
shown to be important in insulin-stimulated GLUT4 translocation (83, 175-176), 
additional factors are clearly necessary to mediate the full effect of insulin, and Tfam-
sensitive ~49 kDa protein may be one of them. Further efforts to identify this substrate 
are ongoing.  
In summary, two distinct functional relationships are revealed in these studies; 
first, a link between mitochondrial function and insulin signaling, in which impaired 
respiratory chain activity enhances insulin signaling to Akt phosphorylation, and second, 
a link between mitochondrial function and glucose transporter trafficking, where 
impairment of respiratory chain function leads to impaired GLUT4 translocation, perhaps 
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through specific defects in phosphorylation of one or more Akt downstream substrates. 
The net result of these effects is impairment in insulin-stimulated glucose transport in 
adipocytes. Although further work is necessary to assess the effects of impaired 
adipocyte mitochondrial function on whole body glucose homeostasis, our results 
indicate that such impairment can be a primary cause of insulin-resistant glucose 
transport at a cellular level.  
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CHAPTER III   
ISOFORM-SPECIFIC REGULATION OF AKT SIGNALING 
BY THE ENDOSOMAL PROTEIN WDFY2 
 
This chapter is in the format that it was published in the J Biol Chem. 
2010;285(19):14101-8, as written by the authors, Walz HA*, Shi X*, Chouinard M, Bue 
CA, Navaroli DM, Hayakawa A, Zhou QL, Nadler J, Leonard DM, and Corvera S. (*, 
These authors contributed equally) 
 
Akira Hayakawa initiated the project. Qionglin Zhou performed the glucose 
uptake assay. My Chouinard performed most of the siRNA knockdowns, and all the qRT-
PCR experiments in Figure 3-6. Catherine Bue performed the yeast two-hybrid 
interaction assays. I was responsible for the analysis of Akt signaling pathway using the 
PAS antibody and helped to make some constructs for yeast two-hybrid assays. Helena 
Walz performed all the imaging work and data processing. She also did some knockdown 
and immunoblotting experiments.  
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Abstract 
Recent work has led to the identification of novel endocytic compartments with 
functional roles in both protein trafficking and growth factor signal transduction. The 
phosphatidylinositol 3-phosphate binding, FYVE domain-containing protein WDFY2 is 
localized to a distinct subset of early endosomes, which are localized close to the plasma 
membrane. Here, we find that the serine/threonine kinase Akt interacts with these 
endosomes in an isoform-specific manner. Using quantitative fluorescence microscopy 
we demonstrate specific co-localization of WDFY2 with endogenous Akt2, but not Akt1. 
Moreover, depletion of WDFY2 leads to impaired phosphorylation of Akt in response to 
insulin due to isoform specific reduction of Akt2, but not Akt1, protein levels, and to a 
marked reduction in the insulin-stimulated phosphorylation of numerous Akt substrates. 
This is accompanied by an impairment in insulin-stimulated glucose transport and, after 
prolonged silencing, a reduction in the level of expression of adipogenic genes. We 
propose that WDFY2-enriched endosomes serve as a scaffold that enables specificity of 
insulin signaling through Akt2.  
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Introduction 
The early endocytic pathway is increasingly being recognized as a complex and 
heterogeneous membrane population in which distinct endosomal populations are 
specialized for the trafficking of different receptor types (177-178). Complexity and 
specialization in the endosomal pathway are achieved by the action of small GTPases and 
by the generation of specific phosphoinositides on the endosomal surface. One of the best 
studied examples of this mechanism is the specific and temporal targeting of proteins 
containing FYVE domains to phosphatidylinositol 3-phosphate (179-182), which is 
present almost exclusively in endosomal membranes. The human genome encodes 
for >30 proteins that contain FYVE domains, several of which are highly conserved and 
which may contribute in different ways toward establishing the complexity and 
functionality of the endocytic pathway. We recently characterized one of these proteins, 
WDFY2, named for its content of WD40 motifs and a FYVE domain (146). In 
Caenorhabditis elegans, WDFY2 depletion impairs endocytosis in coelomocytes, and in 
mammalian cells it defines a distinct set of endosomes that lack the canonical markers 
EEA1 and Rab5 and are further distinguished by their close proximity to the plasma 
membrane (146, 183). 
In addition to internalization, the endosomal pathway plays a critical role in 
modulating signal transduction. Growth factor receptors are internalized immediately 
following activation, and both their fate and their signaling functions are affected by their 
transit through the endocytic pathway (184-188). Different receptors traffic through 
distinct early endosomal compartments (177-178), and their signaling functions are 
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modulated by the specific nature of the endosomes through which they traffic. For 
example, signaling by transforming growth factor β is influenced by the endosomal 
localization of the SMAD-interacting protein SARA, which is found in endosomes 
containing the canonical marker EEA1 (189-190).  
In another example, the endosomal proteins APPL (adaptor protein containing PH 
domain, PTB domain, and leucine zipper motif) 1 and APPL2, which reside in an 
endosomal population devoid of EEA1 (191), regulate signaling by interacting with 
downstream effectors, such as the protein kinase Akt (114-116, 191-193). It has been 
proposed that the interaction of Akt with APPL facilitates the phosphorylation of specific 
substrates (116). Interestingly, WDFY2 has been identified in a yeast two-hybrid screen 
as an interacting partner with protein kinases Akt and protein kinase Cζ (194-195). In 
addition, recent studies indicate that endosomes that contain APPLs bind WDFY2 as they 
lose APPL (183). These studies suggest that WDFY2 may have a specific role in 
modulating signaling through Akt downstream of the interaction of this kinase with 
APPL.  
Akt constitutes a node for many signaling cascades downstream of 
phosphatidylinositol (3,4,5)-trisphosphate, regulating metabolism, protein synthesis, cell 
growth, and survival (62, 196). This diversity in Akt signaling is orchestrated by three 
mammalian isoforms, Akt1, Akt2, and Akt3, that share a conserved structure with three 
functional domains: an N-terminal PH domain, a kinase domain, and a C-terminal 
regulatory domain containing a phosphorylation site (FXXF(S/T)Y) (197). These 
isoforms share ∼80% sequence homology and phosphorylate substrates containing the 
73 
 
 
 
minimal consensus sequence RXRXXp(S/T), where S/T is the phosphorylation site and X 
any amino acid. Studies in isoform-specific Akt knock-out mice indicate that the three 
isoforms have overlapping but distinct physiological functions (196). For example, 
Akt2−/− mice display a strong metabolic phenotype, with diabetes type 2-like symptoms 
(73-74), not seen in Akt1−/− or Akt3−/− mice (142, 198). Similarly, on a cellular level, 
siRNA knockdown studies of Akt1 and Akt2 in 3T3-L1 adipocytes revealed Akt2 as the 
primary isoform involved in insulin signaling despite the presence of both Akt1 and Akt2 
in these cells (199). The mechanisms that fine tune the activities of the three Akt isoforms 
for them to achieve their specific physiological functions are not clear.  
Here, we investigate the role of WDFY2-enriched endosomes in Akt signaling in 
mature 3T3-L1 adipocytes. Using quantitative image analysis, we find an isoform-
specific selective interaction between WDFY2 and Akt2, as opposed to the Akt1 isoform. 
We observe that WDFY2 depletion leads to decreased levels of Akt2 protein levels and 
attenuated insulin-stimulated phosphorylation of Akt. The functional importance of the 
isoform-specific interaction between WDFY2 and Akt2 was demonstrated by decreased 
insulin-stimulated glucose uptake and a global attenuation of phospho-Akt substrate 
phosphorylation in WDFY2-depleted cells. Together, these results indicate that WDFY2 
serves as a molecular scaffold that enables signaling specificity, demonstrating a mode of 
regulation that distinguishes between Akt1 and Akt2. 
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Experimental Procedures 
Tissue Culture and Gene Silencing 
3T3-L1 cells were obtained from American Type Culture Collection and were 
grown under 5% CO2 in Dulbecco's modified Eagle's medium supplemented with 10% 
fetal bovine serum, 50 units of penicillin/ml, and 50 µg of streptomycin/ml, which was 
replaced every 48 hours unless otherwise stated. Three days after confluence, the medium 
was replaced with Dulbecco's modified Eagle's medium containing a differentiation 
mixture consisting of 0.5 mm 3-isobutyl-1-methylxanthine (Sigma), 0.25 µm 
dexamethasone (Sigma), and 1 µm insulin (Sigma). 72 hours later, the medium was 
replaced with Dulbecco's modified Eagle's medium. Gene silencing was conducted 4 
days after differentiation through electroporation (10 nmol of siRNA/15-cm plate). 
Scrambled (Scr) siRNA or siRNA oligonucleotides against mouse WDFY2 were 
obtained from Dharmacon. Electroporation was performed using a Bio-Rad Gene Pulser 
II (0.18 kV and 960 microfarads).  
Antibodies and Fluorescent Probes 
Rabbit antibodies to the full-length WDFY2 protein were affinity-purified against 
full-length bacterially expressed WDFY2. Mouse antibodies to the N terminus of EEA1, 
rabbit PAS antibody (RXRXXp(S/T)) (catalog no. 9614, 1:1000 dilution), phospho-Akt 
(Ser473) antibody (catalog no. 9271), Akt2 (5B5) rabbit monoclonal antibody (catalog no. 
2964), and Akt1 (2H10) mouse monoclonal antibody (catalog no. 2967) were from Cell 
Signaling. Mouse anti-β-actin antibody was from Sigma. Secondary detection was with 
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Alexa Fluor-coupled species-specific antibodies obtained from Molecular Probes 
(Eugene, OR).  
2-Deoxyglucose Uptake 
3T3-L1 adipocytes were plated in a 24-well multiwell tissue culture plate and 
differentiated. The cells were serum-starved for 2 hours in Krebs-Ringer HEPES buffer 
(130 mm NaCl, 5 mm KCl, 1.3 mm CaCl2, 1.3 mm MgSO4, and 25 mm HEPES, pH 7.4, 
supplemented with 0.5% bovine serum albumin, and 2 mm sodium pyruvate) and then 
stimulated with 1 or 100 nM insulin for 30 minutes. Glucose uptake was initiated by 
addition of [1,2-3H]2-deoxy-D-glucose at a final assay concentration of 100 µm, for 5 
minutes, at 37 °C. The cells were washed in ice-cold phosphate-buffered saline and lysed 
with 0.4 ml of 1% Triton X-100. 3H content was determined by scintillation counting. 
Nonspecific deoxyglucose uptake was measured in the presence of 20 µm cytochalasin B 
and subtracted from each determination to obtain specific uptake.  
Quantitative Real-time PCR (qRT-PCR) 
mRNA isolation was performed using the TRIzol reagent protocol (Invitrogen). 
Prior to mRNA collection, the cells were washed twice with ice-cold phosphate-buffered 
saline. The concentration and purity of mRNA were determined by absorbance 
measurement at 260/280 nm. 2 µg of mRNA was used for cDNA synthesis (20-µl 
reaction) using an iScript cDNA synthesis kit (Bio-Rad). For RT-PCR, 1 µl of cDNA was 
used for detection of specific gene targets. Primers used were designed using PrimerBank 
and were synthesized by Operon. Ferritin was used as an internal control. Quantitative 
RT-PCR was run using the MyIQ Real-time PCR system (Bio-Rad).  
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Immunoblotting 
The cells were washed twice with ice-cold phosphate-buffered saline and scraped 
into lysis buffer (1% SDS, 120 mm NaCl, 1.6 mm HEPES, pH 7.4, 800 mm NaF, 4 µm 
NaPPi, and protease inhibitors) and homogenized by seven passages through a 27-gauge 
needle. The samples were centrifuged for 5 minutes at 500 × g, and protein concentration 
was determined by BCA (Pierce). 10 µg of proteins was separated on SDS-PAGE and 
transferred to nitrocellulose. The membranes were blocked with 5% nonfat milk in Tris-
buffered saline with 0.1% Tween 20 and incubated with primary antibodies overnight. 
Anti-rabbit or anti-mouse IgG horseradish peroxidase-conjugated antibodies (Promega) 
were used in combination with enhanced chemiluminescence (PerkinElmer Life Sciences) 
for detection.  
Optical System and Image Analysis 
Epifluorescence images were taken using a Zeiss Axiovert 200 inverted 
microscope with a Zeiss 100 × 1.40 NA oil-immersion objective equipped with a Zeiss 
AxioCam HR CCD camera with 1300 × 1030 pixel resolution. To visualize WDFY2-
enriched endosomes, images were smoothed by convolving with a small, two-
dimensional Gaussian spot that preserved the mean intensity. The local background 
around the endosomes was estimated by convolving with a larger, two-dimensional 
Gaussian and subtracting this from the smoothed images. From this we generated a 
binary masking image by setting the intensity of all positive-valued pixels to 1 and all 
other pixels to 0. We then multiplied the mask by the original images (200).  
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Yeast Two-hybrid Assays 
Strains were made by co-transforming two vectors (pGAD-T7 and pGBK-T7) 
into AH109 (mat a) yeast (Clontech) using standard yeast transformation procedures 
(lithium acetate transformation). AH109 contains MEL1, ADE2, HIS3, and LACZ, 
reporter genes, such that interaction of the bait and prey constructs will allow 
transcription of these four gene products. Vectors used were: pGAD-T7 (empty vector), 
pGBK-T7 (empty vector), pGBK-T7-WDFY2, pGAD-T7-Akt1, and pGAD-T7-Akt2. 
Co-transformed strains were maintained on Synthetic defined-Trp-Leu agar plates. 
Strains were grown overnight (∼16 hours) on a 30 °C wheel in Synthetic defined-Trp-
Leu + kanamycin. Cultures were back-diluted to A = 0.1 in Synthetic defined-Trp-Leu-
Ade-His + kanamycin medium, and after 18–20 hours at 30 °C a quantitative X-α-gal 
assay was performed as described(201). Cultures were combined with X-α-gal buffer, 
and 145 µl was added to a row or column on a 96-well plate. One row/column contained 
medium and X-α-gal buffer only as a blank. Once cell cultures with X-α-gal buffer were 
added to 96-well plates, plates were placed on a shaker at room temperature, and readings 
were done at different time points in a Tecan SAFIRE II at 410 and 600 nm, to monitor 
α-galactosidase activity and growth, respectively. Averages of 8 wells from each strain 
were calculated, and the average blank reading was subtracted.  
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Results 
To elucidate the function of WDFY2-enriched endosomes in a specific functional 
context, we utilized 3T3-L1 adipocytes, where both trafficking of GLUT4 and signaling 
through the insulin receptor can be evaluated. Depletion of WDFY2 led to a significant 
inhibition of insulin-stimulated glucose uptake in 3T3-L1 adipocytes (Figure 3-1, A). 
This effect was due to the combination of decreased insulin sensitivity and reduced basal 
uptake of glucose compared with cells exposed to Scr siRNA and was comparable with 
that seen upon depletion of Akt2, a known required signaling component in insulin-
stimulated glucose uptake. The effectiveness of WDFY2 and Akt2 knockdown by siRNA 
oligonucleotides was evaluated by measuring both mRNA and protein levels of each. 
Compared with Scr, WDFY2 and Akt2 knockdown cells showed a highly significant 
∼85–90% decrease in their respective mRNA (Figure 3-1, B). The levels of WDFY2 
protein, evaluated by immunoblotting, were found to be reduced by ∼60% (Figure 3-1, C, 
top panel), and Akt2 protein was reduced to undetectable levels (Figure 3-1, C, middle 
panel, right lane). Analysis of GLUT4 by immunofluorescence did not reveal significant 
alterations in the levels of the transporter (not illustrated). However, an unexpected 
marked reduction of Akt2 protein levels was observed in WDFY2-depleted cells (Figure 
3-1, C, middle panel), suggesting that the impairment in insulin-stimulated glucose 
transport seen in response to WDFY2 depletion is due to impaired signaling through the 
Akt pathway.  
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Figure 3-1  Effect of WDFY2 depletion on insulin-stimulated glucose uptake  
(A), 3T3-L1 adipocytes, day 5 of differentiation, were transfected with Scr, WDFY2, or 
Akt2 siRNA. 48 hours after transfection, the cells were serum-starved (3 hours), and 2-
deoxyglucose uptake was measured after 30 minutes of insulin stimulation (1 or 100 nM) 
(n = 3, mean cpm ± S.E. (error bars), p < 0.01, Student's t test). (B), WDFY2 and Akt2 
mRNA levels were determined by qRT-PCR (n = 3, p < 0.01, Student's t test). (C), 
lysates from (A) were subjected to SDS-PAGE, and WDFY2 and Akt2 protein levels 
were analyzed by immunoblotting (IB). Clathrin was used as a loading control.  
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Effects of WDFY2 Depletion on Akt 
To determine whether WDFY2 depletion impaired Akt activation, we used a 
phospho-specific antibody to Akt serine 473. Insulin stimulation resulted in a pronounced 
increase in staining intensity in all regions of the cell, predominating in the cell periphery 
and in the nucleus (Figure 3-2, A, lower left panel). Staining in cells depleted of Akt2 was 
much dimmer and probably corresponded to the remaining phosphorylated Akt1 (Figure 
3-2, A, compare upper left and upper and lower center panels). Consistent with a 
negative effect of WDFY2 depletion on Akt signaling, pAkt(473) immunofluorescence in 
insulin-stimulated WDFY2 knockdown cells was significantly reduced compared with 
insulin-stimulated controls (Figure 3-2, A, compare lower left with lower right panels). 
Quantification of the average intensity/cell from several independent experiments 
revealed an average decrease of 50–60% in pAkt(473) staining intensity in response to 
either Akt2 or WDFY2 knockdown in insulin-stimulated cells (Figure 3-2, B).  
To corroborate the immunofluorescence results, we analyzed whole cell extracts 
by western blot. Depletion of WDFY2 caused a significant decrease in the levels of pAkt 
in response to insulin, in particular at submaximal insulin concentration (Figure 3-2, C, 
top panel). Surprisingly, analysis of total Akt proteins levels revealed that WDFY2 
depletion caused a selective decrease in the levels of the Akt2 isoform (Figure 3-2, C, 
second panel from top), leaving Akt1 and control proteins such as actin unaffected 
(Figure 3-2, C, bottom two panels). This result is noteworthy because Akt2 and Akt1 are 
highly homologous, and the mechanisms by which insulin action is dependent 
specifically on Akt2 are unknown. To evaluate the specificity of the observed effects of 
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WDFY2 depletion on Akt2, several different oligonucleotides directed to WDFY2 (Oligo 
1, 2 and 3) and knockdown of another FYVE-domain protein, EEA1, were analyzed 
(Figure 3-2, D). The decrease in Akt2 protein levels correlated with the effectiveness of 
the WDFY2 knockdown and was unaltered in response to EEA1 knockdown, revealing 
specificity for WDFY2 and Akt2 interactions.  
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Figure 3-2  Effect of WDFY2 depletion on Akt phosphorylation  
(A), 3T3-L1 adipocytes transfected with Scr, WDFY2, or Akt2 siRNA 48 hours prior to 
the experiment were serum-starved and insulin-stimulated for 15 minutes (100 nM). The 
cells were briefly washed and fixed in 4% formaldehyde (15 minutes) and 95% methanol 
(5 minutes) prior to immunofluorescence analysis of pAkt(473). (B), average intensity of 
immunofluorescence staining in control and insulin-stimulated cells from A is shown. 20 
frames representing a total of ∼375 cells per group were analyzed and are presented as 
mean intensity/cell ± S.E. (error bars), p < 0.01, Student's t test. (C), 3T3-L1 adipocytes 
transfected with Scr, WDFY2, or Akt2 siRNA 48 hours prior to the experiment were 
serum-starved and insulin (Ins)-stimulated for 15 minutes (1 or 100 nM). Lysates were 
subjected to SDS-PAGE and immunoblotting using pAkt(473), Akt2, Akt1, and actin 
antibodies. (D), 3T3-L1 adipocytes were transfected with Scr, WDFY2, or EEA1 siRNA 
48 hours prior to lysis. Three different WDFY2 oligonucleotides (Oligos) 1–3 were used. 
Lysates were subjected to SDS-PAGE and immunoblotting using antibodies to Akt2, 
WDFY2, and EEA1.  
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To determine whether the decreased levels of Akt2 protein observed in response 
to WDFY2 knockdown were due to transcriptional or post-transcriptional responses, 
Akt2 mRNA and protein levels were analyzed after 24, 48, and 72 hours of WDFY2 
knockdown. Akt2 protein levels were diminished at 24 hours and continued to decrease 
significantly with time (Figure 3-3, A). Interestingly, the initial drop in Akt2 levels, after 
24 hours, was not coupled to a reduction in Akt2 mRNA (Figure 3-3, B). However, at 48 
and 72 hours of WDFY2 knockdown Akt2 mRNA start to fall to significantly lower 
levels (Figure 3-3, B). These results suggest that the initial event following WDFY2 
knockdown is a decrease in Akt2 protein levels.  
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Figure 3-3  Time course of the effect of WDFY2 depletion on Akt2 mRNA and 
protein levels  
(A), 3T3-L1 adipocytes transfected with Scr, WDFY2, or Akt2 siRNA were analyzed for 
the expression of Akt2 by western blot 24, 48, and 72 hours after transfection (n = 3, 
representative blot). (B), WDFY2 and Akt2 mRNA levels were determined 24, 48, and 
72 hours after knockdown of WDFY2 using qRT-PCR (n = 3, mean ± S.E. (error bars), p 
< 0.01, Student's t test).  
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Localization of Endogenous Akt1 and Akt2 Relative to WDFY2 
WDFY2 is localized on a population of early endosomes that lack canonical early 
endosome markers and reside close to the plasma membrane (146). The mechanism by 
which WDFY2 exerts a selective effect on Akt2 levels, but not the highly homologous 
kinase Akt1, could involve a preferential interaction of WDFY2 with Akt2 in response to 
normal cellular compartmentalization of these two kinases. To explore this possibility, 
the localization of endogenous WDFY2 relative to endogenous Akt1 and Akt2 was 
analyzed. 3T3-L1 adipocytes were stimulated with insulin, fixed, and stained with 
antibodies to endogenous WDFY2, and either Akt1 or Akt2. Both Akt1 and Akt2 were 
seen in the nuclear region as well as diffusely distributed in the cytoplasm (Figure 3-4, A 
and B, lower panels). In addition, punctate staining was consistently seen in both starved 
and insulin-stimulated cells stained for Akt2, being more predominant in cells stimulated 
with insulin (Figure 3-4, A, lower panels). WDFY2 staining was much more punctate, 
corresponding to its localization to endosomes (Figure 3-4, A and B, upper panels).  
Because of the broad distribution of Akt1 and Akt2, image overlaps alone would 
be inadequate to evaluate whether meaningful co-localization of either of these kinases 
with WDFY2 exists. To address this issue, we generated binary masks of the images of 
WDFY2 to delineate the regions corresponding to WDFY2-enriched endosomes. When 
superimposed on each image, these masks reveal the signal specifically present in the 
regions occupied by WDFY2-enriched endosomes (Figure 3-4, A and B, center panels). 
To measure the fluorescence intensity outside WDFY2-containing endosomes, the masks 
were displaced by 10 pixels in the x and y axes. As expected, when the masks were 
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superimposed on images of WDFY2, the fluorescence intensity in the mask was much 
higher than that in the displaced mask (Figure 3-4, A and B, compare upper center and 
right panels). When the corresponding Akt2 image was analyzed, significantly higher 
fluorescence intensity was detected within the mask corresponding to WDFY2 
endosomes than in the displaced mask (Figure 3-4, A, compare lower center and right 
panels). In contrast, when Akt1 staining was analyzed, similar fluorescence intensity was 
detected within the mask corresponding to WDFY2 endosomes than within the displaced 
mask (Figure 3-4, B, compare lower center and right panels). These results are quantified 
in Figure 3-4, C and D, in which the fluorescence intensity in the displaced mask is 
expressed relative to that inside the mask from 5–10 cells from independent experiments. 
These results indicate that, at steady state, endogenous Akt2 associates with WDFY2-
enriched endosomes to a much greater extent than endogenous Akt1.  
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Figure 3-4  Co-localization of endogenous Akt isoforms with WDFY2  
3T3-L1 adipocytes at day 7 of differentiation were serum-starved and stimulated with 
100 nM insulin for 30 minutes. Endogenous WDFY2 and Akt2 or Akt1 was detected by 
fluorescent immunostaining. (A) and (B), the left panels display raw images of WDFY2, 
Akt2, or Akt1. Digital binary masks revealing the regions encompassed by WDFY2 
endosomes exclusively were generated. The product of the raw images and the binary 
mask were labeled as Masked and are displayed in the center panels. As a control for 
nonspecificity the generated mask was shifted 10 pixels in the x and y planes and referred 
to as Displaced Mask. The product of the raw image and the Displaced Mask is displayed 
in the right panels. (C) and (D), quantification of fluorescence intensity in the Masked (M) 
or Displaced Masked (DM) WDFY2 and Akt2 or Akt1 images (average of 5–10 cells, 
mean ± S.E. (error bars), p < 0.01, Student's t test).  
  
88 
 
 
 
Effects of Akt2 Depletion on Akt Substrate Phosphorylation 
The decrease in Akt2 levels may underlie the decrease in insulin-stimulated 
glucose transport seen in cells depleted of WDFY2. For this to be the case, the decrease 
in Akt2 levels would have to be of a magnitude sufficient to impair its signaling functions. 
To determine first the relationship between Akt2 levels and Akt substrate 
phosphorylation, we analyzed cell extracts by western blot with anti-pAkt (473) and with 
an antibody (PAS) to the phospho-Akt substrate motif RXRXXp(S/T). Cells transfected 
with Scr or Akt2-directed siRNAs were treated with 10 nM insulin for 5, 15, 30, 45, and 
75 minutes (Figure 3-5, A). In Scr siRNA-transfected cells (Figure 3-5, A and B, left), 
maximal pAkt(473) levels were reached within 5 minutes of insulin addition. In Akt2 
knockdown cells (Figure 3-5, A, right), pAkt(473) levels were diminished at every time 
point after insulin addition, and Akt2 protein levels were reduced to undetectable levels. 
Immunoblotting with PAS antibody revealed numerous substrates phosphorylated in 
response to insulin (Figure 3-5, A and B, left). Although some of these (band I) displayed 
a time course of phosphorylation that closely paralleled that of pAkt(473) (compare 
Figure 3-5, C and D), others (band II) showed maximal phosphorylation at significantly 
later time points (compare Figure 3-5, C and E), or a continuous increase over the time 
period studied (band III, Figure 3-5, F).  
This result suggests that the phosphorylation of some of the proteins detected by 
the PAS antibody is under complex regulation, possibly reflecting variations in Akt 
substrate affinity, spatial constraints, phosphatase activities, or phosphorylation by 
kinases other than Akt2. This latter possibility is suggested by the finding that 
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phosphorylation of some of the proteins detected by the PAS antibody in response to 
insulin was in fact increased in Akt2-depleted cells (Figure 3-5, A, bands IV and V, and 
Figure 3-5, G and H). This finding suggests the presence of at least one kinase that can 
phosphorylate the RXRXXp(S/T) motif and is negatively regulated by Akt2. In addition, 
Akt2 depletion resulted in pronounced changes in the kinetics of phosphorylation of some 
substrates more than in their maximal phosphorylation level (Figure 3-5, A, band III, and 
Figure 3-5, F).  
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Figure 3-5  Effect of WDFY2 depletion on the dynamics of Akt substrate 
phosphorylation  
(A) and (B), 3T3-L1 adipocytes transfected with Scr, Akt2 (A), or WDFY2 (B) siRNA on 
day 5 of differentiation were serum-starved and stimulated on day 7 with 10 nM insulin 
(Ins) for 0, 5, 15, 30, 45, or 75 minutes prior to lysis (n = 3, representative blot). 
Immunoblots were probed with pAkt(473), Akt2, or PAS antibodies. C–H, densitometric 
quantification of pAkt(473) (C) and bands I–V (D–H) in Scr versus Akt2 or WDFY2 
immunoblots. 
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Effects of WDFY2 Depletion on Akt Substrate Phosphorylation 
In cells depleted of WDFY2 (Figure 3-5, B, right), phosphorylation of Akt and of 
virtually all substrates detected with the PAS antibody was significantly reduced at all 
time points measured. This decrease in substrate phosphorylation was consistently more 
pronounced in WDFY2-depleted than in Akt2-depleted cells (compare lower right panels 
in Figure 3-5, A and B). Moreover, the phosphorylation of substrates such as bands IV 
and V, which was increased by Akt2 depletion, was also impaired by WDFY2 depletion 
(Figure 3-5, A, B, G, and H). The broader cellular requirements for WDFY2 than for 
Akt2 are also reflected by changes in gene expression patterns following knockdown of 
these two proteins (Figure 3-6). Indeed, we found that expression levels of numerous 
adipogenic and metabolic genes, including Glut-4, Glut-1, Cycs, Aco2, and nFAS, were 
more significantly decreased after WDFY2 knockdown than after individual Akt2 or 
Akt1 knockdowns, consistent with the finding that WDFY2 depletion impairs adipocyte 
differentiation (202). The finding that WDFY2 depletion has a broader effect on insulin-
stimulated RXRXXp(S/T) substrate phosphorylation than depletion of Akt2 could reflect 
the need for WDFY2 for the activity of other insulin-sensitive kinases that can 
phosphorylate this motif. Also, it is possible that Akt1 may phosphorylate these 
substrates in Akt2-depleted cells, and WDFY2 may be necessary for this compensatory 
function of Akt1, even though under normal conditions it interacts preferentially with 
Akt2.   
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Figure 3-6  Differential effects of WDFY2 and Akt2 knockdown on mRNA of 
proteins key to adipocyte function  
3T3-L1 adipocytes were transfected with Scr, WDFY2 (A), Akt2 (B), or Akt1 (C) siRNA 
on day 4 of differentiation. Samples collected 24, 48, or 72 hours after transfection were 
assayed for mRNA levels of WDFY2, Akt2, and Akt1, respectively, in addition to Glut-4, 
Glut-1, Cycs, Aco2, nFAS, and SREBP1c using qRT-PCR (n = 4, mean ± S.E. (error 
bars), p < 0.01, Student's t test).  
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Preferential Interaction of WDFY2 with Akt2 Compared with Akt1 
The preferential co-localization of Akt2 in endosomes containing WDFY2 and the 
finding that knockdown of WDFY2 preferentially affects the levels and activity of Akt2 
suggest a preferential interaction between WDFY2 and Akt2 in vivo. All Akt isoforms 
share 80% homology at the amino acid level throughout the functional domains common 
to all Akt isoforms. The isoform specificity of WDFY2 binding may result from a higher 
affinity in the interaction between the WD domains of WDFY2 with Akt2 compared with 
Akt1. These differences, however, are lost in over-expression studies, where WDFY2 can 
interact with Akt1 when both proteins are co-expressed (194) (data not shown). The 
difficulty in recapitulating isoform-specific behaviors of Akt isoforms upon over-
expression has also been noted in studies describing a differential interaction of Akt 
isoforms with PH domain leucine-rich repeat protein phosphatases (203). To determine 
whether a significant difference exists in the ability of WDFY2 to interact with Akt1 or 
Akt2, we analyzed the interactions between full-length WDFY2 and full-length, 
hemagglutinin-tagged constructs of Akt2 and Akt1 in a quantitative yeast two-hybrid 
assay (Figure 3-7, A). A significant albeit weak interaction between WDFY2 and full-
length Akt1 and Akt2 was detected by both growth and α-galactosidase in this assay, and 
the interaction of WDFY2 with Akt2 was significantly greater than that with Akt1 
(Figure 3-7, B and C). These results indicate that subtle structural differences between 
these isoforms affect the affinity for WDFY2. These differences may be functionally 
relevant in mammalian cells, accounting for the differential localization of Akt2 and its 
sensitivity to WDFY2 levels.   
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Figure 3-7  Interactions between WDFY2 and Akt1 or Akt2 in a yeast two-hybrid 
assay 
Yeast were co-transformed with the indicated vectors and grown as described under 
“Experimental Procedures.” (A), cells were lysed and analyzed by immunoblotting with 
anti-HA or anti-WDFY2 antibodies to confirm similar levels of expression of both Akts 
and expression of WDFY2 proteins. (B), cells were added to 96-well multiwell dishes, 
and α-galactosidase expression was measured over time. Similar results were obtained 
when measuring growth. (C), quantification of growth after 300 minutes, where the 
statistical significance of the differences was calculated by two-tailed Student's t tests, is 
indicated in the figure. 
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Discussion 
The mechanisms by which the different isoforms of Akt control specific aspects 
of cell function are not fully understood. Here, we find that the endosomal protein 
WDFY2 interacts preferentially with endogenous Akt2 and promotes the maintenance of 
Akt2 protein levels. This interaction is critical, as depletion of WDFY2 leads to 
generalized impairment in downstream substrate phosphorylation and in downstream 
effects of Akt2, such as insulin-stimulated glucose transport. Together with recent work 
demonstrating an important role for the endosomal protein APPL1 in the stimulation by 
Akt2 of glucose transporter translocation, our results underscore the critical role of the 
endocytic pathway in insulin signaling through Akt, and in fine tuning the specific roles 
of Akt isoforms in cell physiology. Thus, further experiments in vitro with purified 
proteins will be necessary to determine the structural basis and the detailed kinetics of the 
interactions between WDFY2 and each Akt isoform, to determine whether this 
mechanism could account for our observations in live cells.  
Indirect mechanisms could also underlie the isoform-specific interaction between 
endogenous Akt2 and WDFY2. Immunofluorescence analysis of endogenous Akt1 and 
Akt2 shown here indicates a substantial amount of these kinases sequestered in the 
nucleus. Thus, subtle changes in the extent of nuclear translocation may lead indirectly to 
a preferential interaction of Akt2 with endosomal components. Further experiments to 
analyze the general determinants of Akt subcellular localization are necessary to test this 
hypothesis.  
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A salient effect of WDFY2 depletion is a decrease in total protein levels of Akt2, 
raising the question of how steady-state levels of Akt isoforms are controlled. The 
decrease in Akt2 protein levels seen in WDFY2-depleted cells occurs prior to a decrease 
in Akt2 mRNA levels, suggesting that posttranscriptional mechanisms such as increased 
degradation may be involved. Ubiquitination and degradation of Akt have been 
demonstrated to occur and be important during the establishment of neuronal polarity 
(204). Ubiquitination and degradation of Akt have also been implicated in the induction 
of insulin resistance by tumor necrosis factor and in tumorigenesis (205-206). However, 
it is not known whether the turnover of Akt1 and Akt2 proceeds at different rates or is 
controlled by distinct mechanisms. The association of Akt2 with WDFY2 on early 
endosomes may protect the kinase from ubiquitination and proteosomal degradation, 
whereas the sequestration of Akt1 in the nucleus may fulfill a similar protective role.  
The findings that Akt interacts with two proteins that are localized to endosomes 
raises the possibility that these interactions may be functionally related. APPL1 has been 
shown to interact in adipocytes with Akt2, and its depletion leads to impairments in 
insulin-stimulated Akt phosphorylation and glucose uptake (115). Paradoxically, over-
expression of full-length APPL1 also suppresses insulin action (115). These results, 
together with recent studies suggesting that APPL-enriched endosomes become enriched 
in WDFY2 as they lose APPL (183), suggest a model in which Akt2 may be transferred 
from APPL to WDFY2 to allow sustained substrate phosphorylation by this kinase 
(Figure 3-8). Knockout of APPL may impair insulin action by preventing the initial 
localization of Akt2 to the endocytic pathway, but over-expression may then impair the 
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transfer of Akt2 to WDFY2. A role for WDFY2 in sustaining Akt2 signaling is suggested 
by immunofluorescence data where cells over-expressing WDFY2 display enhanced 
phospho-Akt staining in response to insulin (data not shown). Further experiments 
imaging Akt dynamics relative to APPL and WDFY2 in live cells will be required to test 
this hypothesis.  
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Figure 3-8  Model for role of WDFY2 in endosomal control of Akt2 signaling  
In this model the initial event in Akt2 activation is the interaction of its PH domain with 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) generated at the plasma membrane. 
Subsequently, the kinase interacts with APPL in the initial phase of endocytosis, when 
the levels of phosphatidylinositol (3,4,5)-trisphosphate decrease. Phosphatidylinositol 3-
phosphate (PI3P) is then generated, and WDFY2 replaces APPL on endosomes. Akt2 
binds to WDFY2 and becomes stabilized and protected from degradation. Substrate 
phosphorylation can proceed from WDFY2-enriched endosomes.  
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CHAPTER IV 
SUMMARY AND DISCUSSION 
This thesis work has investigated the effect of mitochondrial dysfunction on 
insulin signaling and glucose transport in 3T3-L1 adipocytes, showing that mitochondrial 
dysfunction can be a primary cause for insulin resistance in adipocytes. As one of the key 
events in insulin-stimulated glucose uptake in adipocytes, the regulation and activation of 
Akt is of importance. We also examined the role of another intracellular organelle, the 
endosome, in the regulation of signal transduction in 3T3-L1 adipocytes. Particularly we 
studied the endosomal protein WDFY2 and its involvement in Akt signaling transduction, 
revealing a mechanism through which Akt isoform specificity is regulated, at least 
partially, through the preferential interaction with WDFY2 (Figure 4-1). 
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Figure 4-1  Model for insulin regulated glucose uptake in 3T3-L1 adipocytes 
involving the mitochondria and endosomes.  
The depletion of Tfam results in reduced respiratory chain function and ATP synthesis in 
mitochondria, which in turn inhibits GLUT4 translocation to the cell membrane and 
glucose uptake, while increasing total phosphorylation of Akt at Ser473. Endosomal 
protein WDFY2 has a higher affinity for Akt2 than for Akt1, thus specifically regulating 
Akt2 protein stability and its signaling transduction. 
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Mitochondrial Dysfunction and Insulin Resistance in WAT 
In type 2 diabetes, the insulin-responsive organs including liver, skeletal muscle 
and adipose tissue fail to effectively respond to insulin, resulting in elevated blood 
glucose levels. It has been proposed that skeletal muscle accounts for the majority of the 
glucose uptake after a meal, based upon the fact that muscle comprises approximately 40% 
of the total body mass (207). However, a systematic failure of blood glucose control 
could be caused by a subtle imbalance between glucose production and clearance among 
several tissues, including adipose tissue. Therefore, even though adipose tissue does not 
constitute a significant portion of the whole body mass in an average person, its failure to 
take up blood glucose in response to insulin could still be a cause for type 2 diabetes. 
This leads to the idea that a healthy and functional adipose tissue is necessary for whole 
body energy homeostasis. In addition, compromised adipose tissue function is found to 
be associated with severe obesity and type 2 diabetes, further supporting such a 
hypothesis that healthy well-functioning adipose tissue is crucial for whole body energy 
homeostasis. 
Adipocyte differentiation is accompanied by mitochondrial biogenesis (26), 
suggesting a requirement for increased mitochondrial function in adipocytes compared to 
preadipocytes. Although the exact role of mitochondrial biogenesis in adipocytes is not 
known, a growing body of evidence points to a close relationship between adipose 
mitochondrial dysfunction and type 2 diabetes (19-20). It appears that adipocyte 
mitochondrial biogenesis is an adaptive response to support its fat-specific function. 
Therefore we tested the hypothesis that inhibition of adipocyte mitochondrial biogenesis 
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could lead to impaired insulin action, particularly, impaired insulin-stimulated glucose 
uptake. Our approach was to create adipocytes with less mitochondrial biogenesis and 
then evaluate the effect on adipocyte functions.   
There are many types of tissue-specific mitochondrial dysfunction animal models 
available; however none of them are WAT-specific (54-55).  One possible reason is that 
adipose tissue has been conventionally considered as non-active tissue that requires 
limited mitochondrial activity. Another reason could be the lack of a WAT-specific 
promoter. To circumvent the disadvantages with in vivo animal models, we decided to 
employ the 3T3-L1 cell line, which is commonly used as a model for adipocytes 
differentiation and function.  
In order to inhibit mitochondrial biogenesis or, equivalently, mitochondrial 
function, we started with the canonical master regulator of mitochondrial biogenesis 
PGC-1α. However, the activity of PGC-1α is so versatile that interfering with PGC-1α 
could lead to a very broad effect on cell functions and adipocyte differentiation, which 
would further complicate our interpretation of mitochondrial function in adipocytes.  We 
then directly focused on the mitochondrial DNA, which is encapsulated in the 
mitochondrial membrane and encodes thirteen proteins specifically for mitochondrial 
ETC complexes and ATP synthase. The replication and transcription of mtDNA largely 
depend on Tfam.  In fact, both mtDNA copy number and the expression of Tfam are 
markedly induced during adipocyte differentiation, suggesting a requirement for mtDNA 
amplification and transcription during adipogenesis. By introducing Tfam siRNA during 
the 3T3-L1 adipocyte differentiation, we were able to inhibit the increase in mtDNA copy 
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number and transcription. Further analysis revealed that general adipogenesis 
programming was not affected, evidenced by analysis of adipocyte functions and 
morphology. This was later supported by whole genome expression profiling with an 
Affymetrix GeneChip assay, in which less than 0.2% of total nuclear gene expressions 
changed by >1.5-fold (Table 4-1). 
The specific inhibition of Tfam resulted in morphologically normal adipocytes 
with the exception that these adipocytes now showed reduced OXPHOS activity and ATP 
levels. The overall reduced OXPHOS activity was evidenced by a reduction in the 
consumption rate of oxygen, the electron acceptor of the ETC.  As a result, the coupled 
generation of ATP from mitochondrial ATPase was also impaired. This was 
demonstrated in two ways: first, the steady-state intracellular ATP level was reduced by 
10-15%; and second, the dynamic ATP synthesis from ATPase was reduced by 50%. 
Therefore, specific inhibition of Tfam allowed us to create adipocytes with impaired 
mitochondrial function, characterized by lower OXPHOS activity and ATP synthesis. 
The effects of mitochondrial dysfunction in these Tfam-depleted adipocytes were 
then evaluated in the context of insulin-stimulated glucose uptake, which is an important 
function of adipocytes in glucose metabolism. 3H-labeled 2-deoxyglucose (2-DOG) was 
used to determine the insulin-stimulated glucose in these adipocytes. Data showed that 
these Tfam-depleted adipocytes had reduced insulin-stimulated glucose uptake (Figure 2-
5, A).  2-DOG is taken into the cell and is phosphorylated by hexokinase, but cannot be 
further processed along the glycolysis pathway. The removal of 2-DOG by hexokinase 
phosphorylation will facilitate the equilibrium of glucose towards entering the cell. To 
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exclude the possibility that impaired glucose uptake in Tfam-depleted adipocytes results 
from impaired phosphorylation of 2-DOG, a non-phosphorylatable glucose analogue 3-
O-methylglucose was used to determine the glucose transport, which also showed 
reduced glucose uptake in Tfam-depleted adipocytes (Figure 2-5, B). These data suggest 
that mitochondrial dysfunction can impair insulin-stimulated glucose uptake, therefore 
could be a direct cause for insulin resistance in adipocytes. 
We further explored the underlying mechanism for impaired insulin-stimulated 
glucose uptake in Tfam-depleted adipocytes.  Insulin-stimulated activation of Akt and 
translocation of GLUT4 towards the cell membrane have been proposed to be crucial for 
glucose transport in adipocytes. We investigated whether these two events could be 
linked to the observed impairment in glucose uptake in Tfam-depleted adipocytes. First, 
we examined GLUT4 translocation in response to insulin stimulation. Taking advantage 
of TIRF technology, we were able to directly observe and quantify the membrane 
localization of the fixed-and-stained endogenous GLUT4 proteins, eliminating the 
complications of over-expressing a GLUT4 construct. Our data showed that the insulin-
stimulated GLUT4 enrichment on the cell membrane significantly decreased with Tfam 
depletion in adipocytes, although the total cellular GLUT4 protein level was not changed, 
suggesting an impairment in GLUT4 trafficking to the cell surface. We speculated that 
this was due to a failure of Akt activation, since Akt has been shown to play a critical role 
in glucose uptake. At this point, we looked at the phosphorylation of Akt at Ser473 with 
insulin stimulation. Surprisingly, insulin-stimulated phosphorylation of Ser473 was 
increased in Tfam-depleted adipocytes; and this increase was not a result of elevated total 
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Akt protein level. This finding contradicts our belief that Akt phosphorylation should 
correlate with increased glucose transport.   
The paradoxical effect of Tfam-depletion on glucose transport and Akt 
phosphorylation indicates that mitochondrial dysfunction might act through an Akt-
independent mechanism to affect insulin-stimulated glucose uptake. Since Tfam-
depletion impaired mitochondrial respiratory activity and ATP synthesis, we speculated 
whether decreased ATP level in these adipocytes caused such a phenotype. To mimic the 
effect of ATP depletion, we treated the cells with the ETC complex I inhibitor rotenone, 
which rapidly caused an ATP level drop, similar to the drop seen in Tfam-depleted cells 
(Figure 2-6, A). However, such a chemical inhibition on ETC simultaneously impaired 
the insulin signaling to Akt as assessed by Ser473 phosphorylation (Figure 2-6, D). The 
discrepancy in Akt phosphorylation between Tfam-depletion and rotenone inhibition 
reflects the difference between progressive and acute respiratory chain impairment, in 
which Tfam-depletion may elicit compensatory changes during several days of 
differentiation. The increased Akt phosphorylation could be one of such compensatory 
changes. Furthermore, acute inhibition of ETC by rotenone exposure causes a quick 
adaptive change with increased glucose uptake (163), which is opposite to what we 
observed in the Tfam-depleted cells. Thus, acute drug treatment is not an ideal model to 
recapitulate the Tfam-depletion effect on insulin signaling and glucose uptake.  
The increased phospho-Akt in Tfam-depleted adipocytes is not accompanied by 
an increased glucose uptake, suggesting that Akt phosphorylation can be delinked from 
glucose transport. However, there are still possible explanations to reconcile this 
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contradiction without breaking this linkage. For example, it should be noted that, when 
observing phospho-Akt, we did not distinguish between Akt1 and Akt2 isoforms. 
Therefore, it is possible that one of the isoforms, especially Akt2, might be 
hypophosphorylated even though total Akt phosphorylation is enhanced. Since only Akt2 
plays an indispensible role in glucose homeostasis, such a difference in phosphorylation 
of Akt1 and Akt2 could lead to impaired insulin-stimulated glucose uptake while 
exhibiting a higher total Akt phosphorylation. However, this possibility needs to be 
carefully evaluated in terms of Akt1 and Akt2 isoform-specific phosphorylation. 
Additionally, in vivo studies point to a similar increased Akt signaling phenotype with 
mitochondrial dysfunction. For example, the muscle and liver-specific apoptosis inducing 
factor (AIF) knockout mice showed compromised mitochondrial respiratory function, but 
were accompanied by increased insulin sensitivity assessed by Akt phosphorylation (168). 
Muscle-specific Tfam knockout mice were not diabetic and showed increased basal 
glucose uptake (169). Conversely, over-expression of PGC-1α in muscle dramatically 
increased muscle mitochondrial density and ATP synthesis, yet decreased insulin-
stimulated glucose uptake, making the mice more prone to fat-induced insulin resistance 
(208).  Therefore, it appears that cells develop a general feedback response to compensate 
for impaired or enhanced mitochondrial function regardless of in vitro and in vivo 
differences. However, such a feedback mechanism by which cells manage to maintain 
overall energy homeostasis may display different metabolic features depending on tissue 
or cellular content.  In our in vitro 3T3-L1 model, the mitochondrial dysfunction causes 
decreased glucose transport, which is opposite to what was observed in in vivo AIF or 
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Tfam muscle-specific knockout mice (169, 208). This difference may result from the fact 
that muscle-specific AIF or Tfam knockout mice expressed increased GLUT1 and 
GLUT4 protein levels (169, 208), but Tfam-depleted 3T3-L1 adipocytes did not. 
To better understand the mechanism by which Akt phosphorylation and glucose 
transport might be affected by Tfam-depletion, we analyzed the general phosphorylation 
of Akt substrates using the PAS antibody. In accordance with increased phospho-Akt at 
Ser473 in Tfam-depleted adipocytes, several major insulin-stimulated phosphoproteins 
were also increased on western blots detected by PAS. However, an unknown ~49 kDa 
insulin-responsive phosphoprotein had reduced phosphorylation with Tfam-depletion. 
Such an observation implies that, despite a total increase in Akt activation, 
phosphorylation of certain Akt substrate(s) can be down-regulated in Tfam-depleted 
adipocytes. If this observed ~49 kDa protein is a critical component for insulin-
stimulated glucose transport, then it may help to explain our seemingly paradoxical effect 
of Tfam-depletion on Akt phosphorylation and glucose transport.  
In an attempt to isolate and purify this mysterious ~49 kDa protein that is 
hypophosphorylated in Tfam-depleted adipocytes, we coincidently identified a 50 kDa 
protein eukaryotic elongation factor 1A (eEF1A) from a mass spectrometry experiment, 
which can be phosphorylated by Akt upon insulin stimulation (Appendix). However, 
knockdown of eEF1A by siRNA in adipocytes had no effect on insulin-stimulated 
glucose uptake (data not shown), suggesting that eEF1A is not the putative ~49 kDa 
protein that mediates glucose transport.  
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We also tried to explore the general effect of Tfam-depletion on nuclear gene 
expression at the whole genome level with Affymetrix Genechip analysis. Among the 
approximately 45,000 transcripts, only about 50 genes were either up-regulated or down-
regulated by >1.5-fold with Tfam-depletion and none of them changed >3-fold except for 
Tfam (Table 4-1). Such a relatively mild effect on nuclear gene expression implies that 
Tfam-depletion does not have a dramatic impact on general transcription. This is not 
surprising, since the Tfam-depletion specifically interferes with mtDNA and impairs 
OXPHOS and intracellular ATP level, a general effect of insufficient energy supply 
could have occurred at other regulatory levels such as protein synthesis and signal 
transduction, in which energy supply is crucial. One small GTPase, Rab21, which is 
involved in the early endocytic pathway (209), showed a mild decrease in its expression 
level (67% of control) in Tfam-depleted adipocytes. Considering the important role of 
GTPases in vesicle trafficking (84), we tested whether Rab21 plays a role in GLUT4 
translocation and glucose uptake. RNAi mediated knockdown of Rab21 in 3T3-L1 
adipocytes markedly impaired insulin-stimulated glucose uptake (Figure 4-1, B). This 
impairment was accompanied by decreased Akt phosphorylation at Ser473 and Thr308 
(Figure 4-1, A). Although the mechanism of enhanced total Akt phosphorylation in Tfam-
depleted adipocytes is unclear, the down-regulation of Rab21 could be one of the factors 
that contributes to impaired insulin-stimulated glucose uptake in these cells. Many other 
Rab GTPases are also important for endocytosis, in which they help to specify vesicle 
destination or function (210). The observation that knockdown of Rabs (Rab21 and many 
other Rabs not shown here) affects Akt phosphorylation suggests a possible role for 
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endosomes in the regulation of Akt signal transduction. We tested this hypothesis by 
examining the interaction of endosomal protein WDFY2 with Akt1 and Akt2, and 
evaluating the effects of such interactions on Akt isoform-specificity determination. We 
showed that the endosome protein WDFY2 has a higher affinity for Akt2 than for Akt1; 
therefore preferentially regulating Akt1 protein function (Chapter III). 
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Table 4-1 GeneChip analysis of Tfam knockdown in 3T3-L1 adipocytes 
3T3-L1 was electroporated with Tfam siRNA at day 2 of differentiation. Total RNA was 
extracted at day 6 of differentiation. Gene expressions were analyzed with Affymetrix 
GeneChip® Mouse Genome 430 2.0 Array. The genes that changed expression level by > 
1.5-fold (up or down) are listed in the table above. 
Gene Symbol Down-
regulation 
Gene Symbol Up-
regulation 
Tfam 
BC010981 
Mreg 
BC023829 /// LOC100045774 
Vldlr 
Hmox1 
Scd3 
9130401M01Rik 
Ublcp1 
Kdelr3 
Acox2 
LOC100048724 /// Scd3 
Slc4a4 
LOC100045709 /// Ublcp1 
Pdcd11 
1500016O10Rik 
Ndrg1 
Elovl3 
0610010O12Rik 
Ddit3 
Atf3 
Spp1 
2900092E17Rik 
Npc1 
Myd116 
Mt2 
Smad1 
Csnrp2 
Slain2 
Pvr 
Ermp1 
AU019823 
Pfkp 
 
-3.23 
-2.12 
-2.08 
-1.92 
-1.91 
-1.79 
-1.70 
-1.67 
-1.67 
-1.65 
-1.65 
-1.64 
-1.63 
-1.59 
-1.59 
-1.59 
-1.58 
-1.58 
-1.56 
-1.55 
-1.55 
-1.54 
-1.53 
-1.53 
-1.53 
-1.52 
-1.52 
-1.51 
-1.51 
-1.51 
-1.51 
-1.51 
-1.50 
 
BC055107 
Pdzk1 
Car2 
Atp1b1 
Angptl1 
Errfi1 
Igf2 
A030001D16Rik 
Inhbb /// LOC100046802 
Chst1 
D0H4S114 
Cyb561 
Ear2 
Pnpla3 
Ear3 
Ear1 /// Ear12 /// Ear2 /// Ear3 
Ifi27 
Thbd 
Greb1 /// LOC100045413 
Car3 
Hp 
Aqp1 
 
1.50 
1.51 
1.51 
1.51 
1.51 
1.54 
1.55 
1.56 
1.58 
1.60 
1.61 
1.61 
1.64 
1.67 
1.78 
1.80 
1.89 
1.92 
1.96 
2.16 
2.19 
2.20 
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Figure 4-2  Knockdown of Rab21 impairs Akt phosphorylation and glucose 
transport 
(A), siRNA were introduced by electroporation at day 4 of 3T3-L1 adipocyte 
differentiation. Day 7 mature adipocytes were stimulated with 0, 10 or 100 nM insulin for 
15 minutes. Whole cell lysate were subjected to western detection of phospho-Akt. (B), 
Day 7 control or Rab21 knockdown adipocytes were evaluated for the insulin-stimulated 
glucose uptake. Experiments were repeated three times. *, p value<0.001 and **, p 
value<0.01 with student t-test. 
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One intriguing question is whether over-expression of Tfam in 3T3-L1 adipocytes 
increases insulin sensitivity. The actual consequences of Tfam over-expression in 3T3-L1 
adipocytes is hard to predict, but remains of great interest. Although Tfam over-
expression in mice generally increases mtDNA copy number (211), transient over-
expression of Tfam in cultured cells does not (212). In the mice with Tfam over-
expression as well as increased mtDNA, the respiratory chain capacity and mitochondrial 
mass is not changed (211). This suggests that the mtDNA encoded proteins are not the 
rate limiting factors that defines the respiratory chain capacity. Moreover, force-increased 
mtDNA copy number by Tfam and/or Twinkle over-expression in mice results in 
enlarged mtDNA nucleoids, accompanied by inhibited mtDNA transcription and 
increased mtDNA deletion, thus has an overall detrimental effect (213). Interestingly, 
Tfam over-expression in several other studies does ameliorate the mitochondrial 
dysfunction and symptoms under certain situations. For example, Tfam over-expression 
ameliorates mitochondrial deficiency and cardiac failure after myocardial infarction (214) 
and reverses age-dependent memory impairment and mtDNA damage (215) in mice; it 
also protects the cell function from the damage induced by hyperglycemia in 
cardiomyocytes (216) or from the oxidative damage induced by beta-amyloid in SH-
SY5Y cells (217); the delayed neuronal death after transient forebrain ischemia is also 
reduced in Tfam over-expressing mice (218). The protective effect of Tfam over-
expression is not dependent on its mtDNA transcription activity, but rather on its role in 
maintaining the integrity of the mtDNA nucleoid structure (217). It was recently reported 
that Tfam has multiple weak nuclear localization signals (NLS) (219). The Tfam nuclear 
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localization has also been found in a rat hepatoma where Tfam is over-expressed (220). 
The function of nuclear Tfam is not clear but may have cytoprotective effect on DNA 
damage in response to chemotherapeutic drugs (221). This might act through the Tfam 
binding to nuclear DNA, since Tfam has high affinity for mtDNA and help to pack 
mtDNA into nucleoid structure (222). Given the complexity of Tfam over-expression, it 
might not be a good model to evaluate the effect of enhanced mitochondrial OXPHOS 
function in glucose homeostasis. 
In this study, the assessment of insulin action on adipocytes largely depends on 
the radio-labeled glucose uptake assay. Therefore, it is critical that such assays reflect as 
much as possible the actual glucose uptake process in the cell. In a physiological situation, 
the glucose molecule enters the glycolysis pathway and gets metabolized quickly after 
internalization, making it hard to track the uptake event. Therefore, we applied non-
metabolized glucose analogue 2-deoxyglucose or 3-O-methylglucose in the assay. 
However, the non-metabolized glucose analogue continues to accumulate inside the cell 
and its concentration gradually reaches an equilibrium state, inhibiting the further uptake. 
Therefore, it is critical to measure the glucose uptake before the glucose analogue gets 
saturated. For 2-deoxyglucose, a 5-minute time period has been commonly used to reflect 
the actual speed of glucose uptake. However, the 3-O-methylglucose has a much shorter 
equilibration time. It is estimated that the half-time for achieving complete equilibration 
of 3-O-methylglucose in 3T3-L1 adipocytes is 12 and 125 seconds in insulin stimulated 
and basal state, respectively (223). In our study, we adopted 1-minute incubation time to 
accommodate the experimental setting in a multi-well plate, in which time period the 
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intracellular 3-O-methylglucose reaches ~80% of the maximal concentration (223). This 
prolonged incubation time might compromise the accuracy of the measurement, thus 
caution must be taken when interpreting the data.  
Another issue arises with this study is whether Tfam depletion reflects the 
pathophysiological mitochondrial dysfunction in a diabetic state. In fact, in the ob/ob 
diabetic mice, a systematic mitochondrial protein down-regulation is observed (25), with 
about 50% of all mitochondrial protein transcripts decreased. However, the expression of 
Tfam transcript is not among those decreased. The direct manipulation of Tfam was used 
as a tool to introduce a first mitochondrial dysfunction signal to determine the cause-and-
effect relationship between mitochondrial dysfunction and insulin resistance in diabetes. 
Although Tfam depletion caused insulin resistance in 3T3-L1 adipocytes, we did not see 
a general down-regulation of mitochondrial protein transcripts. Furthermore, Tfam 
depletion did not change the nuclear gene expression profile either. In an in vivo situation, 
however, it is possible that Tfam depletion in adipose tissue will eventually cause insulin 
resistance and defects in blood sugar control at the whole body level and in turn will 
further impair the mitochondrial protein expression and function.  
In future studies, several aspects of the Akt signaling that have not been 
investigated in this work will be explored. The isoform-specific phosphorylation of Akt 
will be compared between control and Tfam-depleted adipocytes in response to insulin 
treatment, which will provide clues of whether Akt2 phosphorylation is decreased.  
Further effort will be made to identify the ~49 kDa protein, whose phosphorylation by 
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Akt has been impaired by Tfam-depletion. The function of this protein in glucose 
transport will also be determined.  
Finally, I will extend my study to an in vivo system to test whether fat-specific 
mitochondrial dysfunction can cause insulin resistance in whole body animals. For 
example, we can cross Tfamloxp/Tfamloxp mice with mice expressing Cre recombinase 
from an adipose tissue-specific promoter (e.g. adipocytes P2, aP2) to generate mice with 
fat-specific mitochondrial dysfunction. However, the challenge is that sometimes aP2 
promoter also expresses in BAT (224) and macrophages (225). Therefore the 
interpretation of aP2-driven knockout mice will be complicated. An ideal WAT-specific 
promoter may be discovered in the future. But until then, different fat depots from aP2-
driven Tfam knockout mice can be dissected and evaluated for their individual metabolic 
and functional changes. Such studies will provide a broader picture of fat mitochondrial 
dysfunction in the pathophysiology of insulin resistance and type 2 diabetes. 
Our Tfam-depleted 3T3-L1 adipocytes provides a useful alternative system for 
studying mitochondrial dysfunction in adipose tissue, and also can be expanded to other 
cell lines to study mtDNA function. However, in vivo study is required to assess the 
whole body effect from a single organ mitochondrial dysfunction, especially when such 
an effect causes general feedback responses in the whole body animal. 
As a conclusion, in this study, I have established an in vitro WAT-specific model 
to investigate the question of whether mitochondrial dysfunction causes insulin resistance 
in adipose tissue. The knockdown, instead of knockout, of Tfam circumvents the lethal 
issue accompanied with mitochondrial dysfunction, while it provides very specific and 
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confined effect on mitochondria. Our results show that mitochondrial dysfunction can be 
a primary cause for insulin resistance in adipocytes. The unexpected result is that Tfam-
depletion seems to trigger a feedback response to compensate for the loss of 
mitochondrial function as manifested by increased insulin signaling to Akt.  
Isoform-Specific Regulation of Akt Signaling by WDFY2 
In insulin responsive tissues such as muscle and adipose tissue, Akt signaling 
plays a pivotal role mediating whole body energy homeostasis. Akt acts through a series 
of phosphorylation cascades to affect the functions of downstream pathways, such as 
glycogen synthesis, glucose uptake and fatty acid synthesis. The highly homologous Akt 
isoforms Akt1, Akt2 and Akt3 exhibit distinct but overlapping physiological functions 
during development or diseases (62). The knockout mouse model points to an 
indispensible role for Akt2 in glucose metabolism and insulin sensitivity (73). In 
adipocytes, both Akt1 and Akt2 are expressed and phosphorylated upon insulin 
stimulation, however only Akt2 is critical for glucose uptake. This raises the question of 
how the cells distinguish between these two isoforms according to different physiological 
requirements. 
It came to our attention that Akt isoform-specific regulation may at least rely on a 
mechanism that involves endosomes. The endosomal pathway plays an important role in 
diversifying signal transduction. Different receptors traffic through distinct endosomal 
populations (177-178) and their fates are determined by the endocytic pathway (184-188). 
Recent studies have shown that the endosomal proteins APPL1 and APPL2 may help to 
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determine the Akt1 and Akt2 isoform specificity. For example, Akt2, but not Akt1, was 
found to be localized in APPL-containing endosomes (114-115); and APPL1-containing 
endosomes mediate Akt substrate specificity by dynamically interacting with specific Akt 
substrates (116). Previously, our lab has identified a new endosomal protein WDFY2, 
which defines a distinct endosomal population lacking the canonical markers EEA1 and 
Rab5 (146, 183). We investigated if WDFY2 plays a similar role as APPL1 to mediate 
Akt2 isoform specificity in 3T3-L1 adipocytes, which is a good model to study the 
insulin action and Akt signaling pathway. 
We first examined if WDFY2 had any general effect on insulin signaling in 
mature 3T3-L1 adipocytes, in which we measured the insulin-stimulated glucose uptake.  
The results showed that siRNA-mediated knockdown of WDFY2 had an inhibitory effect 
on insulin-stimulated glucose uptake in 3T3-L1 adipocytes, comparable to Akt2 
knockdown (Figure 3-1, A). This suggested that WDFY2 plays a role in insulin signaling 
and Akt regulation. Surprisingly, the WDFY2 knockdown seemed to directly affect the 
Akt2 protein level (Figure 3-1, C). Since WDFY2 is an endosomal protein, which may 
regulate many substrates including components for general protein synthesis and 
degradation, we examined whether the down regulation of Akt2 protein level is specific. 
In fact, the WDFY2 knockdown had no effect on protein levels of Akt1, and a house 
keeping protein β-actin (Figure 3-2, C). Additionally, the WDFY2 knockdown effect on 
Akt2 protein level was not due to some off-target effects. Different WDFY2 siRNA 
oligos showed different effectiveness on WDFY2 knockdown, which is proportional to 
the extent of the Akt2 protein down-regulation (Figure 3-2, D). Knockdown of another 
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endosome protein EEA1 had no effect on Akt2 protein level. These data suggest that 
endosomal protein WDFY2 has a preferential effect on Akt2 protein level and may 
distinguish the Akt1 and Akt2 functionality in 3T3-L1 adipocytes. 
We were interested in the mechanism by which WDFY2 determines Akt2 
specificity. By immunostaining and fluorescent microscope, we were able to visualize the 
subcellular distributions of endogenous WDFY2, Akt1 and Akt2. WDFY2 localized to a 
subpopulation of endosomes, exhibiting a punctate pattern. However, Akt1 and Akt2 
displayed both nuclear and cytosolic distribution (Figure 3-4, A and B). By looking at the 
distribution of either Akt1 or Akt2 in WDFY2-defined regions, we saw a significant 
difference between these two Akt isoforms. Akt2 is more prone to localize to WDFY2-
containing endosomes (Figure 3-4, C and D). These observations support a hypothesis 
that WDFY2 specifically regulate a portion of Akt2 by preferential co-localization. This 
co-localization might be through direct interaction of WDFY2 and Akt. It has been 
shown that WDFY2 is an Akt1 partner in a yeast two-hybrid screen (194), suggesting the 
existence of a direct protein-protein interaction. The stronger co-localization of Akt2 than 
Akt1 with WDFY2 probably reflects the stronger affinity between Akt2 and WDFY2. 
This was confirmed by our quantitative yeast two-hybrid interaction assay (Figure 3-7), 
in which the yeast strain co-expressing WDFY2 and Akt2 showed stronger reporter 
activity than the yeast strain co-expressing WDFY2 and Akt1. 
In addition to Akt2, WDFY2 may involve in a broader range of target protein 
regulation. For example, protein kinase Cζ and the transcription factor FOXO1 were 
reported to interact with WDFY2 (195, 202). We observed that WDFY2 knockdown had 
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a stronger effect than Akt2 knockdown on a group of metabolic and adipogenic gene 
expressions (Figure 3-6), suggesting that WDFY2 may regulate a variety of different 
targets other than Akt2. Taken together, it appears that WDFY2 interacts with different 
partners to regulate different pathways. 
In diseases like type 2 diabetes and cancer, Akt isoform-specific abnormalities 
have been described frequently in recent years (226). Therefore, understanding the 
mechanism of Akt isoform-specific regulation will help to develop specific therapeutic 
interventions. In our study, we demonstrated that endosomal proteins and the endocytic 
pathway could be a general mechanism by which cells can regulate Akt signal 
transduction in an isoform-specific manner. The molecular details of the endocytic 
regulatory network of Akt isoform specificity will benefit from the identification of other 
components in the WDFY2-containing endosomes. Additionally, investigating the 
differential temporospatial expression, subcellular distribution, substrate specificity, and 
binding partners, will reveal other regulatory mechanisms of Akt isoform specificity. 
Identification of new interacting partners of WDFY2 will be helpful to address the 
versatility of this endosomal protein. 
In the future, work can be done on two aspects to deepen and expand the findings 
described here. First, we can further explore the Akt1 and Akt2 isoform specificity in a 
detailed and systematic manner to draw a bigger picture of the molecular mechanism of 
the specificity. For example, in a specific tissue that exhibits Akt isoform-specificity, we 
can utilize the quantitative proteomics to identify Akt isoform-specific binding partners. 
Comparisons can also be made at the whole-genome expression level with GeneChip 
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analysis. Since Akt mediates many phosphorylation cascades, phosphoprotein profiling 
may also help to identify potential Akt substrates. Second, the specific function of 
WDFY2 in regulating trafficking and signal transduction can be further explored. The 
whole body or tissue-specific WDFY2 transgenic animal can be made to evaluate its in 
vivo functions. 
In summary, we provided one mechanism of how Akt2-specific function in 3T3-
L1 adipocytes is regulated by the endocytic pathway, in which the endosomal protein 
WDFY2 preferentially interacts with and stabilizes Akt2. Our findings underscored the 
complexity of the regulation of Akt signaling in adipocytes and may be valuable for 
developing new therapeutic interventions for the treatment of obesity or type 2 diabetes. 
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APPENDIX 
PHOSPHORYLATION OF EUKARYOTIC ELONGATION 
FACTOR 1A BY AKT AND ITS IMPLICATION IN PROTEIN 
SYNTHESIS AND CELL GROWTH 
Abstract 
Serine/threonine protein kinase Akt mediates signal transductions that control a 
variety of cellular functions including protein synthesis and cell growth. Eukaryotic 
elongation factor 1a (eEF1A) is a GTPase involved in protein synthesis elongation, 
carrying the aminoacyl-tRNA to the peptide elongation site. Here we employ the 
phospho-Akt substrate (PAS) antibody, which recognizes potential Akt substrates, to 
identify eEF1A as an insulin-stimulated phospho-protein recognized by the PAS antibody. 
We show that eEF1A can be phosphorylated by Akt in vitro and two phosphorylation 
sites Thr269 and Thr432 were identified.  Mutation of either phosphorylation site to aspartic 
acid causes protein instability while mutation of either phosphorylation site to alanine did 
not, but decreased the protein translational activity. We hypothesize that Thr269 and Thr432 
are important for eEF1A function.  
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Introduction 
Serine/threonine kinase Akt, also known as protein kinase B (PKB), 
phosphorylates the hydroxyl group of a specific serine or threonine in its substrate. This 
phosphorylation-dependent regulation constitutes an Akt-centered signal transduction 
network downstream of insulin/PI-3K in the cell (227). In muscle and adipose tissue, Akt 
signaling plays a key regulatory role in glucose metabolism, in that Akt is required for 
insulin-stimulated glucose uptake. Akt also regulates protein synthesis and cell growth 
via mammalian target of rapamycin (mTOR) pathways. 
One strategy to dissect Akt-regulated physiological processes is to identify Akt 
substrates, which link Akt and its regulatory targets. Since the identification of glycogen 
synthase kinase as the first Akt substrate (228), much effort has been taken to identify 
new Akt substrates. One breakthrough is that Alessi et al. described the Akt kinase 
minimal recognition motif RXRXXp(S/T)B (229), where R represents arginine, X 
represents any amino acid and B represents bulky hydrophobic residues. A method was 
then developed to identify potential Akt substrates using antibodies based on such motif 
recognition (230). In fact, over 100 non-redundant Akt substrates has been reported in the 
literature, among which approximately 75% contain this minimum motif (61). A 
commercially available phospho-Akt substrate antibody (PAS) has been used 
successfully to identify new Akt substrates in 3T3-L1 adipocytes (82, 166). Here we 
describe the identification of eEF1A as an Akt in vitro substrate using the PAS antibody 
in 3T3-L1 adipocytes. The phosphorylation sites of eEF1A at Thr269 and Thr432 were 
confirmed by an in vitro kinase assay. Mutation of the phosphorylation sites to alanine or 
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aspartic acid negatively regulated translational activity of eEF1A in HeLa cells. We 
hypothesized that Thr269 and Thr432 of eEF1A has regulatory functions on eEF1A activity. 
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Experimental Procedures 
Reagents and Material 
Most of the antibodies used in this study were from Cell Signaling: Rabbit 
Phospho-Akt Substrate (PAS) antibodies (#9611 and #9614). Rabbit eEF1A antibody 
(#2551), Rabbit Akt1 (#2938), Akt2 (#3063), pAkt(Thr308) (#9275), pAkt(Ser473) 
(#9271), pGSK-3α/β (#9327). All antibodies were used at a 1:1000 dilution in TBST 
buffer supplemented with 4% BSA. Mouse anti-beta actin antibody was purchased from 
Sigma. All the active kinase proteins, Akt1 (#7535), Akt2 (#7503), PKC ζ(#7608), S6 
Kinase (#7684), GSK-3α (#7374), and GSK-3β (#7436) were from Cell Signaling.  
Yeast Strain and Plasmids 
The yeast strain M213 and the plasmids are kind gifts from Drs. M.G. Sandbaken 
and M.R. Culbertson. M213 has a following genotype: Matα leu2-3, 112∆tef1::LEU2 
tef2-∆2 lys2-20 his4-713 met2-1 ura3-52 trp1-∆1. This yeast strain contains a plasmid 
YCpMS29 (TEF2, URA3) to support survival. YCpMS41 (TEF2, TRP1) was used to 
replaced YCpMS29. 
Cell Culture and Treatment 
 3T3-L1 cells were maintained and differentiated as described before (56). For 
insulin stimulation, cells were serum starved for 2 hours before insulin addition.  
Wortmannin and rapamycin were added 30 minutes before the addition of insulin as 
indicated. Treated cells were then washed with PBS twice quickly and collected in lysis 
buffer containing 1% SDS and protease and phosphatase inhibitors. 
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eEF1A Recombinant Protein Preparation 
Full length cDNA of mouse eEF1A was cloned into a GST-tagged prokaryotic 
expression vector pGEX-6P-1. eEF1A point mutation was introduced on pGEX-6P-1 
backbone directly by using Quickchange II Site Directed Mutagenesis kit from 
Stratagene according to the manufacturer’s protocol. Recombinant GST-tagged proteins 
were first purified from IPTG induced bacterial culture through GST affinity binding. An 
on-column PreScission protease cutting procedure was performed to remove the GST tag 
and the untagged protein was further concentrated by Amicon® Ultra centrifugal filter. 
The purity and identity of the recombinant proteins were confirmed by Coomassie 
staining and western blots. 
In Vitro Kinase Assay 
The in vitro kinase assay was performed as follows: 5 µl of recombinant protein 
was incubated with 100 ng of active kinase in a 50 µl reaction system (5 mM MOPS, pH 
7.2, 2.5 mM β-glycerophosphate, 1 mM EGTA, 0.4 mM EDTA, 5 mM MgCI2, 0.05 mM 
DTT, 0.1mM ATP, 10 µCi 32P labeled γ-ATP) at room temperature for 1 hour. The 
reactions were then stopped by adding 12.5 µl 5X sample buffer and separated on SDS-
PAGE gel and transferred onto nitrocellulose membrane for either 32P exposure or 
western blot detection of phosphorylated proteins. In some cases the 32P labeled ATP is 
not required. The total protein level of eEF1A in each reaction was also detected by 
western blot as a loading control.  
Adenoviral Delivery of eEF1A shRNA 
The shRNA-expressing vector pSilencer 2.1TM-U6 hygro was used to test several 
shRNAs’ knockdown efficiency first. The shRNA sequences were designed using the 
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Dharmacon siDESIGN Center. The best target sequence of six tested is 5’- 
GGAAACAACTTGACCAAAA-3’, which localizes within the 3’ UTR of eEF1A 
mRNA. The U6-driven shRNA cassette was then transferred from pSilencer 2.1TM-U6 
hygro to an adenoviral shuttle vector for further cloning and packaging into adenovirus. 
For adenoviral infection in cell culture, the optimal multiplicity of infection (MOI) of 
30,000 was used for C2C12 cells for 2 hours and a MOI of 250 for HeLa cells. Cells were 
treated by adenoviruses every other day to deplete the endogenous eEF1A mRNA until 
the end of experiments. 
Yeast Plasmid Shuffle  
TEF2 point mutation was introduced directly on the YCpMS41 plasmid using 
Quickchange® II XL site-directed mutagenesis kit per the manufacturer’s instruction. The 
YCpMS41 was transformed into yeast strain M213. The transformed yeasts harboring 
two plasmids YCpMS29 (TEF2, URA3) and YCpMS41 (TEF2, TRP1) can grow on SD-
Trp plates. Then the yeasts were transferred to 5-FOA containing SD-Trp plates to kick 
out the YCpMS29 plasmid. Before 5-FOA selection, the expression of mutant TEF2 from 
YCpMS41 was confirmed by sequencing the mutated region of TEF2, which was 
amplified by RT-PCR using total RNA extracted from SD-Trp culture.  
Translational Activity Assay 
 For luciferase translational assay, HeLa cells were plated in a 6-well plate at day 
0. At day 1, cells were infected with AdsheEF1A viruses for 2 hours at MOI of 250. At 
day 2, two vectors expressing eEF1A and renilla luciferase (pRL-TK, Promega) 
respectively, were mixed together and co-transfected into HeLa cells using FuGENE 6 
transfection reagent. At day 3, cells from each well were collected and divided into two 
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parts for renilla luciferase activity determination (Dual-Luciferase® Reporter Assay 
System, Promega) and RNA extraction respectively. The raw luminescence unit (RLU) 
from each well was then normalized to the renilla luciferase mRNA level determined by 
quantitative RT-PCR from the same well. β-actin mRNA was used as an internal control 
for the RT-PCR. All experiments were performed in triplicate wells. 
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Results 
Identification of eEF1A as an Insulin-stimulated Phospho-protein 
Akt plays a significant role in insulin-stimulated phosphorylation cascades. To 
better understand the physiology and mechanism of Akt versatility, much focus has been 
applied to identify potential Akt substrates. With the help of phospho-Akt substrate (PAS) 
antibody, one that recognizes an optimal Akt substrate motif RXRXXp(S/T), where S/T is 
the phosphorylation site and X any amino acid, many Akt substrates have been identified 
and characterized. Among them, the Akt substrate AS160 (82) (also known as TBC1D4) 
and TBC1D1 (88) are best known for their activity in GLUT4 translocation. During our 
research on insulin-stimulated adipocytes, we constantly observed an abundance of 
phosphorylated protein products detected by the PAS antibody with a molecular weight 
around 50 kDa (denoted as PAS50 thereafter) on western blots (Figure A-1, A). The 
induction of PAS50 was insulin dose and time-dependent (Figure.A-1, A). One of the 
known Akt substrates in adipocytes around 50 kDa is AS47, which localizes in non-
cytosolic subcellular fraction (166). We found the PAS50 mainly in cytosol and RNAi 
mediated depletion of AS47 did not reduce the PAS50 signal on western blot (data not 
shown), excluding the possibility of AS47 as a major product of PAS50. To identify the 
potential Akt substrate protein(s) in PAS50, we separated insulin-stimulated 3T3-L1 
adipocytes lysate on 5%-15% gradient SDS-PAGE and excised the PAS50 band and sent 
it for mass spectrometry identification. The best hit was eukaryotic elongation factor 1α1 
(eEF1A1), the dominant isoform of eEF1A in adipocytes.  eEF1A1 has a calculated 
molecular weight of 50 kDa, which is consistent with its SDS-PAGE migration pattern. 
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Figure A-1  eEF1A is a potential insulin-stimulated Akt substrate 
(A), 3T3-L1 adipocytes were stimulated with insulin at different concentrations (0-100 
nM) for 30 minutes or at 10 nM for different time (0-60 minutes). Whole cell lysates 
were separated on SDS-PAGE, transferred to nitrocellulose membrane and probed with 
PAS antibody. (B), 3T3-L1 adipocytes were transfected with scramble (S) or Eef1a (E) 
siRNA for 3 days and then were stimulated with insulin. Phospho-Akt substrates were 
detected by PAS antibody. PAS50 refers to proteins ~50 kDa recognized by PAS on 
western blots. (C), 3T3-L1 adipocytes were transfected with scramble (S) or Akt1 (A1) or 
Akt2 (A2) siRNA for 48 hours. Cells were treated with or without 10 nM insulin for 30 
minutes.  Western blots were performed to detect PAS50, Akt1 and Akt2. β-actin was 
used as a loading control. (D), 3T3-L1 adipocytes were pre-treated with or without 
different concentrations of PI-3K inhibitor wortmanin (Wort) or mTORC1 inhibitor 
rapamycin (Rapa), and then stimulated with 10 nM insulin for 30 minutes. The 
phosphorylation of rpS6 was detected by pRPS6 antibody. 
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eEF1A is an in vitro Akt Substrate 
To confirm eEF1A is an Akt substrate, we carried out several strategies. First we 
used siRNA to deplete eEF1A in 3T3-L1 adipocytes. The depletion of eEF1A 
specifically decreased PAS50 signal but not other phospho-proteins on western blots, 
indicating that eEF1A could be a major protein in PAS50 bands (Figure A-1, B). Second, 
we used siRNA to knockdown the two isoforms of Akt in 3T3-L1 adipocytes. Only Akt1, 
but not Akt2 depletion, caused a reduction of PAS50 signal, suggesting that Akt1 is the 
dominant isoform that phosphorylates eEF1A in response to insulin stimulation (Figure 
A-1, C). Interestingly, Akt2 depletion slightly increased PAS50 signal (Figure A-1, C). 
However, this was not because Akt2 knockdown caused an increase in the Akt1 protein 
level (Figure A-1, C). The effect of Akt2 depletion on PAS50 might be due to: 1) Akt2 
has little activity on PAS50 and 2) Akt2 might compete with Akt1 for the substrate 
PAS50.  
To determine the location of PAS50 in the insulin/PI-3K/Akt signaling pathway, 
we analyzed the effect of specific inhibitors on PAS50. First, the inhibition of PI-3K, a 
kinase downstream of insulin and upstream of Akt, by wortmannin totally abolished 
PAS50 (Figure A-1, D), suggesting that PAS50 is phosphorylated upon insulin 
stimulation in a PI-3K dependent manner.  Second, inhibition of mTORC1 by rapamycin 
totally abolished the phosphorylation of ribosomal protein S6 (rpS6), but had no effect on 
PAS50 phosphorylation induced by insulin (Figure A-1, D). These two assays indicate 
that PAS50 is phosphorylated by a kinase downstream of PI-3K but upstream of 
mTORC1. Akt is one of such kinases. 
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Pecorari et al. reported eEF1A as a pAkt interacting protein. eEF1A can be 
detected both from anti-pAkt1 and anti-pAkt2 immunoprecipitations (231). However, 
Pecorari et al. showed that eEF1A could not be phosphorylated by Akt in an in vitro 
kinase assay with a GST-tagged truncated recombinant eEF1A protein (1-173aa) 
containing a putative Akt phosphorylation site at Thr72. We tested whether Akt can 
phosphorylate a full-length recombinant eEF1A protein in vitro. We first purified GST-
eEF1A from bacteria and then removed the GST tag (see Experimental Procedures), 
producing the untagged full-length eEF1A protein. Using this full length protein as a 
substrate, we incubated it with a panel of recombinant protein kinases that are activated 
by insulin in the presence of 32P labeled ATP. Despite the fact that all kinases used in this 
assay exhibited auto-phosphorylation activity shown by 32P autoradiography, only Akt1, 
Akt2, S6K and PKCζ could phosphorylate eEF1A (Figure A-2, A, 32P signal at 50 kDa). 
However, the PAS antibody detected eEF1A only when phosphorylated by Akt1 or Akt2, 
with the latter to a lesser extent (Figure A-2, A). The data strongly suggested that eEF1A 
is an Akt substrate in vitro and the phosphorylation site can be recognized by PAS 
antibody. To further confirm that Akt1 and Akt2 can phosphorylate eEF1A, we used an 
immobilized HA antibody to immunoprecipitated HA-Akt1 and HA-Akt2 from 
transfected mammalian cells. The precipitated kinases were incubated with recombinant 
eEF1A in a kinase assay as above except only cold ATP was used. The PAS antibody 
was able to detect phosphorylated eEF1A both by HA-Akt1 and HA-Akt2 (Figure A-2, 
B). Taken together, Akt can phosphorylate eEF1A on PAS recognizable site(s) in vitro.   
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We observed that Akt1 had stronger activity than Akt2 on phosphorylation of 
eEF1A, even though Akt2 showed stronger auto-phosphorylation activity (Figure A-2, A). 
This was also reflected in Akt1 and Akt2 knockdown experiments, in which knockdown 
of Akt1 isoform showed a reduction of PAS50 signal, but Akt2 did not (Figure A-1, C). 
In a competitive phosphorylation assay, we incubated eEF1A with both Akt1 and Akt2 
kinases together, while varying the amount of Akt1 and Akt2. The results showed that 
Akt1 had stronger phosphorylation activity on the PAS site of eEF1A (Figure A-2, C) 
and Akt2 seemed to compete for eEF1A with Akt1 (Figure A-2, C, last lane). The 
differential in vitro kinase activity of Akt1 and Akt2 appeared to be intrinsic to the 
kinases themselves, and not eEF1A-related. This was supported by the observation of the 
same preferential activity on another Akt substrate GSK-3α/β (Figure A-2, B). Whether 
isoform-specific activity applies to other Akt substrates remains an open question.  
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Figure A-2  eEF1A is phosphorylated by Akt in vitro in a PAS recognizable fashion 
(A), Recombinant protein eEF1A was incubated with different kinases in an in vitro 
kinase assay in the presence of 32P labeled ATP. The eEF1A alone or kinase without 
substrate was used as control. The reactions were then separated on SDS-PAGE and 
transferred onto nitrocellulose membrane for 32P autoradiography exposure. After 
exposure, the same blot was subjected to western blot for detection of either 
phosphorylated or total eEF1A. Bands in the inset at 50 kDa are phosphorylated eEF1A; 
higher bands are auto-phosphorylated kinases. (B), HA-Akt1 or HA-Akt2 were pulled 
down by an immobilized HA antibody from HA-Akt1 or HA-Akt2 transfected COS-7 
cell lysate. The immunoprecipitations were then incubated with recombinant eEF1A 
protein and GSK-3α/β polypeptide in a same in vitro kinase reaction. Afterwards, the 
reactions were separated on SDS-PAGE and probed with antibodies by western blot as 
indicated. The phosphorylation of Akt on Ser473 and Thr308 indicates Akt activation. (C), 
Increasing amount of Akt1 (0-200ng) and 100ng of Akt2 kinase (lane 1-6) or increasing 
amount of Akt2 (0-200ng) and 100ng of Akt1 kinase (lane 7-12) were combined together 
with fixed amount of eEF1A in an in vitro kinase reaction. The reactions were separated 
on SDS-PAGE and probed with PAS for phosphorylated eEF1A and with Akt1, Akt2, 
eEF1A antibodies. 
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eEF1A is Phosphorylated at Thr269 and Thr432 
The PAS antibody recognizes an optimal phosphorylation site within 
RXRXXp(S/T) motif, where S/T is the phosphorylation site and X any amino acid. There 
is only one such site in eEF1A, which is Thr72.  Pecorari et al. showed that this site 
cannot be phosphorylated by Akt in vitro with a truncated eEF1A (1-173aa) (231). 
However, we showed Akt can phosphorylate a full-length eEF1A (1-462aa) in a PAS 
recognizable fashion. This indicates that either the missing part (174-462aa) of eEF1A is 
required for the phosphorylation of Thr72 or there is other unknown site(s) that can be 
phosphorylated by Akt. To identify the potential Akt phosphorylation site on eEF1A, we 
first predicted several possible phosphorylation sites on eEF1A using Netphos2.0 
software. Then we made point mutations of predicted serine or threonine to alanine, 
which cannot be phosphorylated. Wild type or mutant recombinant proteins were 
expressed in bacteria and purified for an in vitro kinase assay. Recombinant protein 
eEF1AT269A, with an alanine substitution for Thr269, failed to be recognized by PAS 
antibody when phosphorylated by Akt1 (Figure A-3, A), suggesting that Thr269 is the 
phosphorylation site on eEF1A that had been observed. Thr269 is located within a motif 
variation RXXp(S/T), which PAS only has minor activity on it. The T269A mutation did 
not totally abolish the 32P signal, suggesting there may be other site(s) that can be 
phosphorylated by Akt1. In a further investigation into additional phosphorylation site(s), 
we employed another phospho-Akt substrate antibody, PAS9611, with a less stringent 
recognition motif (R/K)X(R/K)XXp(S/T). This led to the identification of Thr432 as 
another Akt phosphorylation site (Figure A-3, A). Again, Thr432 turned out to be within 
135 
 
 
 
another variant motif RXXRXp(S/T), on which PAS9611 has minor activity.  In fact, 
Thr432 has been previously reported to be phosphorylated by the kinase PKCδ in vitro 
(232). We showed PKCζ, another PKC isoform, can also phosphorylate this site in vitro 
(Figure A-3, B).To this point, we identified eEF1A Thr269 and Thr432 as Akt 
phosphorylation sites, with the Thr432 shared by Akt, PKCδ and PKCζ. 
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Figure A-3  Akt phosphorylates eEF1A at Thr269 and Thr432 
(A), Wild type and point mutant eEF1A recombinant proteins were incubated with kinase 
Akt1 in the presence of 32P labeled γ-ATP. The reactions were then separated on SDS-
PAGE and transferred to nitrocellulose membrane for 32P autoradiography exposure.  The 
bands at 50 kDa are phosphorylated eEF1A and the higher bands are Akt1 kinase by 
auto-phosphorylation. After exposure, the same blot was subjected to immuno-blotting 
for detecting either phosphorylated eEF1A by PAS or total eEF1A by its antibody. The 
ratios of 32P/Immuno signal of eEF1A are quantified and normalized to wild type. (B), 
The same in vitro kinase assay was performed as in (A) except that kinase PKCζ was 
used instead of Akt1 and with cold ATP.  Western blots were performed to determine 
phosphorylated and total proteins. 
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Phospho-mimic eEF1A protein fail to support cell growth in yeast 
We next investigated if these phosphorylation sites of eEF1A have any biological 
functions. Considering eEF1A is an elongation factor that is critical for protein synthesis, 
we hypothesized that the phosphorylation of eEF1A regulates its function in cell growth. 
We took advantage of the easy genetics of yeast to test whether our eEF1A mutants 
(phospho-defective or phospho-mimic) are capable of supporting normal cell survival. 
The rationale is based on the fact that eEF1A protein is highly homologous from human, 
mouse to yeast, and the phosphorylation sites Thr269 and Thr432 are conserved in yeast (as 
Thr267 and Thr430 in yeast) (Figure A-4, A). Yeast eEF1A proteinis encoded by two genes, 
TEF1 and TEF2. A yeast strain MS213 with non-functional genomic TEF1 and TEF2 is 
viable by carrying a plasmid YCpMS29 (URA3, TEF2), which expresses a functional 
eEF1A protein from wild type TEF2. URA3 gene product converts 5-fluoroorotic acid 
(5-FOA) to 5-fluorouracil, which is toxic to the cell. YCpMS29 plasmid can be kicked 
out and replaced by YCpMS41 (TRP1, TEF2) by growing the yeast containing both 
plasmids on 5-FOA plates. We made phospho-defective (alanine substitution, T→A) or 
phospho-mimic (aspartic acid substitution, T→D) mutation of TEF2 on YCpMS41 and 
transformed the plasmids into strain MS213 to replace YCpMS29 via 5-FOA selection. 
We found that yeast harboring YCpMS29 (URA3, TEF2) and YCpMS41 (TRP1, 
TEF2T267A) can successfully grow on 5-FOA plates, suggesting TEF2T267A can 
functionally replace wild type TEF2 to support cell growth. However, yeast harboring 
YCpMS29 (URA3, TEF2) and YCpMS41 (TRP1, TEF2T267D) failed to grow on 5-FOA 
plates, suggesting TEF2T267D are functionally defective (Figure A-4, B). To exclude the 
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possibility that the failure of supporting cell growth was a result of untranscribed 
TEF2T267D mRNA from the construct, we extracted the total RNA from the yeast 
harboring both YCpMS29 (URA3, TEF2) and YCpMS41 (TRP1, TEF2T267D). Then we 
performed RT-PCR to amplify TEF2 cDNA. Sequencing of the TEF2 amplicon revealed 
that both wild type TEF2 and TEF2T267D were transcribed and there were no extra 
mutations other than T267D (Figure A-4, C). This result suggests that the lost function of 
TEF2T267D occurs post-transcriptionally. Crystal structure of yeast eEF1A protein reveals 
that Thr267 and Thr430 localize to the surfaces of two subdomains and are in between 
subdomains II and III, I and III, respectively. A mutation from threonine (T) to aspartic 
acid (D) introduces a longer side chain and may interfere with the spatial orientation of 
the subdomains and thus cause protein instability (Figure A-4, D). 
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Figure A-4  Phospho-mimic eEF1A protein fail to support yeast growth 
(A), Sequence alignment of human, mouse and yeast version of eEF1A. Shown here is 
only part of the protein sequence that includes Thr269 and Thr432. ○P  indicates the 
phosphorylation site. (B), Yeast with eEF1AT267D fails to grow on a 5-FOA plate. (C), 
Sequencing confirms the coexistence of wild type and mutant transcripts. The DNA 
codon for the amino acid threonine (ACC), alanine (GCC) and aspartic acid (GAC) are 
shown in antisense as the sequencing was performed from the opposite direction. (D), 3-
D structure of yeast eEF1A (PDB id: IF60) displayed using software Pymol. The site 
Thr267 and Thr430 are located in between two subdomains.  
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To determine the underlying mechanism that phospho-mimic eEF1A protein 
failed to support cell survival, we transiently transfected HA-tagged eEF1A constructs 
into HeLa cells. Protein levels were determined 48 hours later by anti-HA antibody on 
western blots. The data showed that the protein expression levels of HA-eEF1AT269D and 
HA-eEF1AT432D are significantly decreased compared to wild type or HA-eEF1AT269A and 
HA-eEF1AT432A (Figure A-5, A, top panel and B, left panel). These decreased expression 
levels were not due to lower transfection efficiency, because the mRNA of HA-
eEF1AT269D and HA-eEF1AT432D in these cells were similar to those of HA-eEF1AT269A 
and HA-eEF1AT432A, and were even higher than those of the wild type HA-eEF1A 
(Figure A-5, C, left panel). Similar results were also observed in 293T cells, with the HA-
eEF1AT269D and HA-eEF1AT432D protein levels decreased, although their mRNA levels 
were not significantly different compared to their phospho-defective counterparts.(Figure 
A-5, A, middle panel, B, right panel and C, right panel). To exclude the possibility that 
such a decrease in phospho-mimic protein level was a transient artificial effect from 
transfection, we also determined the HA-protein levels from stable cell lines, which had 
been selected by antibiotics for at least two weeks. We observed a same result (Figure A-
4, A, bottom panel). Taken together, HA-eEF1AT269D and HA-eEF1AT432D accumulate 
less protein in the cell due to post-transcriptional instability.  
We next sought to determine whether the translational activity of HeLa cells 
expressing mutant version of eEF1A were affected. By transfecting the cells with a 
luciferase expressing vector, we were able to determine the translation activity by 
measuring luciferase activity. We found that over-expression of wild type eEF1A 
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increased the translation activity compared to vector transfected control cells, while cells 
over-expressing either phospho-defective or phospho-mimic eEF1A did not increase the 
translational activity (Figure A-5, D). Since the phospho-mimic eEF1A proteins tends to 
accumulate very little protein level compared to wild type proteins (Figure A-5, E), it 
explains why the cells expressing phospho-mimic eEF1A did not increase translational 
activity. Surprisingly, the phospho-defective eEF1A expressing cells had no increase in 
translational activity either. This data indicates that an alanine mutation might have a 
negative effect on the translational activity of eEF1A. 
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Figure A-5  Phospho-mimic eEF1A protein are not stable in mammalian cells 
(A), HA-tagged wild type (WT) or mutant (T269A, T269D, T432A, and T432D) eEF1A 
were transiently transfected into HeLa or 293T cells. 48 hours later, HA-tagged eEF1A 
protein levels were detected with anti-HA antibody by western blot. Empty vector was 
used as a negative control. Three experiments in both HeLa and 293T cells are shown 
here. Transfected C2C12 cells were selected on G418 to screen stable cell lines. 
Polyclonal stable cell lysate were analyzed for the HA-tagged eEF1A protein level. Actin 
was used as loading control on western blots. (B), Quantification of HA-eEF1A protein 
level by the western blot densitometry from the three experiments in (A). (C), 
Quantification of HA-eEF1A mRNA levels by RT-PCR from the three experiments. (D), 
The translational activity of HeLa cells expressing wild-type or mutant version of eEF1A 
was deduced from the transfected renilla luciferase protein (measured as raw 
luminescence unit (RLU)) normalized to the relative luciferase mRNA level. 
Experiments were performed in triplicates and the data is expressed as mean ± SEM of 
three experimental wells. *, P<0.05, **, P<0.01 compared to HA-WT with t-test. (E), 
HA-eEF1A proteins detected by HA antibody from the cells transfected with different 
constructs as indicated. 
  
143 
 
 
 
REFERENCES 
1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity 
among US adults, 1999-2008. JAMA. 2010;303(3):235-41. 
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general 
information and national estimates on diabetes in the United States, 2007. Atlanta, 
GA: U.S. Department of Health and Human Services, Centers for Disease Control 
and Prevention, 2008. 
3. Wild SH, Byrne CD. ABC of obesity. Risk factors for diabetes and coronary heart 
disease. BMJ. 2006;333(7576):1009-11. 
4. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol 
Cell Endocrinol. 2010;316(2):129-39. 
5. Jansky L. Non-shivering thermogenesis and its thermoregulatory significance. 
Biol Rev Camb Philos Soc. 1973;48(1):85-132. 
6. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological 
significance. Physiol Rev. 2004;84(1):277-359. 
7. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown 
adipose tissue in adult humans. Am J Physiol Endocrinol Metab. 
2007;293(2):E444-52. 
8. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. 
Identification and importance of brown adipose tissue in adult humans. N Engl J 
Med. 2009;360(15):1509-17. 
9. White UA, Stephens JM. Transcriptional factors that promote formation of white 
adipose tissue. Mol Cell Endocrinol. 2010;318(1-2):10-4. 
10. Gupta RK, Arany Z, Seale P, Mepani RJ, Ye L, Conroe HM, et al. Transcriptional 
control of preadipocyte determination by Zfp423. Nature. 2010;464(7288):619-23. 
11. Seale P, Kajimura S, Yang W, Chin S, Rohas LM, Uldry M, et al. Transcriptional 
control of brown fat determination by PRDM16. Cell Metab. 2007;6(1):38-54. 
12. Tiraby C, Tavernier G, Lefort C, Larrouy D, Bouillaud F, Ricquier D, et al. 
Acquirement of brown fat cell features by human white adipocytes. J Biol Chem. 
2003;278(35):33370-6. 
13. Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. 
Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) 
activation of epididymally derived white adipocyte cultures reveals a population 
of thermogenically competent, UCP1-containing adipocytes molecularly distinct 
from classic brown adipocytes. J Biol Chem. 2010;285(10):7153-64. 
14. Barbatelli G, Murano I, Madsen L, Hao Q, Jimenez M, Kristiansen K, et al. The 
emergence of cold-induced brown adipocytes in mouse white fat depots is 
determined predominantly by white to brown adipocyte transdifferentiation. Am J 
Physiol Endocrinol Metab. 2010;298(6):E1244-53. 
15. Cinti S. Transdifferentiation properties of adipocytes in the Adipose Organ. Am J 
Physiol Endocrinol Metab. 2009. 
144 
 
 
 
16. Katic M, Kennedy AR, Leykin I, Norris A, McGettrick A, Gesta S, et al. 
Mitochondrial gene expression and increased oxidative metabolism: role in 
increased lifespan of fat-specific insulin receptor knock-out mice. Aging Cell. 
2007;6(6):827-39. 
17. Kaaman M, Sparks LM, van Harmelen V, Smith SR, Sjolin E, Dahlman I, et al. 
Strong association between mitochondrial DNA copy number and lipogenesis in 
human white adipose tissue. Diabetologia. 2007;50(12):2526-33. 
18. Laplante M, Festuccia WT, Soucy G, Gelinas Y, Lalonde J, Berger JP, et al. 
Mechanisms of the depot specificity of peroxisome proliferator-activated receptor 
gamma action on adipose tissue metabolism. Diabetes. 2006;55(10):2771-8. 
19. Dahlman I, Forsgren M, Sjogren A, Nordstrom EA, Kaaman M, Naslund E, et al. 
Downregulation of electron transport chain genes in visceral adipose tissue in 
type 2 diabetes independent of obesity and possibly involving tumor necrosis 
factor-alpha. Diabetes. 2006;55(6):1792-9. 
20. Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, Han SS, et al. Mitochondria are 
impaired in the adipocytes of type 2 diabetic mice. Diabetologia. 2006;49(4):784-
91. 
21. Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van Hal N, et 
al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial 
biogenesis and induce beta-oxidation in white fat. Diabetologia. 
2005;48(11):2365-75. 
22. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial 
biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. 
2005;54(5):1392-9. 
23. Bogacka I, Ukropcova B, McNeil M, Gimble JM, Smith SR. Structural and 
functional consequences of mitochondrial biogenesis in human adipocytes in vitro. 
J Clin Endocrinol Metab. 2005;90(12):6650-6. 
24. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. 
Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of 
diabetic patients. Diabetes. 2005;54(3):880-5. 
25. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, et al. 
Mitochondrial remodeling in adipose tissue associated with obesity and treatment 
with rosiglitazone. J Clin Invest. 2004;114(9):1281-9. 
26. Wilson-Fritch L, Burkart A, Bell G, Mendelson K, Leszyk J, Nicoloro S, et al. 
Mitochondrial biogenesis and remodeling during adipogenesis and in response to 
the insulin sensitizer rosiglitazone. Mol Cell Biol. 2003;23(3):1085-94. 
27. Sorbris R, Monti M, Nilsson-Ehle P, Wadso I. Heat production by adipocytes 
from obese subjects before and after weight reduction. Metabolism. 
1982;31(10):973-8. 
28. Chen H, Chan DC. Mitochondrial dynamics in mammals. Curr Top Dev Biol. 
2004;59:119-44. 
29. Liesa M, Palacin M, Zorzano A. Mitochondrial dynamics in mammalian health 
and disease. Physiol Rev. 2009;89(3):799-845. 
145 
 
 
 
30. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling 
mitochondrial biogenesis and function. Genes Dev. 2004;18(4):357-68. 
31. Kang D, Kim SH, Hamasaki N. Mitochondrial transcription factor A (TFAM): 
roles in maintenance of mtDNA and cellular functions. Mitochondrion. 2007;7(1-
2):39-44. 
32. Pohjoismaki JL, Wanrooij S, Hyvarinen AK, Goffart S, Holt IJ, Spelbrink JN, et 
al. Alterations to the expression level of mitochondrial transcription factor A, 
TFAM, modify the mode of mitochondrial DNA replication in cultured human 
cells. Nucleic Acids Res. 2006;34(20):5815-28. 
33. Poulton J, Morten K, Freeman-Emmerson C, Potter C, Sewry C, Dubowitz V, et 
al. Deficiency of the human mitochondrial transcription factor h-mtTFA in 
infantile mitochondrial myopathy is associated with mtDNA depletion. Hum Mol 
Genet. 1994;3(10):1763-9. 
34. Choi YS, Kim S, Pak YK. Mitochondrial transcription factor A (mtTFA) and 
diabetes. Diabetes Res Clin Pract. 2001;54 Suppl 2:S3-9. 
35. Lee SH, Lee S, Jun HS, Jeong HJ, Cha WT, Cho YS, et al. Expression of the 
mitochondrial ATPase6 gene and Tfam in Down syndrome. Mol Cells. 
2003;15(2):181-5. 
36. Belin AC, Bjork BF, Westerlund M, Galter D, Sydow O, Lind C, et al. 
Association study of two genetic variants in mitochondrial transcription factor A 
(TFAM) in Alzheimer's and Parkinson's disease. Neurosci Lett. 2007;420(3):257-
62. 
37. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. 
Cell. 2006;125(7):1241-52. 
38. Forner F, Kumar C, Luber CA, Fromme T, Klingenspor M, Mann M. Proteome 
differences between brown and white fat mitochondria reveal specialized 
metabolic functions. Cell Metab. 2009;10(4):324-35. 
39. Harris RA, Leland MC, Mahoney JM, Mapes JP. Regulatory function of 
mitochondria in lipogenesis. Lipids. 1973;8(12):711-6. 
40. Reshef L, Olswang Y, Cassuto H, Blum B, Croniger CM, Kalhan SC, et al. 
Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem. 
2003;278(33):30413-6. 
41. Nye CK, Hanson RW, Kalhan SC. Glyceroneogenesis is the dominant pathway 
for triglyceride glycerol synthesis in vivo in the rat. J Biol Chem. 
2008;283(41):27565-74. 
42. Gonzalez-Baro MR, Lewin TM, Coleman RA. Regulation of Triglyceride 
Metabolism. II. Function of mitochondrial GPAT1 in the regulation of 
triacylglycerol biosynthesis and insulin action. Am J Physiol Gastrointest Liver 
Physiol. 2007;292(5):G1195-9. 
43. Stone SJ, Levin MC, Zhou P, Han J, Walther TC, Farese RV, Jr. The endoplasmic 
reticulum enzyme DGAT2 is found in mitochondria-associated membranes and 
has a mitochondrial targeting signal that promotes its association with 
mitochondria. J Biol Chem. 2009;284(8):5352-61. 
146 
 
 
 
44. Rossmeisl M, Syrovy I, Baumruk F, Flachs P, Janovska P, Kopecky J. Decreased 
fatty acid synthesis due to mitochondrial uncoupling in adipose tissue. FASEB J. 
2000;14(12):1793-800. 
45. Fassina G, Dorigo P, Gaion RM. Equilibrium between metabolic pathways 
producing energy: a key factor in regulating lipolysis. Pharmacol Res Commun. 
1974(6):1-21. 
46. Daval M, Diot-Dupuy F, Bazin R, Hainault I, Viollet B, Vaulont S, et al. Anti-
lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol 
Chem. 2005;280(26):25250-7. 
47. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an 
endocrine organ: from theory to practice. J Pediatr (Rio J). 2007;83(5 
Suppl):S192-203. 
48. Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ 
and its role in obesity. Arch Med Res. 2008;39(8):715-28. 
49. Koh EH, Park JY, Park HS, Jeon MJ, Ryu JW, Kim M, et al. Essential role of 
mitochondrial function in adiponectin synthesis in adipocytes. Diabetes. 
2007;56(12):2973-81. 
50. Braakman I, Helenius J, Helenius A. Role of ATP and disulphide bonds during 
protein folding in the endoplasmic reticulum. Nature. 1992;356(6366):260-2. 
51. Sun J, Xu Y, Deng H, Sun S, Dai Z, Sun Y. Intermittent high glucose exacerbates 
the aberrant production of adiponectin and resistin through mitochondrial 
superoxide overproduction in adipocytes. J Mol Endocrinol. 2010;44(3):179-85. 
52. Frier BC, Williams DB, Wright DC. The effects of apelin treatment on skeletal 
muscle mitochondrial content. Am J Physiol Regul Integr Comp Physiol. 
2009;297(6):R1761-8. 
53. Civitarese AE, Ukropcova B, Hulver M, Defronzo R, Mandarino L, Scherer P, et 
al. Adiponectin receptors mediated regulation of mitochondrial bioenergetics in 
skeletal-muscle. Diabetes. 2005;54:A91-A. 
54. Vempati UD, Torraco A, Moraes CT. Mouse models of oxidative phosphorylation 
dysfunction and disease. Methods. 2008;46(4):241-7. 
55. Torraco A, Diaz F, Vempati UD, Moraes CT. Mouse models of oxidative 
phosphorylation defects: powerful tools to study the pathobiology of 
mitochondrial diseases. Biochim Biophys Acta. 2009;1793(1):171-80. 
56. Shi X, Burkart A, Nicoloro SM, Czech MP, Straubhaar J, Corvera S. Paradoxical 
effect of mitochondrial respiratory chain impairment on insulin signaling and 
glucose transport in adipose cells. J Biol Chem. 2008;283(45):30658-67. 
57. Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, Xie M, et al. Adipose 
mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and 
improved by rosiglitazone. Diabetes. 2007;56(7):1751-60. 
58. Semple RK, Crowley VC, Sewter CP, Laudes M, Christodoulides C, Considine 
RV, et al. Expression of the thermogenic nuclear hormone receptor coactivator 
PGC-1alpha is reduced in the adipose tissue of morbidly obese subjects. Int J 
Obes Relat Metab Disord. 2004;28(1):176-9. 
147 
 
 
 
59. Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in 
the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab. 
2008;295(1):E29-37. 
60. Giovannone B, Scaldaferri ML, Federici M, Porzio O, Lauro D, Fusco A, et al. 
Insulin receptor substrate (IRS) transduction system: distinct and overlapping 
signaling potential. Diabetes Metab Res Rev. 2000;16(6):434-41. 
61. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 
2007;129(7):1261-74. 
62. Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in 
development and disease. Biochem Soc Trans. 2007;35(Pt 2):231-5. 
63. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219(3):713-
25. 
64. Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, et al. Physiological 
role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat 
adipose cells. Mol Endocrinol. 1997;11(13):1881-90. 
65. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, et al. Protein kinase 
B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell 
Biol. 1999;19(6):4008-18. 
66. Katome T, Obata T, Matsushima R, Masuyama N, Cantley LC, Gotoh Y, et al. 
Use of RNA interference-mediated gene silencing and adenoviral overexpression 
to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol 
Chem. 2003;278(30):28312-23. 
67. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively 
active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and 
glucose transporter 4 translocation. J Biol Chem. 1996;271(49):31372-8. 
68. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al. Role 
of translocation in the activation and function of protein kinase B. J Biol Chem. 
1997;272(50):31515-24. 
69. Tanti JF, Grillo S, Gremeaux T, Coffer PJ, Van Obberghen E, Le Marchand-
Brustel Y. Potential role of protein kinase B in glucose transporter 4 translocation 
in adipocytes. Endocrinology. 1997;138(5):2005-10. 
70. Ducluzeau PH, Fletcher LM, Welsh GI, Tavare JM. Functional consequence of 
targeting protein kinase B/Akt to GLUT4 vesicles. J Cell Sci. 2002;115(Pt 
14):2857-66. 
71. Chen X, Al-Hasani H, Olausson T, Wenthzel AM, Smith U, Cushman SW. 
Activity, phosphorylation state and subcellular distribution of GLUT4-targeted 
Akt2 in rat adipose cells. J Cell Sci. 2003;116(Pt 17):3511-8. 
72. Ng Y, Ramm G, Lopez JA, James DE. Rapid activation of Akt2 is sufficient to 
stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab. 2008;7(4):348-
56. 
73. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, et al. Insulin 
resistance and a diabetes mellitus-like syndrome in mice lacking the protein 
kinase Akt2 (PKB beta). Science. 2001;292(5522):1728-31. 
148 
 
 
 
74. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, et al. 
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency 
in mice lacking Akt2/PKB beta. J Clin Invest. 2003;112(2):197-208. 
75. Ikonomov OC, Sbrissa D, Dondapati R, Shisheva A. ArPIKfyve-PIKfyve 
interaction and role in insulin-regulated GLUT4 translocation and glucose 
transport in 3T3-L1 adipocytes. Exp Cell Res. 2007;313(11):2404-16. 
76. Berwick DC, Dell GC, Welsh GI, Heesom KJ, Hers I, Fletcher LM, et al. Protein 
kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles. 
J Cell Sci. 2004;117(Pt 25):5985-93. 
77. Liu J, Kimura A, Baumann CA, Saltiel AR. APS facilitates c-Cbl tyrosine 
phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 
adipocytes. Mol Cell Biol. 2002;22(11):3599-609. 
78. Chang L, Chiang SH, Saltiel AR. TC10alpha is required for insulin-stimulated 
glucose uptake in adipocytes. Endocrinology. 2007;148(1):27-33. 
79. Mitra P, Zheng X, Czech MP. RNAi-based analysis of CAP, Cbl, and CrkII 
function in the regulation of GLUT4 by insulin. J Biol Chem. 
2004;279(36):37431-5. 
80. Minami A, Iseki M, Kishi K, Wang M, Ogura M, Furukawa N, et al. Increased 
insulin sensitivity and hypoinsulinemia in APS knockout mice. Diabetes. 
2003;52(11):2657-65. 
81. Molero JC, Jensen TE, Withers PC, Couzens M, Herzog H, Thien CB, et al. c-
Cbl-deficient mice have reduced adiposity, higher energy expenditure, and 
improved peripheral insulin action. J Clin Invest. 2004;114(9):1326-33. 
82. Kane S, Sano H, Liu SC, Asara JM, Lane WS, Garner CC, et al. A method to 
identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein 
with a Rab GTPase-activating protein (GAP) domain. J Biol Chem. 
2002;277(25):22115-8. 
83. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, et al. Insulin-
stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 
translocation. J Biol Chem. 2003;278(17):14599-602. 
84. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell 
Biol. 2009;10(8):513-25. 
85. Sano H, Eguez L, Teruel MN, Fukuda M, Chuang TD, Chavez JA, et al. Rab10, a 
target of the AS160 Rab GAP, is required for insulin-stimulated translocation of 
GLUT4 to the adipocyte plasma membrane. Cell Metab. 2007;5(4):293-303. 
86. Sano H, Roach WG, Peck GR, Fukuda M, Lienhard GE. Rab10 in insulin-
stimulated GLUT4 translocation. Biochem J. 2008;411(1):89-95. 
87. Ishikura S, Bilan PJ, Klip A. Rabs 8A and 14 are targets of the insulin-regulated 
Rab-GAP AS160 regulating GLUT4 traffic in muscle cells. Biochem Biophys 
Res Commun. 2007;353(4):1074-9. 
88. Roach WG, Chavez JA, Miinea CP, Lienhard GE. Substrate specificity and effect 
on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. Biochem 
J. 2007;403(2):353-8. 
149 
 
 
 
89. Chavez JA, Roach WG, Keller SR, Lane WS, Lienhard GE. Inhibition of GLUT4 
translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal 
muscle, is partially relieved by AMP-activated protein kinase activation. J Biol 
Chem. 2008;283(14):9187-95. 
90. Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, et al. TBC1D1 is a 
candidate for a severe obesity gene and evidence for a gene/gene interaction in 
obesity predisposition. Hum Mol Genet. 2006;15(18):2709-20. 
91. Meyre D, Farge M, Lecoeur C, Proenca C, Durand E, Allegaert F, et al. R125W 
coding variant in TBC1D1 confers risk for familial obesity and contributes to 
linkage on chromosome 4p14 in the French population. Hum Mol Genet. 
2008;17(12):1798-802. 
92. Chen S, Murphy J, Toth R, Campbell DG, Morrice NA, Mackintosh C. 
Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and 
AMPK activators. Biochem J. 2008;409(2):449-59. 
93. Taylor EB, An D, Kramer HF, Yu H, Fujii NL, Roeckl KS, et al. Discovery of 
TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in 
mouse skeletal muscle. J Biol Chem. 2008;283(15):9787-96. 
94. Bilan PJ, Schertzer JD. Brought in by force: AMPK, TBC1D1, and contraction-
stimulated glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab. 
2009;296(5):E965-6. 
95. An D, Toyoda T, Taylor EB, Yu H, Fujii N, Hirshman MF, et al. TBC1D1 
regulates insulin- and contraction-induced glucose transport in mouse skeletal 
muscle. Diabetes. 2010;59(6):1358-65. 
96. Pehmoller C, Treebak JT, Birk JB, Chen S, Mackintosh C, Hardie DG, et al. 
Genetic disruption of AMPK signaling abolishes both contraction- and insulin-
stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal 
muscle. Am J Physiol Endocrinol Metab. 2009;297(3):E665-75. 
97. Peck GR, Chavez JA, Roach WG, Budnik BA, Lane WS, Karlsson HK, et al. 
Insulin-stimulated phosphorylation of the Rab GTPase-activating protein 
TBC1D1 regulates GLUT4 translocation. J Biol Chem. 2009;284(44):30016-23. 
98. Funai K, Cartee GD. Inhibition of contraction-stimulated AMP-activated protein 
kinase inhibits contraction-stimulated increases in PAS-TBC1D1 and glucose 
transport without altering PAS-AS160 in rat skeletal muscle. Diabetes. 
2009;58(5):1096-104. 
99. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, et al. Growth 
retardation and increased apoptosis in mice with homozygous disruption of the 
Akt1 gene. Genes Dev. 2001;15(17):2203-8. 
100. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is 
required for normal growth but dispensable for maintenance of glucose 
homeostasis in mice. J Biol Chem. 2001;276(42):38349-52. 
101. Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, 
Watanabe T, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) 
in postnatal brain development but not in glucose homeostasis. Development. 
2005;132(13):2943-54. 
150 
 
 
 
102. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al. 
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone 
development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes 
Dev. 2003;17(11):1352-65. 
103. Yang ZZ, Tschopp O, Di-Poi N, Bruder E, Baudry A, Dummler B, et al. Dosage-
dependent effects of Akt1/protein kinase Balpha (PKBalpha) and 
Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system 
development in mice. Mol Cell Biol. 2005;25(23):10407-18. 
104. Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA. Life 
with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display 
impaired glucose homeostasis and growth deficiencies. Mol Cell Biol. 
2006;26(21):8042-51. 
105. Bae SS, Cho H, Mu J, Birnbaum MJ. Isoform-specific regulation of insulin-
dependent glucose uptake by Akt/protein kinase B. J Biol Chem. 
2003;278(49):49530-6. 
106. Gonzalez E, McGraw TE. Insulin-modulated Akt subcellular localization 
determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A. 
2009;106(17):7004-9. 
107. Kim YB, Peroni OD, Franke TF, Kahn BB. Divergent regulation of Akt1 and 
Akt2 isoforms in insulin target tissues of obese Zucker rats. Diabetes. 
2000;49(5):847-56. 
108. Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, Inazawa J, et al. PH 
domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell. 
2009;136(3):535-50. 
109. Calera MR, Martinez C, Liu H, Jack AK, Birnbaum MJ, Pilch PF. Insulin 
increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem. 
1998;273(13):7201-4. 
110. Hill MM, Clark SF, Tucker DF, Birnbaum MJ, James DE, Macaulay SL. A role 
for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in 
adipocytes. Mol Cell Biol. 1999;19(11):7771-81. 
111. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, Krook A, et al. 
siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-
2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab. 
2006;4(1):89-96. 
112. Yoshizaki T, Imamura T, Babendure JL, Lu JC, Sonoda N, Olefsky JM. Myosin 
5a is an insulin-stimulated Akt2 (protein kinase Bbeta) substrate modulating 
GLUT4 vesicle translocation. Mol Cell Biol. 2007;27(14):5172-83. 
113. Yamada E, Okada S, Saito T, Ohshima K, Sato M, Tsuchiya T, et al. Akt2 
phosphorylates Synip to regulate docking and fusion of GLUT4-containing 
vesicles. J Cell Biol. 2005;168(6):921-8. 
114. Nechamen CA, Thomas RM, Dias JA. APPL1, APPL2, Akt2 and FOXO1a 
interact with FSHR in a potential signaling complex. Mol Cell Endocrinol. 
2007;260-262:93-9. 
151 
 
 
 
115. Saito T, Jones CC, Huang S, Czech MP, Pilch PF. The interaction of Akt with 
APPL1 is required for insulin-stimulated Glut4 translocation. J Biol Chem. 
2007;282(44):32280-7. 
116. Schenck A, Goto-Silva L, Collinet C, Rhinn M, Giner A, Habermann B, et al. The 
endosomal protein Appl1 mediates Akt substrate specificity and cell survival in 
vertebrate development. Cell. 2008;133(3):486-97. 
117. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science. 
2005;307(5712):1098-101. 
118. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. 
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that 
mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. 
Dev Cell. 2006;11(6):859-71. 
119. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 
maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and 
substrate specificity. Cell. 2006;127(1):125-37. 
120. Wan X, Helman LJ. Levels of PTEN protein modulate Akt phosphorylation on 
serine 473, but not on threonine 308, in IGF-II-overexpressing 
rhabdomyosarcomas cells. Oncogene. 2003;22(50):8205-11. 
121. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, 
et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is 
associated with high-risk cytogenetics and predicts poor overall survival in acute 
myeloid leukaemia. Leukemia. 2009;23(6):1029-38. 
122. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, et al. 
Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose 
homeostasis. Genes Dev. 2005;19(18):2199-211. 
123. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein 
synthesis to cell size. Trends Biochem Sci. 2006;31(6):342-8. 
124. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid 
regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 
2009;296(4):E592-602. 
125. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard 
controlling cell growth. Biochem J. 2008;412(2):179-90. 
126. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP 
activity and regulates mTOR signaling. Genes Dev. 2003;17(15):1829-34. 
127. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates 
the mTOR kinase. Curr Biol. 2005;15(8):702-13. 
128. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating 
Tsc2. Nat Cell Biol. 2002;4(9):658-65. 
129. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG. Regulation of 
eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a 
conserved serine which undergoes dephosphorylation in response to insulin. 
FEBS Lett. 1998;421(2):125-30. 
152 
 
 
 
130. Welsh GI, Proud CG. Regulation of protein synthesis in Swiss 3T3 fibroblasts. 
Rapid activation of the guanine-nucleotide-exchange factor by insulin and growth 
factors. Biochem J. 1992;284 ( Pt 1):19-23. 
131. Proud CG. eIF2 and the control of cell physiology. Semin Cell Dev Biol. 
2005;16(1):3-12. 
132. Rogers GW, Jr., Richter NJ, Lima WF, Merrick WC. Modulation of the helicase 
activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem. 
2001;276(33):30914-22. 
133. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, et 
al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is 
modulated by S6 kinases. EMBO J. 2004;23(8):1761-9. 
134. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, et al. The 
mTOR/PI3K and MAPK pathways converge on eIF4B to control its 
phosphorylation and activity. EMBO J. 2006;25(12):2781-91. 
135. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of 
the translation preinitiation complex through dynamic protein interchange and 
ordered phosphorylation events. Cell. 2005;123(4):569-80. 
136. Venema RC, Peters HI, Traugh JA. Phosphorylation of valyl-tRNA synthetase 
and elongation factor 1 in response to phorbol esters is associated with stimulation 
of both activities. J Biol Chem. 1991;266(18):11993-8. 
137. Venema RC, Peters HI, Traugh JA. Phosphorylation of elongation factor 1 (EF-1) 
and valyl-tRNA synthetase by protein kinase C and stimulation of EF-1 activity. J 
Biol Chem. 1991;266(19):12574-80. 
138. Peters HI, Chang YW, Traugh JA. Phosphorylation of elongation factor 1 (EF-1) 
by protein kinase C stimulates GDP/GTP-exchange activity. Eur J Biochem. 
1995;234(2):550-6. 
139. Chang YW, Traugh JA. Insulin stimulation of phosphorylation of elongation 
factor 1 (eEF-1) enhances elongation activity. Eur J Biochem. 1998;251(1-2):201-
7. 
140. Carlberg U, Nilsson A, Nygard O. Functional properties of phosphorylated 
elongation factor 2. Eur J Biochem. 1990;191(3):639-45. 
141. Redpath NT, Foulstone EJ, Proud CG. Regulation of translation elongation factor-
2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J. 
1996;15(9):2291-7. 
142. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of 
elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J. 
2001;20(16):4370-9. 
143. Knebel A, Morrice N, Cohen P. A novel method to identify protein kinase 
substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta. 
EMBO J. 2001;20(16):4360-9. 
144. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in 
elongation factor 2 kinase modulates the activity of the kinase and its binding to 
calmodulin. Mol Cell Biol. 2004;24(7):2986-97. 
153 
 
 
 
145. Gonzalez-Gaitan M. Signal dispersal and transduction through the endocytic 
pathway. Nat Rev Mol Cell Biol. 2003;4(3):213-24. 
146. Hayakawa A, Leonard D, Murphy S, Hayes S, Soto M, Fogarty K, et al. The 
WD40 and FYVE domain containing protein 2 defines a class of early endosomes 
necessary for endocytosis. Proc Natl Acad Sci U S A. 2006;103(32):11928-33. 
147. Unger RH. Minireview: weapons of lean body mass destruction: the role of 
ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144(12):5159-65. 
148. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulation and 
metabolic syndrome. Diabetes Obes Metab. 2007;9(1):1-10. 
149. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of 
fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 
diabetes mellitus. Ann N Y Acad Sci. 2002;967:363-78. 
150. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. 
Obesity-associated improvements in metabolic profile through expansion of 
adipose tissue. J Clin Invest. 2007;117(9):2621-37. 
151. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-
derived resistin-like molecule-beta selectively impair insulin action on glucose 
production. J Clin Invest. 2003;111(2):225-30. 
152. Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory 
protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167-
75. 
153. Picard F, Guarente L. Molecular links between aging and adipose tissue. Int J 
Obes (Lond). 2005;29 Suppl 1:S36-9. 
154. Linford NJ, Beyer RP, Gollahon K, Krajcik RA, Malloy VL, Demas V, et al. 
Transcriptional response to aging and caloric restriction in heart and adipose 
tissue. Aging Cell. 2007;6(5):673-88. 
155. Hresko RC, Heimberg H, Chi MM, Mueckler M. Glucosamine-induced insulin 
resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP. J 
Biol Chem. 1998;273(32):20658-68. 
156. Beale EG, Antoine B, Forest C. Glyceroneogenesis in adipocytes: another 
textbook case. Trends Biochem Sci. 2003;28(8):402-3. 
157. Falkenberg M, Larsson NG, Gustafsson CM. DNA replication and transcription in 
mammalian mitochondria. Annu Rev Biochem. 2007;76:679-99. 
158. Asin-Cayuela J, Gustafsson CM. Mitochondrial transcription and its regulation in 
mammalian cells. Trends Biochem Sci. 2007;32(3):111-7. 
159. Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. 
J Cell Biochem. 2006;97(4):673-83. 
160. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, et al. 
Mitochondrial transcription factor A is necessary for mtDNA maintenance and 
embryogenesis in mice. Nat Genet. 1998;18(3):231-6. 
161. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for 
linking genomes to life and the environment. Nucleic Acids Res. 
2008;36(Database issue):D480-4. 
154 
 
 
 
162. Axelrod D. Total internal reflection fluorescence microscopy in cell biology. 
Traffic. 2001;2(11):764-74. 
163. Bashan N, Burdett E, Guma A, Sargeant R, Tumiati L, Liu Z, et al. Mechanisms 
of adaptation of glucose transporters to changes in the oxidative chain of muscle 
and fat cells. Am J Physiol. 1993;264(2 Pt 1):C430-40. 
164. Nishikawa T, Araki E. Impact of mitochondrial ROS production in the 
pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal. 
2007;9(3):343-53. 
165. Imoto K, Kukidome D, Nishikawa T, Matsuhisa T, Sonoda K, Fujisawa K, et al. 
Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating 
kinase 1 on insulin signaling. Diabetes. 2006;55(5):1197-204. 
166. Gridley S, Lane WS, Garner CW, Lienhard GE. Novel insulin-elicited 
phosphoproteins in adipocytes. Cell Signal. 2005;17(1):59-66. 
167. Chavez JA, Gridley S, Sano H, Lane WS, Lienhard GE. The 47kDa Akt substrate 
associates with phosphodiesterase 3B and regulates its level in adipocytes. 
Biochem Biophys Res Commun. 2006;342(4):1218-22. 
168. Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, et al. Targeted 
deletion of AIF decreases mitochondrial oxidative phosphorylation and protects 
from obesity and diabetes. Cell. 2007;131(3):476-91. 
169. Wredenberg A, Freyer C, Sandstrom ME, Katz A, Wibom R, Westerblad H, et al. 
Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. 
Biochem Biophys Res Commun. 2006;350(1):202-7. 
170. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, et al. Reversible 
oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with 
peptide growth factors. Proc Natl Acad Sci U S A. 2004;101(47):16419-24. 
171. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for 
suicide and survival. J Cell Physiol. 2002;192(1):1-15. 
172. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, et al. 
Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. 
Cell Metab. 2005;1(6):409-14. 
173. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, et al. Mitochondrial 
complex III is required for hypoxia-induced ROS production and cellular oxygen 
sensing. Cell Metab. 2005;1(6):401-8. 
174. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, et al. 
Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular 
oxygen sensing and hypoxic HIF-alpha activation. Cell Metab. 2005;1(6):393-9. 
175. Karlsson HK, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson 
H. Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in 
skeletal muscle of type 2 diabetic subjects. Diabetes. 2005;54(6):1692-7. 
176. Zeigerer A, McBrayer MK, McGraw TE. Insulin stimulation of GLUT4 
exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. 
Mol Biol Cell. 2004;15(10):4406-15. 
155 
 
 
 
177. Lakadamyali M, Rust MJ, Zhuang X. Ligands for clathrin-mediated endocytosis 
are differentially sorted into distinct populations of early endosomes. Cell. 
2006;124(5):997-1009. 
178. Leonard D, Hayakawa A, Lawe D, Lambright D, Bellve KD, Standley C, et al. 
Sorting of EGF and transferrin at the plasma membrane and by cargo-specific 
signaling to EEA1-enriched endosomes. J Cell Sci. 2008;121(Pt 20):3445-58. 
179. Corvera S, D'Arrigo A, Stenmark H. Phosphoinositides in membrane traffic. Curr 
Opin Cell Biol. 1999;11(4):460-5. 
180. Driscoll PC. Solving the FYVE domain--PtdIns(3)P puzzle. Nat Struct Biol. 
2001;8(4):287-90. 
181. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through 
phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol. 
1999;11(2):219-25. 
182. Lindmo K, Stenmark H. Regulation of membrane traffic by phosphoinositide 3-
kinases. J Cell Sci. 2006;119(Pt 4):605-14. 
183. Zoncu R, Perera RM, Balkin DM, Pirruccello M, Toomre D, De Camilli P. A 
phosphoinositide switch controls the maturation and signaling properties of APPL 
endosomes. Cell. 2009;136(6):1110-21. 
184. Kittler JT, Moss SJ. Neurotransmitter receptor trafficking and the regulation of 
synaptic strength. Traffic. 2001;2(7):437-48. 
185. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of 
cancer. Nat Rev Cancer. 2008;8(11):835-50. 
186. Raiborg C, Bache KG, Mehlum A, Stenmark H. Function of Hrs in endocytic 
trafficking and signalling. Biochem Soc Trans. 2001;29(Pt 4):472-5. 
187. von Zastrow M. Role of endocytosis in signalling and regulation of G-protein-
coupled receptors. Biochem Soc Trans. 2001;29(Pt 4):500-4. 
188. Wiley HS, Burke PM. Regulation of receptor tyrosine kinase signaling by 
endocytic trafficking. Traffic. 2001;2(1):12-8. 
189. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic 
pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 
2003;5(5):410-21. 
190. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-
enriched early endosomes: role in signaling to Smad2. J Cell Biol. 
2002;158(7):1239-49. 
191. Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, 
Habermann B, et al. APPL proteins link Rab5 to nuclear signal transduction via 
an endosomal compartment. Cell. 2004;116(3):445-56. 
192. Lin DC, Quevedo C, Brewer NE, Bell A, Testa JR, Grimes ML, et al. APPL1 
associates with TrkA and GIPC1 and is required for nerve growth factor-mediated 
signal transduction. Mol Cell Biol. 2006;26(23):8928-41. 
193. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 
binds to adiponectin receptors and mediates adiponectin signalling and function. 
Nat Cell Biol. 2006;8(5):516-23. 
156 
 
 
 
194. Fritzius T, Burkard G, Haas E, Heinrich J, Schweneker M, Bosse M, et al. A WD-
FYVE protein binds to the kinases Akt and PKCzeta/lambda. Biochem J. 
2006;399(1):9-20. 
195. Fritzius T, Frey AD, Schweneker M, Mayer D, Moelling K. WD-repeat-propeller-
FYVE protein, ProF, binds VAMP2 and protein kinase Czeta. FEBS J. 
2007;274(6):1552-66. 
196. Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27(50):6473-88. 
197. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of 
PKB/AKT--a major therapeutic target. Biochim Biophys Acta. 2004;1697(1-2):3-
16. 
198. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, et al. 
Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol 
Cell Biol. 2005;25(5):1869-78. 
199. Jiang ZY, Zhou QL, Coleman KA, Chouinard M, Boese Q, Czech MP. Insulin 
signaling through Akt/protein kinase B analyzed by small interfering RNA-
mediated gene silencing. Proc Natl Acad Sci U S A. 2003;100(13):7569-74. 
200. Bellve KD, Leonard D, Standley C, Lifshitz LM, Tuft RA, Hayakawa A, et al. 
Plasma membrane domains specialized for clathrin-mediated endocytosis in 
primary cells. J Biol Chem. 2006;281(23):16139-46. 
201. Evans DR, Swirsding KA, Taillon BE, Simons JF. "One plate/three-reporter" 
assay format for the detection and validation of yeast two-hybrid interactions. 
Biotechniques. 2004;37(5):840-3. 
202. Fritzius T, Moelling K. Akt- and Foxo1-interacting WD-repeat-FYVE protein 
promotes adipogenesis. EMBO J. 2008;27(9):1399-410. 
203. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, 
PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating 
distinct Akt isoforms. Mol Cell. 2007;25(6):917-31. 
204. Yan D, Guo L, Wang Y. Requirement of dendritic Akt degradation by the 
ubiquitin-proteasome system for neuronal polarity. J Cell Biol. 2006;174(3):415-
24. 
205. Medina EA, Afsari RR, Ravid T, Castillo SS, Erickson KL, Goldkorn T. Tumor 
necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the 
caspase-dependent ubiquitination of Akt. Endocrinology. 2005;146(6):2726-35. 
206. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, et al. Negative 
Regulation of AKT Activation by BRCA1. Cancer Res. 2008;68(24):10040-4. 
207. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) 
in older persons is associated with functional impairment and physical disability. J 
Am Geriatr Soc. 2002;50(5):889-96. 
208. Choi CS, Befroy DE, Codella R, Kim S, Reznick RM, Hwang YJ, et al. 
Paradoxical effects of increased expression of PGC-1alpha on muscle 
mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc 
Natl Acad Sci U S A. 2008;105(50):19926-31. 
157 
 
 
 
209. Simpson JC, Griffiths G, Wessling-Resnick M, Fransen JA, Bennett H, Jones AT. 
A role for the small GTPase Rab21 in the early endocytic pathway. J Cell Sci. 
2004;117(Pt 26):6297-311. 
210. Somsel Rodman J, Wandinger-Ness A. Rab GTPases coordinate endocytosis. J 
Cell Sci. 2000;113 Pt 2:183-92. 
211. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, et al. 
Mitochondrial transcription factor A regulates mtDNA copy number in mammals. 
Hum Mol Genet. 2004;13(9):935-44. 
212. Maniura-Weber K, Goffart S, Garstka HL, Montoya J, Wiesner RJ. Transient 
overexpression of mitochondrial transcription factor A (TFAM) is sufficient to 
stimulate mitochondrial DNA transcription, but not sufficient to increase mtDNA 
copy number in cultured cells. Nucleic Acids Res. 2004;32(20):6015-27. 
213. Ylikallio E, Tyynismaa H, Tsutsui H, Ide T, Suomalainen A. High mitochondrial 
DNA copy number has detrimental effects in mice. Hum Mol Genet. 
2010;19(13):2695-705. 
214. Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, et al. 
Overexpression of mitochondrial transcription factor a ameliorates mitochondrial 
deficiencies and cardiac failure after myocardial infarction. Circulation. 
2005;112(5):683-90. 
215. Hayashi Y, Yoshida M, Yamato M, Ide T, Wu Z, Ochi-Shindou M, et al. Reverse 
of age-dependent memory impairment and mitochondrial DNA damage in 
microglia by an overexpression of human mitochondrial transcription factor a in 
mice. J Neurosci. 2008;28(34):8624-34. 
216. Suarez J, Hu Y, Makino A, Fricovsky E, Wang H, Dillmann WH. Alterations in 
mitochondrial function and cytosolic calcium induced by hyperglycemia are 
restored by mitochondrial transcription factor A in cardiomyocytes. Am J Physiol 
Cell Physiol. 2008;295(6):C1561-8. 
217. Xu S, Zhong M, Zhang L, Wang Y, Zhou Z, Hao Y, et al. Overexpression of 
Tfam protects mitochondria against beta-amyloid-induced oxidative damage in 
SH-SY5Y cells. FEBS J. 2009;276(14):3800-9. 
218. Hokari M, Kuroda S, Kinugawa S, Ide T, Tsutsui H, Iwasaki Y. Overexpression 
of mitochondrial transcription factor A (TFAM) ameliorates delayed neuronal 
death due to transient forebrain ischemia in mice. Neuropathology. 
2010;30(4):401-7. 
219. Pastukh V, Shokolenko I, Wang B, Wilson G, Alexeyev M. Human mitochondrial 
transcription factor A possesses multiple subcellular targeting signals. FEBS J. 
2007;274(24):6488-99. 
220. Dong X, Ghoshal K, Majumder S, Yadav SP, Jacob ST. Mitochondrial 
transcription factor A and its downstream targets are up-regulated in a rat 
hepatoma. J Biol Chem. 2002;277(45):43309-18. 
221. Pietrowska M, Kolodziejczyk I, Widlak P. Mitochondrial transcription factor A is 
the major protein in rodent hepatocytes that recognizes DNA lesions induced by 
N-acetoxy-acetylaminofluorene. Acta Biochim Pol. 2006;53(4):777-82. 
158 
 
 
 
222. Kaufman BA, Durisic N, Mativetsky JM, Costantino S, Hancock MA, Grutter P, 
et al. The mitochondrial transcription factor TFAM coordinates the assembly of 
multiple DNA molecules into nucleoid-like structures. Mol Biol Cell. 
2007;18(9):3225-36. 
223. Frost SC, Lane MD. Evidence for the involvement of vicinal sulfhydryl groups in 
insulin-activated hexose transport by 3T3-L1 adipocytes. J Biol Chem. 
1985;260(5):2646-52. 
224. Ross SR, Graves RA, Greenstein A, Platt KA, Shyu HL, Mellovitz B, et al. A fat-
specific enhancer is the primary determinant of gene expression for adipocyte P2 
in vivo. Proc Natl Acad Sci U S A. 1990;87(24):9590-4. 
225. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, et al. 
Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in 
apolipoprotein E against atherosclerosis. Nat Med. 2001;7(6):699-705. 
226. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and 
cancer. Cell Cycle. 2009;8(16):2502-8. 
227. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein Kinase B 
(PKB/Akt), a Key Mediator of the PI3K Signaling Pathway. Curr Top Microbiol 
Immunol. 2010. 
228. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of 
glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 
1995;378(6559):785-9. 
229. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. Molecular 
basis for the substrate specificity of protein kinase B; comparison with MAPKAP 
kinase-1 and p70 S6 kinase. FEBS Lett. 1996;399(3):333-8. 
230. Zhang H, Zha X, Tan Y, Hornbeck PV, Mastrangelo AJ, Alessi DR, et al. 
Phosphoprotein analysis using antibodies broadly reactive against phosphorylated 
motifs. J Biol Chem. 2002;277(42):39379-87. 
231. Pecorari L, Marin O, Silvestri C, Candini O, Rossi E, Guerzoni C, et al. 
Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and 
regulates their proliferation, survival and motility. Mol Cancer. 2009;8:58. 
232. Kielbassa K, Muller HJ, Meyer HE, Marks F, Gschwendt M. Protein kinase C 
delta-specific phosphorylation of the elongation factor eEF-alpha and an eEF-1 
alpha peptide at threonine 431. J Biol Chem. 1995;270(11):6156-62. 
 
 
